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The mammalian target of rapamycin (mTOR) is an atypical serine/threonine kinase, 
evolutionary conserved from yeast to human, which forms two functional distinct and 
independently regulated multiprotein complexes, dubbed mTORC1 and mTORC2. 
mTORC1 contains mTOR, raptor, mLST8, PRAS40 and DEPTOR, and is sensitive to 
the immunosuppressive and anti-cancer drug rapamycin. mTORC1 regulates 
translation via phosphorylation of S6K1 and 4E-BP1, two well-characterized effector 
proteins. mTORC2 consists of mTOR, rictor, mLST8, mSIN1, protor and DEPTOR, 
and is rapamycin-insensitive. It regulates the organization of the actin cytoskeleton 
and is involved in cell survival.  
Both mTORC1 and mTORC2 are stimulated by growth factors, but only mTORC1 is 
controlled as well by cellular energy status and nutrients such as amino acids. How 
cells sense amino acid sufficiency to control protein synthesis and eventually cell 
growth is largely unknown. Amino acid deprivation results in rapid dephosphorylation 
of S6K1 and 4E-BP1, while amino acid stimulation leads to the rapid mTORC1-
mediated phosphorylation of these molecules. Moreover, amino acid stimulation 
triggers the re-localization of mTORC1 to late endosomes/lysosomes, where Rheb is 
supposed to be localized and thereby allowing Rheb to directly interact with and 
activate mTORC1. Additionally, vacuolar protein sorting 34 (Vps34), the sole class III 
phosphatidylinositol 3-kinase (PI3K), and its phospholipid product 
phosphatidylinositol 3-phosphate [PtdIns(3)P] have also been implicated in mTORC1 
activation. However, concerns exist in connecting Vps34 with mTORC1 regulation. 
Therefore, we have decided to investigated in more depth the role of Vps34 and 
PtdIns(3)P in the amino acid pathway to mTORC1. Ectopic expression of either wild 
type or kinase-dead human Vps34 (hVps34) did not change mTORC1 activity. 
Deletion of hVps34 by RNAi did not result in a complete decrease of mTORC1 
activation, indicating that another PI3K might generate PtIns(3)P. Depletion of the 
class II PI3K isoforms PI3K-C2α and PI3K-C2β, which have been demonstrated to 
generate PtdIns(3)P as well, leads to an isoform specific regulation of mTORC1 
activity. PI3K-C2α deletion increased, while PI3K-C2β knockdown only partially 
reduced mTORC1 activity. However, by directly affecting cellular PtdIns(3)P 
availability either by sequestering PtdIns(3)P with a tandem FYVE domain 
(Fab1/YOTB/Vac1/EEA1; named after the first four proteins in which it was identified) 
or by acute treatment with exogenous PtdIns(3)P, mTORC1 activity almost 
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completely decreased or strongly increased, respectively. These results confirm the 
requirement of PtdIns(3)P in the mTORC1 pathway.  
Consistent with the requirement of PtdIns(3)P in endosomal homeostasis, we 
reasoned that PtdIns(3,5)P2, which is generated by PIKfyve using PtdIns(3)P as 
substrate and required for early to late endosome trafficking, might as well be 
implicated in the amino acid-dependent pathway to mTORC1. Pharmacologic 
inhibition of PIKfyve strongly decreased mTORC1-mediated phosphorylation of S6K1 
without affecting the catalytic activity of mTOR and PtdIns(3)P generation, and 
abrogated the translocation of mTOR to late endosomes indicating that the inhibiting 
effect on mTORC1, induced through the inhibition of PIKfyve, is probably due to a 
defect in endosomal membrane transport to late endosomes.  
We are the first to show that PtdIns(3,5)P2, generated by PIKfyve, is involved in 
mTORC1 activation and moreover, demonstrating that an unperturbed endosomal 
transport is required for late endosomal re-localization of mTORC1 induced by amino 
acids.  
However, the above described result cannot be generalized for different cell lines. 
While in HEK293 cells PIKfyve inhibition strongly blocked mTORC1 activity, in A375 
cells, an aggressive melanoma cell line, the inhibition was less pronounced. This can 
be explained that A375 cells have a constitutive active MAPK pathway due to B-Raf 
V600E mutation, which impinges on mTORC1 activity. Therefore, this indicates that 
cancer cells with mutated MAPK or PI3K-Akt/PKB pathway cannot be treated solely 







The target of rapamycin (TOR) story began with the isolation of the bacterium 
Streptomyces hygroscopicus from a soil sample collected in Easter Island (Rapa Nui 
in the native language), that produces a macrolide called rapamycin after Rapa Nui, 
the location of its discovery (Vezina et al., 1975). Besides having anti-fungal 
properties, rapamycin possesses immunosuppressive and anti-proliferative 
properties. Moreover, in a yeast genetic screen rapamycin treatment led to the 
identification of two independent genes that, when mutated, conferred resistance to 
rapamycin. These two genes were named target of rapamycin 1 and 2 (TOR1 and 
TOR2) (Heitman et al., 1991). Importantly, follow up studies on TOR functions 
revealed TOR being fundamental in cell growth and cell proliferation. Rapamycin 
treatment or inactivation of both TOR genes in yeast resulted in a severe decrease in 
translation initiation and an arrest in the early G1 phase of the cell cycle (Barbet et 
al., 1996; Kunz et al., 1993). Moreover, inhibition of TOR functions in yeast 
phenocopied the physiological changes characteristic of nutrient starved cells that 
arrest the cell cycle in G1 due to loss of translation and enter into G0 (Barbet et al., 
1996). The role of TOR in nutrient response has also been found in higher 
eukaryotes. Genetic studies in Drosophila melanogaster revealed that loss of dTOR 
and amino acid withdrawal cause similar phenotypes including reduction in cell size 
and proliferative defects leading to G1 arrest (Oldham et al., 2000; Zhang et al., 
2000). In mammalian cells, amino acid insufficiency and inhibition of mammalian 
TOR (mTOR; also known as FRAP, RAFT1 and RAPT) function by rapamycin 
selectively induce dephosphorylation of the two best-characterized mTOR substrates 
p70 ribosomal S6 kinase (S6K1) and eukaryotic initiation factor 4E-binding protein 1 
(4E-BP1, also known as PHAS1) (Burnett et al., 1998; Hara et al., 1998; Iiboshi et al., 
1999) and rapamycin treatment reduces cell size (Fingar et al., 2002). In metazoan, 
TOR responds to a plethora of signals such as growth factors, nutrients, energy and 
stress. Nonetheless, in mammals nutrients in form of amino acids seem to be the 
most critical signal for mTOR activation, inasmuch as in the absence of amino acids 




2.1 Molecular composition of mTOR complexes 
 
2.1.1 The TOR protein 
 
TOR is a large protein of approximately 280 kDa and was originally identified in 1991 
in Saccharomyces cerevisiae (Heitman et al., 1991) and since then homologues 
have been found in other eukaryotes including fungi, plants, worms, flies and 
mammals (Jacinto and Hall, 2003) indicating that TOR is conserved in all eukaryotes. 
Yeast contains two TOR genes, TOR1 and TOR2, while higher eukaryotes contain 
only one TOR gene (Wullschleger et al., 2006). TOR is the founding member of the 
phosphatidylinositol 3-kinase-related protein kinase (PIKK) family (Kunz et al., 1993; 
Schmelzle and Hall, 2000; Wullschleger et al., 2006). All PIKK members, including 
TOR, ATM (ataxia-telangiectasia mutated), ATR (ATM and Rad3 related), DNA-PK 
(DNA-dependent protein kinase), SMG-1 (suppressor of morphogenesis in genitalia-
1) and TRRAP (transformation/transcription domain associated protein), contain a 
conserved C-terminal region with strong homology to the catalytic domain of 
phosphatidylinositol 3-kinases (PI3Ks) (Abraham, 2004). Despite this homology to 
lipid kinases, TOR and the other PIKK members are Ser/Thr protein kinases, except 
TRRAP that has no catalytic activity (Abraham, 2004). The N-terminus of TOR 
contains 20 tandem repeats of 37-43 amino acids termed HEAT repeats (huntingtin, 
elongation factor 3, a subunit of protein phosphatase 2A and TOR1) (Andrade and 
Bork, 1995) and each HEAT motif forms a pair of antiparallel α-helices (Groves et al., 
1999). The HEAT repeats in TOR mediate protein-protein interaction (Kim et al., 
2002) and membrane localization (Drenan et al., 2004; Kunz et al., 2000; Liu and 
Zheng, 2007; Sabatini et al., 1999). Next to the HEAT repeats is the FAT (FRAP, 
ATM and TRRAP) domain followed by the FRB (FKBP12-rapamyicin binding) 
domain, the catalytic and the FATC (FAT C-terminus) domain (Fig. 1). The FAT 
domain is present in all PIKK members and is found in combination with FATC 
domain that is located at the very C-terminus of TOR. Both domains are believed to 
function in protein-protein interactions (Jacinto and Hall, 2003) and FATC to be 
essential for protein kinase activity (Abraham, 2004). The FRB domain is the 
FKBP12-rapamycin binding site that upon binding of FKB12-rapamycin complex 
inhibits TOR function (Schmelzle and Hall, 2000). Consistent with the many protein-
protein interaction domains in TOR, TOR forms a multiprotein complex.  
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Initial studies in Saccharomyces cerevisiae revealed that TOR1 and TOR2 act as 
nutrient sensors and control cell size and proliferation (Barbet et al., 1996). In 
Drosophila melanogaster and Caenorhabditis elegans inactivation of the TOR 
homologue caused developmental arrests that resembled the developmental arrest 
of starved larvae (Long et al., 2002; Oldham et al., 2000; Zhang et al., 2000). In mice, 
TOR is also needed for development, inasmuch as homozygous mTOR deletion 
resulted in embryonic lethality due to defect in cell proliferation and cell growth 
(Gangloff et al., 2004; Murakami et al., 2004). 
 
2.1.2 Components of mammalian TOR complex 1 and 2 
 
TOR forms two functionally distinct and independently regulated complexes, TOR 
complex 1 (TORC1) and TOR complex 2 (TORC2) (Table1 summarizes the 
components of the single complex and their functions). Both complexes are sensitive 
to growth factors but only TORC1 is rapamycin and nutrient-sensitive, while TORC2 
is rapamycin and nutrient-insensitive (Loewith et al., 2002; Wullschleger et al., 2006). 
Many of the TOR complex 1 and 2 components are highly conserved from yeast to 
mammals (Loewith et al., 2002) (Table 1). Mammalian TORC1 (mTORC1) (Fig. 1) 
contains mTOR, raptor (regulatory-associated protein of mTOR; homologue of the 
yeast KOG1) (Hara et al., 2002; Kim et al., 2002; Loewith et al., 2002), mLST8 
(mammalian lethal with sec thirteen, also known as GβL) (Kim et al., 2003), PRAS40 
(proline-rich Akt substrate of 40 kDa) (Fonseca et al., 2007; Sancak et al., 2007; 
Thedieck et al., 2007) and DEPTOR (DEP domain-containing mTOR-interacting 
protein) (Peterson et al., 2009).  
 
mTORC2 (Fig. 1) also contains mTOR, mLST8 and DEPTOR but no raptor and 
PRAS40. Instead, mTORC2 contains rictor (rapamycin-insensitive companion of 
mTOR; the yeast AVO3 homologue) (Sarbassov et al., 2004), mSIN1 (mammalian 
stress-activated map kinase-interacting protein 1; the yeast AVO1 homologue) (Frias 
et al., 2006; Jacinto et al., 2006; Yang et al., 2006) and Protor (protein observed with 






Fig. 1: Components of mammalian TORC1 and TORC2 and their domain organizations. 
Mammalian target of rapamycin (mTOR) complex 1 (mTORC1) and mTORC2 are multi-protein 
complexes with shared and unique components. Both complexes contain mTOR, mammalian lethal with 
sec thirteen 8 (mLST8) and DEP domain-containing mTOR-interacting protein (DEPTOR). Specific to 
mTORC1 are regulatory-associated protein of mTOR (raptor) and proline-rich Akt substrate of 40 kDa 
(PRAS40). Unique to mTORC2 are rapamycin-insensitive companion of mTOR (rictor), mammalian 
stress-activated map kinase-interacting protein 1 (mSin1) and protein observed with rictor (protor).  
The N-terminus of mTOR contains two large blocks of HEAT repeats, which mediate protein-protein 
interactions. Following the HEAT repeats are the FAT domain, the FRB domain (the binding site of 
FKBP12-rapamycin complex) that is only accessible by FKBP12-rapamycin in mTORC1, the Ser/Thr 
kinase domain and the C-terminal FATC domain. PRAS40 contains proline-rich regions at the N-
terminus. Raptor contains many protein-binding domains consisting with its function as a scaffolding 
protein. Next to the raptor-N-terminal conserved (RNC) domain are three HEAT repeats followed by 
seven WD40 repeats at the C-terminus. DEPTOR consists of two DEP domains at the N-terminus and a 
PDZ domain at the C-terminus. The structure of mLST8 consists almost entirely of seven WD40 
repeats. Rictor and Protor do not have any recognizable functional domains. mSin1 contains a Ras 
binding domain (RBD) and pleckstrin homology (PH) domain that probably interacts with phospholipids. 
HEAT: huntingtin, elongation factor 3, a subunit of protein phosphatase 2A and TOR1; FAT: FRAP, 
ATM and TRRAP; FRB: FKBP12-rapamycin binding; DEP, disheveled, egl-10, pleckstrin; PDZ: 






Table 1: Mammalian TORC components and functions and their orthologues in yeast  
Mammals yeast Function 
mTOR TOR1, TOR2 Ser/Thr protein kinase of mTORC1 and mTORC2 
Raptor KOG1 Defining component of mTORC1; mTOR scaffold protein that 
brings substrates to the mTOR kinase 
mLST8 (GβL) LST8 Component of mTORC1 and mTORC2; stabilizes mTOR 
complexes and is required for mTOR kinase activity, scaffold 
protein 
PRAS40  Component of mTORC1; raptor-binding protein; negatively 
regulates mTORC1 kinase activity 
DEPTOR  Component of mTORC1 and mTORC2; negatively regulates 
mTORC1 and mTORC2 activation 
Rictor AVO3 Defining component of mTORC2; required for complex stability 
and mTORC2 activity  
mSin1 AVO1 Component of mTORC2; required for complex assembly and 
stability; important for mTORC2 activity and intracellular 
membrane localization 
 AVO2 Component of yeast TORC2; non-essential protein; no 
mammalian homologue found  
Protor  Component of mTORC2; rictor-binding protein 
 
2.1.3 Molecular functions of the individual mTOR-associated 
proteins 
 
Raptor is highly conserved among all eukaryotes and all raptor homologues have at 
their N-termini a unique domain named RNC (raptor-N-terminal conserved) divided 
into 3 blocks. RNC is followed by three HEAT repeats and seven WD40 repeats near 
the C-terminus (Hara et al., 2002; Kim et al., 2002) (Fig. 1). The association between 
Raptor and mTOR requires the HEAT repeats of mTOR and multiple sites on raptor 
(Kim et al., 2002). Raptor is a mTOR scaffold protein that interacts with the known 
mTORC1 substrates (4E-BP1 and S6K1) by binding to their TOS (TOR signaling) 
motifs and thus presenting S6K1 and 4E-BP1 to the mTORC1 kinase for 
phosphorylation (Hara et al., 2002; Nojima et al., 2003; Schalm and Blenis, 2002). 
Raptor plays a positive role in maintaining an active mTORC1 pathway, as deletion 
of raptor expression negatively affects the activation of mTORC1 downstream 
effectors, cell size and embryonic development (Guertin et al., 2006; Hara et al., 
2002; Kim et al., 2002; Polak et al., 2008). Moreover, the interaction between raptor 
and mTOR is sensitive to nutrient availability. In nutrient deprived conditions, raptor-
mTOR association is stable and strong, whereas in nutrient-rich conditions it is 
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unstable. A strong association of raptor with mTOR results in the inhibition of the 
mTOR catalytic activity (Kim et al., 2002).  
 
mLST8 (also named GβL) is a component of both mTOR complexes (Kim et al., 
2003; Sarbassov et al., 2004), consists of seven WD40 repeats and, like mTOR and 
raptor, is conserved through all eukaryotes (Kim et al., 2003) (Fig. 1). mLST8 binds 
strongly to the catalytic domain of mTOR in both complexes and is necessary for the 
catalytic activity of mTOR and stability of both complexes (Kim et al., 2003; 
Wullschleger et al., 2005). Consisting to its essential role for both TOR complexes, 
homologous deletion of mLST8 results in embryonic lethality (Guertin et al., 2006). 
 
PRAS40 is a proline-rich protein having proline-rich regions at the N-terminus, 
otherwise lacking known domains (Kovacina et al., 2003) (Fig. 1) and it seems to be 
conserved only in higher eukaryotes (Oshiro et al., 2007; Vander Haar et al., 2007). It 
associates with raptor through its TOS motif and is thus mTORC1 specific (Fonseca 
et al., 2007; Oshiro et al., 2007; Wang et al., 2007). The primary function of PRAS40 
is to inhibit mTORC1 signaling to its physiological substrates S6K1 and 4E-BP1. The 
inhibitory effect on mTORC1 signaling is relieved through phosphorylation of 
PRAS40 by mTORC1 and Akt/PKB (product of the retrovirus AKT8/Protein Kinase B) 
(Fonseca et al., 2007; Oshiro et al., 2007; Sancak et al., 2007; Vander Haar et al., 
2007; Wang et al., 2008a).  
 
DEPTOR is an mTOR-interacting protein found in both mTOR complexes and 
negatively regulates mTORC1 and mTORC2 activities (Peterson et al., 2009). It is 
only found in vertebrates and contains at its N-terminus two DEP (disheveled, egl-10, 
pleckstrin) domains and a PDZ (postsynaptic density 95, discs large, zonula 
occludens-1) domain at the C-terminus (Peterson et al., 2009) (Fig. 1). The 
interaction between mTOR and DEPTOR involves the FAT domain of mTOR and the 
PDZ domain of DEPTOR (Peterson et al., 2009). Interestingly, DEPTOR is an 
unstable protein and is rapidly degraded following stimulation with growth factors 
(Peterson et al., 2009). 
 
Rictor does not contain any functional domains and is not well conserved among 
eukaryotes (Fig. 1); however, rictor homologues share common domain architectures 
(Sarbassov et al., 2004). Rictor is the defining component of mTORC2 (Jacinto et al., 
2004; Sarbassov et al., 2004) and essential for both mTORC2 complex formation 
and its biological function (Sarbassov et al., 2005; Yang et al., 2006). Rictor deletion 
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in mice has been demonstrated to be embryonic lethal underscoring its essential role 
in mTORC2 function (Guertin et al., 2006).  
 
mSin1 is an essential component of mTORC2 (Frias et al., 2006; Jacinto et al., 2006; 
Yang et al., 2006) and contains a Raf-like Ras binding domain (RBD) followed by a 
pleckstrin homology (PH) domain at the C-terminus (Schroder et al., 2007) (Fig. 1). 
The PH domain of mSin1 has been demonstrated to bind to phosphoinositides and to 
localize to both the plasma membrane and to a large cytoplasmic structure (Schroder 
et al., 2007). Therefore, mSin1 might guide mTORC2 to the plasma membrane. 
Indeed, in yeast Avo1, the mSin1 homologue, has been shown to be necessary to 
target TORC2 to the plasma membrane (Berchtold and Walther, 2009). mSin1 forms 
a tight complex with rictor and is also involved in the interaction with mTOR. Together 
with rictor, mSin1 is required for integrity, complex formation and for the kinase 
activity of mTORC2 (Frias et al., 2006; Yang et al., 2006). mSin1 interacts with 
Akt/PKB suggesting that mSin1 might serve as a scaffold to present Akt/PKB to 
mTORC2 (Jacinto et al., 2006). One interesting aspect of Sin1 is that in human, in 
contrast to other species, five different Sin1 isoforms exists that are generated by 
alternative splicing (Schroder et al., 2004) but only three of them (isoform 1, 2 and 5) 
assemble separately into mTORC2 thereby generating three distinct complexes 
(Frias et al., 2006). All three different mTORC2s phosphorylate the hydrophobic motif 
Ser473 of Akt/PKB in vitro, but only two complexes containing hSin1.1 and hSin1.2 
isoforms are regulated by insulin (Frias et al., 2006). This indicates that in human the 
three distinct mTORC2s may respond to different signals.  
 
Protor does not possess any recognizable functional domains (Fig. 1) and no 
homologues have been found in lower eukaryotes, including yeast and Drosophila 
(Pearce et al., 2007). Protor binds specifically to rictor and is thus a component of 
mTORC2. Alike DEPTOR, it is not involved in assembly and integrity of mTORC2 
(Pearce et al., 2007).  
 
2.2 Downstream targets of the mTOR complexes 
 
Consistent with the distinct subunits composition of mTORC1 and mTORC2 and the 
fact that only mTORC1 is rapamycin sensitive, substrate specificity is also 
determined by the TOR complex. The best known substrates of mTORC1 are 
eukaryotic translation initiation factor 4E (eIF4E)-binding protein (4E-BP1) and the 
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p70 ribosomal protein S6 kinase (S6K1) (Burnett et al., 1998). Phosphorylation of 4E-
BP1 and S6K1 by mTORC1 requires the recruitment of both substrates to mTORC1 
through raptor followed by the phosphorylation by the mTOR kinase (Hara et al., 
2002; Nojima et al., 2003; Schalm and Blenis, 2002). Consequently, by 
phosphorylation activated S6K1 and inactivated 4E-BP1 regulate mRNA translation 
initiation and progression. Hypophosphorylated 4E-BP1 is bound to eIF4E 
(eukaryotic initiation factor 4E), but when hyperphosphorylated (on Thr37, Thr46, 
Ser65 and Thr70) 4E-BP1 dissociates from eIF4E and allows eIF4E to be 
incorporated into the eIF4F complex. eIF4F complex is recruited via eIF4E to the 5’-
cap of mRNA permitting the translational machinery to be assembled and translation 
to be initiated (Gingras et al., 2001). CAP-containing mRNAs encode for proteins 
important for cell proliferation, such as c-Myc and cyclin-D1 (Sonenberg and Gingras, 
1998). Activation of S6K1 by Thr389 phosphorylation by mTORC1 leads to the 
translation of a different subset of mRNAs containing a terminal oligopolypyrimidine 
(TOP) track at the 5’-end. These types of mRNA encode for proteins of the 
translational machinery, such as ribosomes and elongation factors (Jefferies et al., 
1997; Wullschleger et al., 2006).  
Another physiological substrate of mTORC1 is PRAS40 (Fonseca et al., 2007; 
Oshiro et al., 2007; Wang et al., 2007). PRAS40 exerts a negative effect on 
mTORC1 downstream substrates probably by competing with 4E-BP1 and S6K1 for 
binding to raptor (Oshiro et al., 2007; Wang et al., 2007). PRAS40 is phosphorylated 
on Ser183 and Ser221 by mTORC1 in a rapamycin-dependent manner (Oshiro et al., 
2007; Wang et al., 2008a) and alike other mTORC1 substrates, PRAS40 
phosphorylation is positively influenced by Rheb (Ras homologue enriched in brain) 
and negatively affected by TSC1/TSC2 (tuberous sclerosis complex 1 and 2) 
complex (Oshiro et al., 2007). The inhibitory function of PRAS40 on mTORC1 is 
relieved through binding of phosphorylated PRAS40 to 14-3-3 (cytosolic anchor 
protein) and induces PRAS40 to dissociate from raptor. Moreover, PRAS40 has been 
found to be a substrate of Akt/PKB that in response to insulin treatment is 
phosphorylated on Thr246 in a wortmannin-dependent but rapamycin-independent 
manner and as a result mTORC1 activity is de-repressed through the association of 
PRAS40 to 14-3-3 (Fonseca et al., 2007; Kovacina et al., 2003; Oshiro et al., 2007; 
Sancak et al., 2007; Vander Haar et al., 2007; Wang et al., 2007). Both mTORC1 
(stimulated by nutrients) and Akt/PKB (stimulated by insulin) phosphorylate and 





Under nutrient replete conditions mTORC1 negatively regulates the catabolic 
process macroautophagy (commonly termed autophagy), bulk degradation of 
cytoplasmic components such as organelles and proteins. Autophagy is upregulated 
during periods of starvation resulting in the sequestration of cytoplasmic components 
into a double-membrane vacuolar structure termed autophagosome. Upon fusion 
with a lysosome an autolysosome is formed, where its content is degraded providing 
a nutrient source to sustain anabolic processes such as protein synthesis and energy 
production that will allow cell survival until nutrients become available again 
(Codogno and Meijer, 2005; Klionsky, 2007; Simonsen and Tooze, 2009). Autophagy 
is controlled by mTORC1 through the regulation of the protein complex composed of 
Ser/Thr kinase ULK1 (unc-51-like kinase, yeast Atg1 homologue), Atg13 (autophagy-
related gene 13) and FIP200 (focal adhesion kinase family-interacting proteine of 200 
kDa, yeast Atg17 homologue) (Stipanuk, 2009). ULK1 kinase activity is regulated by 
Atg13 and FIP200 and the heterotrimeric complex is essential for the initiation of 
autophagosome formation (Stipanuk, 2009). Under condition of high nutrient 
availability mTORC1 phosphorylates both ULK1 and Atg13 and negatively affects the 
kinase activity of ULK1 thus repressing the initiation of autophagy (Stipanuk, 2009). 
 
The cellular function of mTORC2 is less clear but it is involved in the reorganization 
of the cytoskeleton and cell survival (Jacinto et al., 2004; Sarbassov et al., 2004). 
mTORC2 has been shown to phosphorylate the hydrophobic motifs in Akt/PKB, 
PKCα (protein kinase C α) and SGK1 (serum- and glucocorticoid-induced protein 
kinase 1) (Guertin and Sabatini, 2005), all members of the AGC protein kinase family 
(Pearce et al., 2010). Akt/PKB is the best-characterized substrate of mTORC2 and 
lays downstream of the growth factor-activated PI3K pathway. mTORC2 
phosphorylates Akt/PKB at Ser473 (Hresko and Mueckler, 2005) and facilitates 
PDK1 (3-phosphoinositide-dependent protein kinase 1) to phosphorylate Thr308 
resulting in the full activation of Akt/PKB (Fig. 2). Activated Akt/PKB controls 
mTORC1 activity in response to growth factors, by releasing the inhibitory effect of 
the TSC1/TSC2 complex and PRAS40 (Inoki et al., 2002; Sancak et al., 2007; 







Fig. 2: The mTOR signaling pathway regulated by growth factors and energy status (simplified). 
Activated insulin receptor recruits and phosphorylates IRS1 that binds and activates PI3K. PI3K 
phosphorylates at the plasma membrane PtdIns(4,5)P2 to generate PtdIns(3,4,5)P3, which recruits 
Akt/PKB and PKD1 to the plasma membrane mediated by the binding of their pleckstrin homology (PH) 
domains to PtdIns(3,4,5)P3. PDK1 phosphorylates the activation loop of Akt/PKB at Thr308 (T308). 
Growth factors also activate mTORC2 by an unknown mechanism near the plasma membrane, where 
mTORC2 may be recruited through binding of mSin1 to phospholipids, which allows mTORC2 to 
phosphorylate Akt/PKB on the hydrophobic motif Ser473 (S473). Active Akt/PKB phosphorylates TSC2 
within the TSC1/TSC2 complex on multiple sites thereby blocking the GTPase-activating protein (GAP) 
activity in TSC2 to act towards Rheb, allowing Rheb-GTP to accumulate. Rheb-GTP activates mTORC1 
that inactivates the inhibitor of translational initiation 4E-BP1 by phosphorylation on multiple sites, and 
activates the activator of translation S6K1 by phosphorylating the hydrophobic motif Thr389 (T389). 
PDK1 then phosphorylates the activation loop of S6K1 at Thr229 (T229) leading to the full activation of 
S6K1. mTORC1 blocks autophagy by phosphorylating both ULK1 and Atg13 thereby negatively 
affecting the kinase activity of ULK1. Together this leads to increased protein synthesis and cell growth. 
Akt/PKB can also directly activate mTORC1 by phosphorylating PRAS40 that gets sequestered by 14-3-
3 proteins into the cytoplasm, thereby relieving the inhibitory constraint on mTORC1. DEPTOR is 
phosphorylated by mTOR leading to the release of DEPTOR from mTORC1 and to its degradation, thus 
further activating mTORC1 signaling. Once active, both mTORC1 and S6K1 phosphorylates IRS1 on 
multiple sites leading to the dissociation of IRS1 from the insulin receptor and to its degradation. This is 
a negative feedback mechanism in order to attenuate PI3K/Akt signaling. A second negative feedback 
loop  has  been  proposed,   where  S6K1  phosphorylates  rictor  thereby  negatively  affecting  Ser473  
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(Fig. 2 continued) 
phosphorylation and activation of Akt/PKB. 
The MAPK pathway also impinges positively on mTORC1 signaling. Both activated ERK1/2 and RSK1 
can either activate mTORC1 indirectly by phosphorylating TSC2 and inactivating the GAP activity 
towards Rheb or directly by phosphorylating raptor on multiple sites. 
To ensure that cells do not continue to grow under unfavorable conditions, as by withdrawal of glucose, 
amino acids, energy and oxygen, mTORC1 complex is rapidly inactivated by the LKB1/AMPK pathway. 
Upon LKB1- and AMP-dependent activation of AMPK, AMPK directly phosphorylates TSC2 within 
TSC1/TSC2 and activates the GAP activity of TSC2 towards Rheb, hydrolyzing Rheb-GTP to Rheb-
GDP and thus inhibiting mTORC1 signaling. mTORC1 activity can also be directly suppressed by 
AMPK-dependent phosphorylation of raptor, which results in its binding to 14-3-3 proteins. AMPK can 
also be activated by CaMKK-dependent manner due to an increase in intracellular Ca
2+
 concentration. 
RTK: receptor tyrosine kinase; InR: insulin receptor; IRS1: insulin receptor substrate 1; PI3K: 
phosphatidylinositol 3-kinase; PDK1: phosphoinositide dependent kinase 1; TSC: tuberous sclerosis 
complex; Rheb: Ras homologue enriched in brain; 4E-BP1: translation initiation factor 4E-binding 
protein 1; S6K: p70 ribosomal S6 kinase 1; ULK1: unc-51-like kinase 1; Atg13: autophagy-related gene 
13; FIP200: focal adhesion kinase family interacting protein of 200 kDa; LKB1: liver kinase B1; AMPK: 
AMP protein kinase; AMP: adenosine monophosphate; CaMKK: calcium/calmodulin-dependent protein 
kinase kinase; GRB2: growth factor receptor-bound protein 2; SOS: son-of-sevenless; NF1: 
neurofibromin; MEK: MAPK/ERK kinase; ERK: extracellular-signal related kinase; RSK1: p90 ribosomal 
S6 kinase 1. 
 
2.3 Upstream signals to mTOR complex1 
 
A plethora of signals can activate mTORC1 including nutrients, growth factors and 
cellular energy levels, while stress conditions as nutrient starvation, osmotic stress 
and hypoxia (condition of low oxygen) inactivates mTORC1. In contrary, mTORC2 is 
activated only by growth factors by an unknown mechanism. 
 
2.3.1 mTORC1 regulated by growth factors 
 
The best described pathway that activates mTORC1 is via the growth factor insulin 
(Fig. 2). Insulin binds to its cognate tyrosine kinase receptor, the insulin receptor, 
promoting the activation of the receptor and the recruitment and activation of insulin 
receptor substrate 1 (IRS1). IRS1 recruits PI3K that phosphorylates 
phosphatidylinositol (4,5)-biphosphate [PtdIns(4,5)P2] in the plasma membrane to 
phosphatidylinositol (3,4,5)-triphosphate [PtdIns(3,4,5)P3]. Both Akt/PKB and PDK1 
are then recruited to the plasma membrane through binding of their pleckstrin 
homology (PH) domains to PtdIns(3,4,5)P3. This allows Akt/PKB to be activated 
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through phosphorylation on Thr308 by PDK1 and Ser473 by mTORC2, which is 
activated by growth factors by an unknown mechanism (Manning and Cantley, 2007). 
Once active, Akt/PKB phosphorylates many downstream targets including multiple 
sites in TSC2 as Ser939, Ser1130 and Thr1462, which forms a functional complex 
with TSC1 (Manning and Cantley, 2003; Manning et al., 2002). TSC2 contains a 
GTPase-activating protein (GAP) that, when in complex with TSC1 is active and 
stimulates the intrinsic GTPase activity of the small G-protein Rheb, thereby 
promoting the conversion of GTP-bound active Rheb into its GDP-bound inactive 
state (Manning and Cantley, 2003; Tee et al., 2003). Phosphorylation of TSC2 by 
Akt/PKB impairs the ability of the TSC1/TSC2 complex to act as a GAP towards 
Rheb, allowing GTP-bound Rheb to accumulate and to activate mTORC1 (Inoki et 
al., 2003a). Akt/PKB can also activate mTORC1 directly by phosphorylating and 
relieving the inhibitory constraint of PRAS40 on mTORC1 (Sancak et al., 2007; 
Vander Haar et al., 2007; Wang et al., 2007). The inhibitory constraint exerted by 
DEPTOR on mTORC1 is relieved through phosphorylation by mTOR that eventually 
leads to the release of DEPTOR from mTORC1 and to its degradation (Peterson et 
al., 2009). Active mTORC1 phosphorylates its downstream effectors S6K1 at Thr389 
and 4E-BP1 on multiple sites (Thr37, Thr46, Ser65 and Thr70) promoting mRNA 
translation, ribosome biogenesis and protein synthesis (Burnett et al., 1998; Wang et 
al., 2005). PDK1 phosphorylates phospho Thr389-primed S6K1 on Thr229 in a 
reaction independent of PDK1 binding to PtdIns(3,4,5)P3 leading to the full activation 
of S6K1 (Manning and Cantley, 2007). A negative feedback loop exists to attenuate 
the PI3K-Akt/PKB-mTORC1 signaling that involves phosphorylation of IRS1 by active 
S6K1 and mTORC1 on Ser302 and Ser636/Ser639, respectively (Harrington et al., 
2004; Tzatsos and Kandror, 2006). Phosphorylated IRS1 is impaired to associate 
with the insulin receptor and is targeted for proteosomal degradation leading to the 
inability of insulin to activate PI3K and Akt/PKB (Harrington et al., 2004; Harrington et 
al., 2005; Manning, 2004; Tzatsos and Kandror, 2006).  
 
Recently, another S6K1-mediated feedback mechanism has been identified that 
does not involve IRS1. S6K1 phosphorylates the mTORC2 component rictor on 
Thr1135 in a rapamycin-sensitive manner and thereby negatively regulating Akt/PKB 
phosphorylation and activation (Dibble et al., 2009; Julien et al., 2010) (Fig. 2). 
However, this mechanism needs still verification, because a recent report 
demonstrated that phosphorylation of rictor on Thr1135 does not attenuate Akt/PKB 
phosphorylation (Treins et al., 2010). Furthermore, the physiological importance of 
rictor phosphorylation is also unclear, inasmuch as Thr1135 phosphorylation does 
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neither affect mTORC2 assembly nor alter mTORC2 kinase activity (Dibble et al., 
2009; Julien et al., 2010). 
 
In addition to the above described PI3K-Akt/PKB pathway, activation of the 
Ras/MAPK (mitogen-activated protein kinase) pathway also leads to mTORC1 
activation (Fig. 2). Growth factor activated receptor tyrosine kinase (RTK) recruits 
GRB2 (growth factor receptor-bound protein 2) followed by the recruitment of the Ras 
GEF (guanine nucleotide-exchange factor) son-of-sevenless (SOS) that activates 
Ras promoting a signaling cascade via Raf towards MEK1/2 (MAPK / ERK kinase) 
stimulating ERK1/2 (extracellular-signal related kinases 1 and 2, also referred as 
MAPK1/2) (Shaw and Cantley, 2006). Activated ERK interacts with and directly 
phosphorylates TSC2 at Ser664 leading to the disruption of the TSC1/TSC2 complex 
and therefore to the activation of mTORC1 signaling (Ma et al., 2005). The ERK1/2 
substrate RSK1 (p90 ribosomal S6 kinase 1) also signals to the mTORC1 pathway 
by relieving the inhibitory effect of TSC1/TSC2 complex on mTORC1 by 
phosphorylating TSC2 at Ser1798 (Roux et al., 2004). Both ERK1/2 and RSK1 can 
also directly target mTORC1 by phosphorylating raptor on multiple sites, including 
Ser8, Ser696, Ser855 and Ser863 by ERK1/2 and on Ser719, Ser721 and Ser722 by 
RSK1 (Carriere et al., 2008; Carriere et al., 2011; Langlais et al., 2011). Raptor 
phosphorylation positively stimulates mTORC1 activity to its downstream effectors 
without influencing the association of raptor with mTOR or its substrates S6K1 and 
4E-BP1 (Carriere et al., 2008; Carriere et al., 2011). 
Interstingly, Ser863 on raptor has been reported to be phosphorylated by mTOR 
following insulin stimulation or under conditions of Rheb overexpression (Foster et 
al., 2010; Wang et al., 2009), which renders mTORC1 activity insensitive to serum 
and nutrient starvation (Long et al., 2005a; Long et al., 2005b). Together this 
suggests that the MAPK pathway and the PI3K-Akt/PKB synergize at the level of 
raptor phosphorylation to activate mTORC1 signaling and that MAPK pathway can 
independently of the PI3K-Akt/PKB pathway activate mTORC1 activity. Moreover, 
raptor, besides to its role in substrate binding seems to be an important integration 




2.3.2 mTORC1 regulated by energy status 
 
Information regarding the intracellular energy and oxygen status of the cell is also 
sensed by mTORC1. In cases of stress such as energy depletion and hypoxia 
LKB1/AMPK pathway inhibits mTORC1 activity and cell growth (Fig. 2). LKB1 (liver 
kinase B1) is a key upstream activator of AMPK (adenosine monophosphate-
activated protein kinase). LKB1 exists as a heterotrimeric protein complex with 
STRAD (STE20-related adaptor) and MO25 (mouse protein 25), two regulatory 
subunits required for the kinase activity of LKB1 (Shackelford and Shaw, 2009). 
Similar to LKB1, AMPK is a heterotrimer composed of a catalytic subunit (AMPKα) 
and two regulatory subunits (AMPKβ and AMPKγ) (Shackelford and Shaw, 2009). 
When the intracellular ratio AMP/ATP is high either due to an excessive ATP 
consumption or reduced aerobic ATP production, in case of hypoxia, AMP is bound 
by AMPKγ promoting the phosphorylation of AMPKα at Thr172 by LKB1 and thus 
activating AMPK (Shackelford and Shaw, 2009). Active AMPK directly 
phosphorylates TSC2 on Thr1227 and Ser1345 and activates the TSC1/TSC2 
complex (Inoki et al., 2003b). As a result of TSC1/TSC2 activation GTP-bound Rheb 
is converted to the inactive GDP-bound Rheb resulting in the inhibition of mTORC1 
signaling (Inoki et al., 2003b). Intriguingly, active AMPK can, independent of 
TSC1/TSC2 complex, directly block mTORC1 activity by phosphorylating raptor on 
two serines, Ser722 and Ser792 (Gwinn et al., 2008), which results in raptor binding 
to 14-3-3 and suppression of mTORC1 kinase activity (Gwinn et al., 2008). AMPK 
can also, independent of LKB1, be phosphorylated and activated by 
calcium/calmodulin-dependent protein kinase kinase (CaMKK), which is triggered 
through influx of calcium (van Veelen et al., 2011). The role of AMPK is to restore the 
cellular energy balance. Consistently, AMPK activation induces relocalization of the 
glucose importer GLUT4 to the plasma membrane of muscle cells to internalize 
glucose in order to gain energy through glycolysis (Hardie, 2007; van Veelen et al., 
2011). Moreover, AMPK phosphorylates several targets to enhance energy-




2.3.3 mTORC1 regulated by amino acids 
 
The components of the insulin/growth factor-mediated activation of mTORC1 are well 
characterized, while the elements mediating the nutrient input to mTORC1 have just 
started to be unraveled. Nutrients, such as amino acids, positively regulate mTORC1 
activity and signaling. In the absence of amino acids the two best-characterized 
mTORC1 substrates, S6K1 and 4E-BP1, are rapidly dephosphorylated (Hara et al., 
1998; Wang et al., 1998) due to the action of the protein phosphatase 2A (PP2A) 
(Peterson et al., 1999). Interestingly, amino acid-mediated activation of mTORC1 is 
dominant over the growth factor stimulated pathway (Hara et al., 1998), because in 
the absence of amino acids insulin treatment alone is insufficient to drive S6K1 and 
4E-BP1 phosphorylation (Hara et al., 1998). The amino acid-sensing pathway to 
mTORC1 is distinct from that controlled by the growth factor-PI3K-Akt/PKB pathway. 
In agreement, it has been previously demonstrated that amino acids act on mTORC1 
independent of the TSC1/TSC2 complex, as amino acid depletion can still inhibit 
mTORC1-mediated S6K1 phosphorylation in the absence of TSC2 (Nobukuni et al., 
2005; Roccio et al., 2006; Smith et al., 2005). However, Rheb is absolutely required 
in the amino acid-mediated activation of mTORC1, inasmuch as in the absence of 
Rheb amino acid stimulation is ineffective in stimulating mTORC1 signaling (Sancak 
et al., 2010; Sancak et al., 2008). On the other hand, overexpression of Rheb 
overcomes the inhibitory constraint of amino acid withdrawal on mTORC1 activation 
(Long et al., 2005a; Long et al., 2005b). Nevertheless, Rheb does not activate 
mTORC1 signaling by altering the intracellular amino acid levels, because Rheb 
does not influence the uptake of amino acids or glucose (Hall et al., 2007). Moreover, 
depletion of Rheb or TOR has been demonstrated to decrease the rates of protein 
synthesis and ribosome production without altering the rates of amino acid import 
(Hall et al., 2007). Instead, Rheb activates mTORC1 through a direct association with 
the catalytic domain of mTOR in an amino acid-dependent manner (Long et al., 
2005a). Interestingly, the ability of Rheb to associate with mTOR is not dependent on 
GTP loading (Long et al., 2005a; Long et al., 2005b). In contrast, guanyl nucleotide 
deficient Rheb mutant binds mTOR more tightly than wild type Rheb (Long et al., 
2005a; Long et al., 2005b). Nevertheless, mTOR kinase activity is positively affected 
only by GTP-charged Rheb (Long et al., 2005a; Long et al., 2005b). Even though 
Rheb GTP loading is not affected by amino acid withdrawal, amino acid withdrawal 
inhibits the interaction between Rheb and mTOR (Long et al., 2005b). Consistently, 
upon amino acid stimulation mTORC1 has been demonstrated to translocate to 
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Rheb-positive late endosomes/lysosomes thereby facilitating the interaction between 
mTOR and Rheb and thereby activating mTORC1 (Sancak et al., 2010; Sancak et 
al., 2008). 
 
Less is know about the GEF regulating the conversion of Rheb-GDP to Rheb-GTP. 
In Drosophila TCTP (translationally controlled tumor protein) has been found to be a 
GEF for Rheb (Hsu et al., 2007). However, follow up studies in mammalian cells 
revealed that reducing TCTP expression does not affect mTORC1 signaling in 
response to amino acid or insulin treatment (Rehmann et al., 2008; Wang et al., 
2008b). The GDP/GTP ratio of Rheb bound nucleotide does not change in response 
to insulin in TCTP knockdown cells compared to control cells (Rehmann et al., 2008). 
Additionally, overexpresison of TCTP does not rescue mTORC1 signaling in amino 
acid-depleted cells (Wang et al., 2008b), and MEFs from TCTP null mice show 
normal mTORC1 activation upon serum stimulation (Chen et al., 2007). Together, 
this suggests that, at least in mammals, TCTP is unlikely a GEF for Rheb. 
 
2.4 Intracellular amino acid sensing 
 
2.4.1 Intracellular amino acid levels modulated by amino acid 
transporters 
 
The question that has captivated many research groups in the last years is how 
amino acids regulate mTORC1 signaling. Unlike the insulin receptor that transduces 
the extracellular signal inside the cell via the PI3K/Akt pathway to mTORC1, there is 
no amino acid receptor that perceives variation in extracellular amino acid levels. 
Instead, mTORC1 senses intracellular amino acids levels (Beugnet et al., 2003; 
Christie et al., 2002). Nonetheless, extracellular amino acids modulate the levels of 
intracellular amino acids through amino acid transporters at the plasma membrane. 
In Xenopus oocytes, that are relative impermeable to amino acids and lack amino 
acid transporters, extracellular leucine is unable to stimulate mTORC1 activity 
(Christie et al., 2002). But expression of a System L amino acid transporter (also 
known as LAT1), which is a transporter for neutral amino acids such as leucine, 
enables Xenopus oocytes to respond to extracellular leucine by S6K1 
phosphorylation in a rapamycin-dependent manner (Christie et al., 2002). 
Furthermore, in mammalian cells starved for amino acids, mTORC1 signaling is 
inactive and unresponsive to insulin (Hara et al., 1998). However, treatment with 
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translation inhibitors such as cycloheximide to block protein synthesis allows insulin-
dependent activation of mTORC1 even in the absence of amino acids in the medium, 
inasmuch as protein synthesis inhibition results in an accumulation of intracellular 
amino acids allowing mTORC1 signaling (Beugnet et al., 2003).  
 
The main amino acids able to activate mTORC1 pathway are essential amino acids 
(EAA) such as leucine, tryptophan, phenylalanine and arginine (Blommaart et al., 
1995; Hara et al., 1998; Wang et al., 1998). Nonetheless, addition of EAA alone to 
amino acid starved cells has little effect in mTORC1 activation (Nicklin et al., 2009) 
(Fig. 3). Instead, EAA has to act together with the nonessential amino acid glutamine 
in a two step transport mechanism to regulate mTORC1 activity (Nicklin et al., 2009). 
First, glutamine is transported into cells through the high affinity sodium (NA+)-
dependent glutamine transporter SLC1A5, a System ASC transporter (also named 
ASCT2). Second, intracellular glutamine is used as an efflux substrate to regulate the 
uptake of extracellular leucine through the heterodimeric SLC7A5/SLC3A2 antiporter, 
a System L transporter (also named LAT1/4F2hc), which subsequently leads to 
activation of mTORC1 (Nicklin et al., 2009) (Fig. 3). Intriguingly, there are some 
tumor lines such as the breast cancer cell line MCF7 that have elevated intracellular 
glutamine levels allowing EAA alone in a one transport mechanism to activate 
mTORC1 pathway (Nicklin et al., 2009). In addition, it has been reported that in some 
tumors glutamine synthetase is overexpressed (reviewed in Nicklin et al., 2009) or 
amino acid transporters are upregulated (Fuchs and Bode, 2005; Yanagida et al., 
2001) probably to sustain the increased protein synthesis for continuous growth and 
proliferation of tumors. 
 
Together, this implies the existence of an intracellular amino acid sensor that acts 
upstream of mTORC1 (Fig. 3). However, the mode of action of this amino acid 
sensor is unknown. Candidate mediators acting downstream of amino acids have 
been identified, including Rag GTPases, p62, V-ATPase, PAT1 and PAT4, Vps34, 
the sterile 20 (STE20) family kinase mitogen-activated protein kinase kinase kinase 
kinase 3 (MAP4K3), Rab5, and Vps39. The mode of action of the potential amino 




Table 2: Proteins that might be involved in mTORC1 activation and subcellular localization by 
amino acids 
Mammals yeast Function 
TSC1/TSC2  Rheb GTPase-activating protein; no homologues in 
Saccharomyces cerevisiae  
Rheb ScRheb 
SpRhb1 
Small GTPase; activates mTORC1 through direct interaction with 
mTOR; is important for development as Rheb knockout mice are 
embryonic lethal (Goorden et al., 2011); 
Saccharomyces cerevisiae Rheb is involved in the uptake of 
arginine and lysine (Urano et al., 2000). 
Schizosaccharomyces pombe Rhb1 (Rheb homologue) is essential 
for cell growth and division (Mach et al., 2000).  
RagA/B Gtr1 Small GTP binding proteins; regulates mTORC1 activation by 
amino acids by guiding mTORC1 to the Rheb-containing 
endosomal compartment; function as a heterodimer where RagA/B 





combination is the most active. 
RagC/D Gtr2 




Rag GTPases interacting complex; anchors TORC1 to late 
endosomes/lysosomes via Rag proteins 
Vps39 / Vam6 Vps39 / Vam6 Vam6 functions as a Gtr1 GEF in Saccharomyces cerevisiae; in 
mammalian cells no Rag GEF has been found yet. 
GEF for Rab7; required for the conversion of early endosomes to 
late endosomes; deletion impairs amino acid- and insulin-
stimulated mTORC1 activity. 
V-ATPase  Localized on endosomal membranes such as lysosomes; 
hydrolysis of ATP; involved in mTORC1 activation by amino acids. 
PATs  Localized on endosomal compartment; senses amino acids 
availability to mTORC1 by an unknown mechanism. 
p62  Similar function as the Ragulator; required for the Rag-mTORC1 
interaction and directs mTORC1 to lysosomes. 
Vps34 Vps34 Class III PI3K; generates PtdIns(3)P from PtdIns; might be 
involved in the amino acid sensing through mTORC1 either acting 
as an potential amino acid signaling mediator or by regulating the 
formation of late endosomes/lysosomes, where mTORC1 can 
interact with Rheb. 
p150 / Vps15 Vps15 Ser/Thr-like kinase; Vps34 adaptor protein; localizes Vps34 to 
cellular membranes. 
MAP4K3 Ste20-related Protein kinase; signals nutrient availability to mTORC1. 
PP2AT61ε  Ser/Thr protein phosphatase; inhibits MAP4K3 by 
dephosphorylation. 
PLD  Hydrolysis of PC to PA; amino acid- and mitogenic-dependent 
activation; regulates mTORC1 signaling; involved in autophagy. 
Rab5  Early endosomal marker; constitutive active Rab5 impairs amino 
acid- and insulin-stimulated mTORC1 activity. 
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Fig. 3: Intracellular accumulation of amino 
acids positively signals to mTORC1 through a 
putative intracellular amino acid sensor. In a 
two step transport mechanism amino acids, 
especially essential amino acids such as leucine, 
are enriched intracellularly involving a System 
ASC transporter, for glutamine uptake, coupled to 
a bidirectional System L transporter. Glutamine 
(Gln) is transported through the System ASC 
transporter into cells in a Na
+
-dependent manner. 
Next glutamine is exported through the system L 
transporter in exchange for extracellular essential 
amino acids that accumulate within cells. A 
putative amino acid sensor senses intracellular 
amino acids and activates mTORC1 through an 
unknown pathway. Cells starved for glutamine 
are unable to take up essential amino acids, 
which results in the inhibition of mTORC1. Gln: 
glutamine; EAA: essential amino acids; PM: 
plasma membrane. 
 
2.4.2 mTORC1 regulated by Rag GTPases 
 
Key components in the regulation of the amino acid-dependent mTORC1 activation 
are the Ras-related small GTP-binding (Rag) proteins. Mammals express four Rag 
proteins (RagA, RagB, RagC and RagD), with high sequence similarity between 
RagA and RagB (97%) and RagC and RagD (81%) (Sekiguchi et al., 2001). The Rag 
proteins function as heterodimers, RagA or RagB dimerizes with RagC or RagD and 
unlike most Ras family GTPases, Rag proteins lack any membrane targeting 
sequences (Sekiguchi et al., 2001). Another interesting aspect is that in the 
heterodimer one Rag is GTP- and the other is GDP-charged.  
Two recent reports have provided evidence that the Rag proteins (Rag heterodimers) 
are required for amino acids to activate mTORC1 signaling in Drosophila and in 
mammalian cells (Kim et al., 2008; Sancak et al., 2008). Rag proteins interact with 
mTORC1 in an amino acid-dependent manner mediated by the interaction with raptor 
(Sancak et al., 2008). Furthermore, the GTP/GDP loading status of the Rag proteins 
is crucial for the association with mTORC1. The heterodimer with RagA/B in the GTP 
and RagC/D in the GDP form is active and strongly binds to raptor (Sancak et al., 
2008). In response to amino acid treatment GTP charging of RagA/B increases and 
concomitantly augments the association of the Rag proteins with mTORC1. 
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Moreover, in respect to the intracellular localization of mTORC1, amino acids 
treatment relocates mTORC1 from tiny puncta distributed throughout the cytoplasm 
to late endosomes/lysosomes (Sancak et al., 2008), where Rheb resides thereby 
promoting mTORC1 activation. Interestingly, depletion of either the Rag proteins or 
of raptor by RNA interference (RNAi) prevents the recruitment of mTORC1 to late 
endosomes/lysosomes in response to amino acids and strongly reduces mTORC1 
activity (Kim et al., 2008; Sancak et al., 2008). Additionally, expression of constitutive 
active RagA/B renders mTORC1 activity insensitive to amino acid starvation (Kim et 
al., 2008; Sancak et al., 2008). A direct relationship of Rag proteins and TORC1 
activation is also phenotypically visible in Drosophila, where overexpression of 
constitutive active dRagA increases cell size under starvation conditions, while 
dominant-negative dRagA decreases cell size under nutrient-rich conditions (Kim et 
al., 2008). Therefore, the Rag proteins are specifically involved in the amino acid-
dependent mTORC1 signaling pathway and the following mechanism has been 
proposed how amino acids positively regulate mTORC1 signaling (Fig. 4A). Upon 
amino acid stimulation RagA/B becomes GTP charged, promoting Rag heterodimer 
to interact with raptor and eventually recruiting mTORC1 to late 
endosomes/lysosomes, where Rheb resides thereby promoting interaction with and 
activation of mTORC1 (Sancak et al., 2008). This model explains why TSC2 
knockout MEFs, which have constitutive active Rheb, are still sensitive to amino 
acids starvation, and only by amino acid treatment mTORC1 comes together with 
Rheb on the same endosomal compartment where they can interact. 
 
Since Rag proteins lack any membrane anchoring sequences (Sekiguchi et al., 
2001), the question is how mTORC1 is targeted by the Rag proteins to endosomal 
membranes. Membrane anchorage is mediated by the Ragulator (Rag and mTORC1 
regulator), a heterotrimeric complex composed of MP1, p14 and p18 (Sancak et al., 
2010). p18 is myristoylated and palmitoylated and is localized on late 
endosomes/lysosomes (Nada et al., 2009). Moreover, p18 is the principal Rag-
binding subunit of the Ragulator (Sancak et al., 2010) thereby anchoring the Rag 
proteins on late endosomes/lysosomes. The association between Ragulator and the 
Rag proteins is constitutive, inasmuch as it is independent of the amino acid 
availability and of the GTP/GDP charged status of the Rag proteins (Sancak et al., 
2010). But Ragulator-Rag complex is an amino acid-regulated docking site for 
mTORC1 on late endosomal/lysosomal membranes as upon amino acid treatment 
RagA/B is GTP loaded and binds to mTORC1 (via raptor) thereby relocalizing 
mTORC1 to Rheb-containing late endosomes/lysosomes (Sancak et al., 2010) (Fig. 
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4A). Consisting with this model, artificial targeting of raptor to late 
endosomes/lysosomes constitutively localizes mTORC1 to late 
endosomes/lysosomes and renders mTORC1 activity resistant to amino acid 
starvation and eliminates the requirement of the Ragulator-Rag complex in mTORC1 
signaling (Sancak et al., 2010). Nonetheless, mTORC1 localization alone is not 
sufficient for its activation, because deletion of Rheb expression blocks mTORC1 
activation in response to amino acids (Sancak et al., 2010).  
Interestingly, Rag GTPases homologous has been observed in yeast and, alike in 
Drosophila and mammalian cells, they function in the amino acid-dependent TORC1 
activation (Binda et al., 2009). Gtr1 is homologous to RagA/B and Gtr2 to RagC/D, 
and the heterodimer is active when Gtr1 is GTP- and Gtr2 is GDP-loaded. Alike 
RagA/B, Gtr1 interacts with and activates TORC1 in an amino acid-sensitive manner, 
and Gtr1 in its GTP-charged form can physically interact to TORC1 (Binda et al., 
2009). TORC1 and the Gtr proteins localize on the vacuolar membrane, the yeast 
equivalent of lysosomes (Binda et al., 2009). Homologous of the Ragulator subunits 
have not been found in yeast, but the mammalian Ragulator-Rag complex may be 
functionally similar to the yeast EGO (exit from growth arrest) complex. The EGO 
complex consists of Ego1, Ego3, Gtr1 and Gtr2, and like p18 in mammalian cells, 
Ego1 is myristoylated and targets the EGO complex to the vacuole (De Virgilio and 
Loewith, 2006). Moreover, Ego3 displays structural conservation to MP1 and p14 
(Kogan et al., 2010) indicating Ego1 and Ego3 being the potential yeast Ragulator. 
Despite these similarities, TOR1 localization is not dependent on amino acid 
availability, inasmuch as leucine deprivation does not alter the localization of TOR1, 
Gtr1 or Ego1, even though amino acids control the association of TORC1 with Gtr1 
(Binda et al., 2009). Nonetheless, structural conservation of TOR membrane-
targeting constituents between yeast and mammalian cells suggests a common 
mechanism for sensing and signaling amino acids availability to TORC1.  
In response to amino acid stimulation RagA/B is GTP charged but a Rag GEF has 
not been found yet. However, a good candidate is found in Saccharomyces 
cerevisiae where Vps39 (vacuolar protein sorting 39; also named Vam6) has been 
found to be the GEF for Gtr1p (Binda et al., 2009). The mammalian Vps39 seems not 
to act as a Rag GEF, although knockdown of Vps39 reduces mTORC1 activity (Flinn 






Fig. 4: Amino acid-induced mTORC1 activation via Rag GTPases (two complexes are proposed). 





 heterodimer is localized on the late endosome/lysosome, while mTORC1 is 




 heterodimer is formed and raptor 
binds to RagA/B
GTP
 thereby guiding mTORC1 from an unknown cellular compartment to the late 
endosomal/lysosomal membrane, where mTORC1 interacts with Rheb and promotes mTORC1 
activation and signaling. (B) A distinct complex composed of p62 and Rag heterodimer recruits 
mTORC1 to late endosomes/lysosomes by amino acid treatment in an analogous manner as the 
Ragulator-Rag complex, resulting in the association between Rheb and mTORC1 and eventually to the 
activation of mTORC1. 
 
A distinct complex consisting of p62 and the Rag proteins has been recently reported 
to recruit mTORC1 to the late endosome/lysosome in response to amino acids 
without the involvement of the Ragulator (Duran et al., 2011) (Fig. 4B). p62 is an 
adaptor protein that interacts with different signaling proteins to regulate cellular 
functions (reviewed in Duran et al., 2011). Here, p62 specifically associates with 
mTORC1, but not mTORC2, through its interaction with raptor and is selectively 
required for mTORC1 activation in response to amino acid but not to insulin 
treatment (Duran et al., 2011). Moreover, p62 selectively interacts with RagC/D but 
not with RagA/B (Duran et al., 2011). Like raptor, p62 preferentially interacts with 
active RagA/BGTP-RagC/DGDP heterodimer, while interaction with one of the Ragulator 
components (p18, p14, MP1) has not been observed. Overexpression of p62 
promotes GTP-loading of RagB in amino acid starved cells thus mimicking amino 
acid stimulation (Duran et al., 2011). Interestingly, p62 and RagC colocalizes on late 
endosomes/lysosomes membranes independently of amino acid availability (Duran 
et al., 2011), which is reminiscent of the localization of the Ragulator and Rag 
proteins (Sancak et al., 2010). Consistently, amino acid stimulation leads to the 
translocation of mTORC1 to p62 containing late endosomes/lysosomes, while in p62 
deficient cells late endosomes/lysosomes localization of mTORC1 is abrogated 
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(Duran et al., 2011). Therefore, p62 promotes the formation of an active Rag 
complex to induce Rag-mTORC1 interactions and translocation of mTORC1 to late 
endosomes/lysosomes. Consequently, p62 provides a second docking site for 
mTORC1 activation. However, it is unclear what the cellular purpose is to have two 
distinct complexes (p62/Rags vs. Ragulator/Rags) with apparently similar functions.  
There are several open questions as how do Rag GTPases sense amino acid 
availability within a cell and how are they GTP and GDP loaded? Is there a 
mammalian Rag GTPase GEF that is activated by amino acid sufficiency? 
Conversely, is there a Rag GTPase GAP that switch off the amino acid signal? 
 
Recently, the activity of vacuolar H+-adenosine triphosphatase ATPase (V-ATPase) 
has been found to be necessary for mTORC1 activation by amino acids (Zoncu et al., 
2011). Inhibition of the V-ATPase, either by pharmacological inhibition or gene 
silencing, prevents amino acid-induced mTORC1 translocation onto lysosomes and 
activation of mTORC1 signaling. However, the overexpression of GTP-charged RagB 
can bypass the need of V-ATPase function. Therefore, the author placed V-ATPase 
downstream of amino acids but upstream of Rag proteins (Zoncu et al., 2011). But 
how mechanistically V-ATPase can activate mTORC1 is not known. V-ATPase 
physically interacts with Ragulator and Rag GTPases and amino acid stimulation 
induces a structural rearrangement of the V-ATPase-Ragulator-Rag complex that 
somehow activates mTORC1. Furthermore, the authors claim that sensing of 
intralysosomally accumulated amino acids initiates signaling to mTORC1, inasmuch 
as overexpression of PAT1 (proton-assisted amino acid transporter 1; a lysosomal 
localized symporter of amino acids and protons) (Boll et al., 2004), or permeabilized 
lysosomal membrane empties the lysosomes of amino acids and blocks mTORC1 
activity (Zoncu et al., 2011). How exactly amino acids within the lysosomal lumen are 
sensed is not known, but a good candidate could be the PATs by themselves. PAT1 
and PAT4 have recently been demonstrated to be indispensable in amino acid 
induced mTORC1 activation. Interestingly, the effect of PATs has not been 
dependent on their ability to shuttle amino acids (Heublein et al., 2010). The ability of 
the PATs to sense amino acids is probably due to their endosomal localization but 
how they mechanistically do it is not known. Alternatively, they may facilitate amino 
acid transport across endomembranes where mTORC1 resides in order to directly 




2.4.3 mTORC1 regulated by Vps34 
 
Vps34 (vacuolar protein sorting 34) has been originally identified in Saccharomyces 
cerevisiae as a protein involved in the transport of newly synthesized soluble 
hydrolases from the Golgi to the lysosome-like vacuole (Herman and Emr, 1990). 
Mammalian Vps34 has been cloned and shown to be ubiquitously expressed (Volinia 
et al., 1995). Vps34 exclusively phosphorylates phosphatidylinositol (PtdIns) to 
generated phosphatidylinositol 3-phosphate [PtdIns(3)P]. In both yeast and 
mammals, Vps34 exists in a complex with Vps15 (in mammals also named p150), a 
N-terminal myristoylated Ser/Thr-like protein kinase (Stack et al., 1993; Volinia et al., 
1995). Due to this myristoylation moiety in Vps15, Vps34 is targeted to cellular 
membranes where PtdIns resides (Christoforidis et al., 1999; Murray et al., 2002; 
Stack et al., 1993; Stein et al., 2003). Additionally, Vps15 serves to regulate the lipid 
kinase activity of Vps34 in yeast and probably also in mammals (Panaretou et al., 
1997; Petiot et al., 2000; Stack et al., 1993).  
In addition to play a role in vesicular trafficking, Vps34 has been shown to be 
required for the initiation of the autophagic pathway (Simonsen and Tooze, 2009) 
and it has been proposed to mediate the amino acid signal to mTORC1 (Byfield et 
al., 2005; Nobukuni et al., 2005). Deletion of Vps34 by small interference RNA 
(siRNA) blocks amino acid- and insulin-stimulated mTORC1 activation, whereas 
insulin-stimulated Akt/PKB phosphorylation on Ser473 is not affected (Byfield et al., 
2005; Nobukuni et al., 2005). In the presence of amino acids, overexpression of 
epitope-tagged Vps34 leads to a marked increase in mTORC1 activity compared to 
control cells (Nobukuni et al., 2005). Sequester of the Vps34 lipid product PtdIns(3)P 
by ectopic expression of a tandem FYVE domain (from Fab1p, YOTB, Vac1p, EEA1 
(early endosomal antigen 1)) reduces amino acid-induced mTORC1 activation 
(Nobukuni et al., 2005). Moreover, amino acid treatment of starved cells leads to an 
increase in Vps34 activity and in intracellular PtdIns(3)Ps (Nobukuni et al., 2005) 
further underscoring the link between Vps34 and mTORC1 in the amino acid-
dependent pathway. Furthermore, a mechanism has been proposed how 
extracellular amino acids can regulate Vps34 activity in a Ca2+-dependent manner 
(Gulati et al., 2008). Amino acids induce an extracellular Ca2+ influx into the cell 
inducing Ca2+/calmodulin (CaM) complex formation. Ca2+/CaM binds to and activates 
Vps34 leading to increased PtdIns(3)P generation and eventually to mTORC1 
activation (Gulati et al., 2008). However, there are several concerns in presenting 
Vps34 as an amino acids sensor towards mTORC1. (1) Yan et al. (2009) questioned 
the Ca2+ mechanism (Gulati et al., 2008) by demonstrating that Vps34 activity is not 
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affected by Ca2+ chelators or CaM inhibitors (Yan et al., 2009). (2) Overexpression of 
hVps34 increases mTORC1 activity only in the presence, but not in the absence of 
amino acids (Nobukuni et al., 2005). Overexpression of kinase inactive version of 
Vps34 has never been analyzed in order to determine whether the increase of 
mTORC1 activity was due to Vps34 kinase activity or just an off-target effect. (3) 
Increased PtdIns(3)P levels due to amino acid stimulation have not been quantified. 
(4) In mammalian C2C12 cells, amino acid treatment appears to inhibit rather than to 
activate Vps34 (Tassa et al., 2003). (5) In yeast, Vps34 mutants (severe defects in 
vacuolar protein sorting, temperature-sensitive growth defect, defect in 
osmoregulation and in vacuole segregation during mitosis) do not recapitulate the 
phenotypes of TOR1 and TOR2 mutants (cell cycle arrest in G1) (Barbet et al., 1996; 
Herman and Emr, 1990). (6) In a Drosophila study, Vps34 loss-of-function mutants 
display disrupted autophagy and endocytosis but TORC1 signaling pathway is not 
affected (Juhasz et al., 2008).  
Recently, Vps34 knockout mice have been generated showing that they die between 
E7.5 and E8.5 of embryogenesis (Zhou et al., 2011). Vps34 mutant embryos have 
reduced proliferation and drastically decreased mTORC1 activity, determined by the 
phosphorylation of ribosomal S6, the downstream target of S6K1 (Zhou et al., 2011). 
Decreased mTORC1 activity signifies reduced availability of amino acids. It is known 
that during early stages of development the embryo is dependent on amino acids and 
glucose (Martin and Sutherland, 2001), and the period just before implantation of the 
embryo into the uterus, amino acid uptake is inhibited (reviewed in Martin and 
Sutherland, 2001). Therefore, the only way to acquire amino acids is through 
catabolic processes such as autophagy. During autophagy proteins and organelles 
are sequestered into autophagosomes that deliver their content to lysosomes for 
degradation into amino acids to be re-used for protein synthesis and ATP generation. 
Vps34 is involved in both the autophagic process and vesicular trafficking to 
lysosomes (Simonsen and Tooze, 2009). Consequently, it might be possible that the 
phospho-S6 phenotype in Vps34 mutant embryos (Zhou et al., 2011) is rather a 
consequence of nutrient shortage due to disrupted autophagy and vesicular 
trafficking than a direct involvement of Vps34 on mTORC1. Mice have been 
generated where Vps34 was conditionally deleted in postmitotic sensory neurons 
(Zhou et al., 2010). These Vps34-deleted neurons have been demonstrated to 
accumulate ubiquitin-positive aggregates and enlarged vesicles (Zhou et al., 2010), 





2.4.4 mTORC1 regulated by MAP4K3 
 
MAP4K3 is another possible mediator of the amino acid-induced mTORC1 activation. 
MAP4K3, a Ste20-related MAP4K3, has been identified in a screen of Drosophila 
protein kinases required for signaling to dS6K (Findlay et al., 2007). Overexpression 
of MAP4K3 activates mTORC1 in serum-starved cells leading to the phosphorylation 
of S6K1 and 4E-BP1, while depletion of MAP4K3 by siRNA suppresses mTORC1 
activity induced by amino acid stimulation. Moreover, activity of MAP4K3 per se is 
regulated by amino acid sufficiency but not by insulin stimulation or rapamycin 
treatment, placing MAP4K3 downstream of amino acids but upstream of mTORC1 
(Findlay et al., 2007). Ser170 in the kinase domain of MAP4K3 has been identified to 
be critical for kinase activity (Yan et al., 2010). Depriving cells of amino acids inhibits 
MAP4K3 Ser170 phosphorlyation, while amino acids addition reversed the response. 
Importantly, insulin has no effect on Ser170 phosphorylation. Moreover, mutation of 
Ser170 to alanine abolishes MAP4K3 activity and blocks mTORC1-mediated 
phosphorylation of S6K1 in response to amino acids. Ser170 phosphorylation is 
transphosphorylated by another MAP4K3, whereas dephosphorylation is mediated 
by the Ser/Thr phosphatase PP2AT61ε. In response to amino acid withdrawal, the 
regulatory/targeting subunit PR61ε of PP2AT61ε associates with MAP4K3 thereby 
recruiting MAP4K3 to PP2AT61ε leading to a rapid Ser170 dephosphorylation and 
suppression of mTORC1 activity (Yan et al., 2010). A model has been proposed that 
upon amino acid withdrawal, PP2AT61ε associates with MAP4K3 and 
dephosphorylates Ser170 therefore inactivating MAP4K3 and signaling to mTORC1 
(Yan et al., 2010). Interestingly, the ability of MAP4K3 to activate mTORC1 is 
impaired when RagC and RagD are suppressed (Yan et al., 2010) indicating that 
either MAP4K3 lies downstream of the Rag proteins or MAP4K3 is not the major 
regulator of the amino acid input to mTORC1.  
 
2.4.5 mTORC1 regulated by phospholipase D (PLD) and 
phosphatidic acid (PA) 
 
mTORC1 can also be activated by phosphatidic acid (PA) generated through the 
hydrolysis of phosphatidylcholine catalyzed by phospholipase D (PLD). 
Overexpression of PLD1 activates mTORC1, while PLD1 knockdown blocks 
mitogenic activation of mTORC1 signaling (Fang et al., 2003). Similarly, exogenous 
added PA to serum-starved cells stimulates mTORC1 activity in a rapamycin-
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dependent manner, whereas inhibition of cellular PA accumulation by 1-butanol 
treatment reduces serum-stimulated mTORC1 activity (Fang et al., 2001). 
Interestingly, the stimulatory effect of PA is absent in cells deprived of amino acids 
(Fang et al., 2001), indicating that an amino acid signal is required for the action of 
PA. PA regulates mTORC1 through a direct interaction with the FRB domain of 
mTOR and competes with the FKBP12-rapamycin complex for binding to mTOR 
(Fang et al., 2001). Consistently, elevated cellular PA levels render cells less 
sensitive to rapamycin (Chen et al., 2003). Mutational analysis has demonstrated that 
Arg2109 in the mTOR FRB domain is critical for the interaction with PA. Because the 
catalytic activity of mTOR is not affect by PA stimulation or by disrupting PA binding 
(Fang et al., 2001), it is not known how PA mechanistically activates mTORC1 
signaling. But, it has been reported that Rheb interacts with and activates PLD1 in a 
GTP-dependent manner (Sun et al., 2008) generating PA that binds to and activates 
mTORC1. The production of PA by Rheb-meditated activation of PLD1 is therefore 
an additional mode of how Rheb can regulate mTORC1, besides its direct interaction 
with mTOR (Long et al., 2005a; Long et al., 2005b). Because both PLD1 and mTOR 
are localized on intracellular membranes, there is a possibility that both localize in 
close proximity. Therefore, when PLD1 is activated by Rheb, PA is produced and that 
due to its appropriate cellular localization can bind to mTOR and activate mTORC1 
kinase. Indeed, Yoon et al. has recently shown that in response to amino acids 
stimulation, PLD1 translocates from a cytoplasmic compartment to lysosomal 
membranes that is paralleled by the lysosomal translocation of mTORC1 (Yoon et 
al., 2011). Lysosomal translocation requires PtdIns(3)P generated by human Vps34 
(hVps34) (Yoon et al., 2011). Additionally, PLD1 is activated by amino acids in a 
hVps34- and PtdIns(3)P-dependent manner. Both amino acid-dependent lysosomal 
translocation and activation of PLD1 are needed to activate mTORC1. Interestingly, 
translocation of PLD1 is independent of Rag proteins, Ragulator and raptor 
suggesting that a Vps34-PLD1 pathway exists that activates mTORC1 in parallel to 
the Rag pathway (Yoon et al., 2011). Nevertheless, there are some concerns about 
the Vps34-PLD1 connection in the activation of mTORC1. Translocation and 
activation of PLD1 are supposed to be mediated by the phox (PX) homology domain 
of PLD1 through binding to PtdIns(3)P (Yoon et al., 2011). However, there is 
evidence that PX of PLD1 does not bind to PtdIns(3)P (Du et al., 2003). The isolated 
PLD1-PX domain localizes to endosomal compartments that do not colocalize with 
EEA1, a protein that binds specifically to PtdIns(3)P through its FYVE domain. 
Moreover, treatment with wortmannin does not affect PLD1-PX localization, unlike to 
p40-PX (phox domain of p40 that also specifically binds to PtdIns(3)P) that upon 
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wortmannin treatment delocalizes to the cytoplasm (Du et al., 2003). It should also be 
considered that membrane association can be mediated independently of the PX 
domain, either through the PH or a PtdIns(4,5)P2 binding motif that are found in 
PLD1 (Du et al., 2003; Frohman and Morris, 1999). In addition being activated by 
amino acids (Xu et al., 2011; Yoon et al., 2011), PLD1 activity is also enhanced by 
nutrient deprivation (Dall'Armi et al., 2010) suggesting a role of PLD1 in the 
regulation of autophagy. Indeed, PLD1-deficient MEFs or PLD1-deleted liver tissues 
exhibit defects in starvation-induced autophagy (Dall'Armi et al., 2010). PLD1 stability 
seems to be dependent on Vps34, because silencing of Vps34 dramatically 
decreases the levels of ectopically expressed and of endogenous PLD1 (Dall'Armi et 
al., 2010) explaining why in Yoon et al. PLD1 activity is Vps34 dependent (Yoon et 
al., 2011). Together, this indicates that Vps34 and PLD1 are involved in both the 
regulation of autophagy and mTORC1 signaling.  
 
2.4.6 mTORC1 regulated by endosomal trafficking 
 
There are numerous evidences connecting mTORC1 signaling with endosomes 
(Flinn et al., 2010; Hennig et al., 2006; Sancak et al., 2010; Sancak et al., 2008; 
Takahashi et al., 2012), thereby indicating that vesicular trafficking might be 
important for proper mTORC1 activation. In fact, constitutive active Rab5 (meaning 
GTP-charged Rab5), a small GTPase that regulates membrane transport through 
early endosomes (Callaghan et al., 1999; Simonsen et al., 1998), inhibits insulin- and 
amino acids-dependent mTORC1 activation (Flinn et al., 2010; Li et al., 2010), while 
the insulin-stimulated Akt/PKB activation (phosphorylation on Thr308) is not affected 
(Flinn et al., 2010) excluding a block in the growth factor signaling. In addition, 
overexpression of Gapex-5, a GEF for Rab5, blocks amino acid-mediated mTORC1 
activation further supporting a role of Rab5 in mTORC1 regulation (Li et al., 2010). 
The effect of Rab5 is specific on mTORC1, because in resting cells constitutive 
active Rab5 does not affect mTORC2-mediated Akt/PKB Ser473 phosphorylation, 
while mTORC1-mediated S6K1 Thr389 phosphorylation is blocked (Li et al., 2010). 
Interestingly, constitutive active Rab5 blocks mTORC1 signaling induced by 
constitutive active RagA in the presence and in the absence of amino acids (Li et al., 
2010), while it does not block mTORC1 activity induced by Rheb overexpression 
(Flinn et al., 2010; Li et al., 2010) most likely due to the mislocalization of 
overexpressed Rheb to other mTOR-containing compartments.  
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In cells, early endosomes (Rab5 positive) are converted into late endosomes (Rab7 
positive). This maturation process is referred to as Rab5-to-Rab7 conversion, 
because Rab5 is replaced by Rab7 on the same endosome (Rink et al., 2005). This 
Rab5-to-Rab7 conversion can be blocked by constitutive active Rab5 thereby 
forming a Rab5/Rab7 hybrid endosome (Flinn et al., 2010; Rink et al., 2005). Similar 
to the constitutive active Rab5 phenotype, knockdown of Vps39 blocks Rab5-to-Rab7 
conversion (Flinn et al., 2010; Rink et al., 2005) and inhibits mTORC1 activation in 
response to insulin stimulation (Flinn et al., 2010). Vps39 has GEF activity toward 
Rab7 (Rink et al., 2005; Wurmser et al., 2000) and is a subunit of the class C 
VPS/HOPS (homotypic fusion and protein sorting) complex that is necessary to elicit 
Rab5-to-Rab7 conversion (Rink et al., 2005). The Rab5-to-Rab7 conversion is a 
sequential and complicated processes simplified as follows: The class C VPS/HOPS 
complex and Rab7-GDP are recruited by Rab5-GTP to the early endosome (Rink et 
al., 2005) thereby forming a hybrid endosome containing both Rab5 and Rab7. 
Vps39 subunit of the class C VPS/HOPS complex activates Rab7 to the GTP form 
(Rink et al., 2005; Wurmser et al., 2000), Rab5 is then converted to the inactive GDP 
form and displaced from the hybrid endosome thereby creating a late endosome (Fig. 
5). Constitutive active Rab5 or deletion of Vps39 leads to the formation of a hybrid 
Rab5/Rab7 positive endosome (Flinn et al., 2010; Rink et al., 2005) that is unable to 
proceed to a late endosome, where mTORC1 should interact with Rheb upon amino 
acid stimulation (Fig. 5). Therefore, it is possible that the formation of late endosomes 
is a prerequisite for amino acid- and insulin-dependent mTORC1 activation, as it is 
the place where the Ragulator-Rag-mTORC1 complex is assembled. Therefore, 
Vps39, Rab5 and Rab7 are more likely involved in the progression from early to late 
endosomes, rather than being engaged in nutrient signaling to mTORC1. With this in 
mind, Vps34 might also participate in the same endosomal processing as it controls 
vesicular transport (Stack et al., 1995) and therefore affecting mTORC1 signaling 
indirectly. 
If late endosomes function as a “signaling platform” for mTORC1, how can then 
mTORC1 regulatory proteins such as Rheb, Ragulator/Rag proteins recognize late 
endosomes among the plethora of different organelles within a cell? Can they sense 
differences in intraluminal pH value between early and late endosomes? Or can they 
recognize different lipid compositions on the endosomal membrane? 
 
Alike Rab5-to-Rab7 conversion, the PtdIns(3)P-to-PtdIns(3,5)P2 conversion plays an 
indisputable role in the early to late endosome conversion. PtdIns(3)P and 
PtdIns(3,5)P2 are two phospholipids that contribute to the identity of early and late 
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endosomes. PtdIns(3)P is mostly found on early endosomal membranes and 
synthesized by Vps34 (Schu et al., 1993), while PtdIns(3,5)P2 is generated by the 
PtdIns(3)P 5-kinase PIKfyve (Fab1 in yeast) on cellular membranes as late 
endosomes and multivesicular bodies (MVBs) (Michell et al., 2006; Vicinanza et al., 
2008). It is possible that PIKfyve might also be involved in the maturation process, as 
PIKfyve dysfunction impairs normal endosomal processing (Shisheva, 2008). 
Therefore, PIKfyve could impinge on the mTORC1 late endosomal localization and 
signaling. So far, there is no data available dealing with an involvement of PIKfyve, 
directly or indirectly, in the mTORC1 signaling pathway and it would be of great 




Fig. 5: Continuous endosomal transport/maturation required to set up an amino acid signaling 
platform on late endosomes for mTORC1 localization and signaling (hypothetical). During 
maturation from early to late endosomes, Rab5 is substituted for Rab7. An early endosome is defined 
through the associated components such as Rab5 and the phosphoinositide PtdIns(3)P generated by 
the early endosomal localized Vps34, while late endosomes contain Rab7. The formation of a late 
endosome is likely preceded by the transiently formed hybrid Rab5/Rab7 endosome. Rab5-GTP recruits 
Rab7-GDP and the class C Vps/HOPS complex to the early endosome thereby forming the hybrid 
endosome (Rink et al., 2005). The class C Vps/HOPS complex subunit Vps39 (also named Vam6) has 
GEF activity towards Rab7 and activates it to the GTP form (Rink et al., 2005; Wurmser et al., 2000), 
while Rab5 is converted to the inactive GDP form and removed from the hybrid endosome leading to the 
formation of a late endosome, where Ragulator (p18-p14-MP1)-Rag complex can be assembled in order 
to recruit mTORC1 upon amino acid stimulation. Rab5-to-Rab7 conversion is paralleled by the 
PtdIns(3)P-to-PtdIns(3,5)P2  conversion  implicating  PIKfyve in the  conversion process as  it  generates 
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(Fig. 5 continued) 
PtdIns(3,5)P2 from PtdIns(3)P. Vps34 is found on both early and late endosomes, where it generates 
PtdIns(3)P that serves first in the recruitment of PIKfyve to late endosomes and probably also to the 
hybrid endosome via its FYVE domain and second as substrate for the generation of PtdIns(3,5)P2. 
Maturation of an early endosome to a late endosome can be blocked at the hybrid endosome level by 
overexpressing Rab5-GTP that impedes Rab5 to be removed, or by Vps39 deletion that keeps Rab7 in 
its inactive state. Together, this hinders the hybrid endosome to proceed to a late endosome and most 
probably the Ragulator-Rag complex to be assembled and eventually blocking mTORC1 activation. 
Hypothetically, pharmacological inhibition of PIKfyve by YM201636 treatment should also block early to 
late endosome maturation at the hybrid endosome stage. 




Amino acid-induced activation of mTORC1 is a hot topic research field at the 
moment. As outlined above many molecules that transmit the amino acid signal to 
mTORC1 have been identified. Moreover, mTORC1 regulation has been linked to 
endosomal compartments. Consistently, PtdIns(3)P, which is predominantly found on 
early endosomes, has been proposed to be implicated in mTORC1 signaling. 
However, PtdIns(3,5)P2 that is found on late endosomes, the compartment where 
mTORC1 interacts with Rheb, has not been ascribed a regulatory role to mTORC1 
yet. Figure 5 shows a hypothetical connection between mTORC1 and PtdIns(3,5)P2 
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The components involved in the growth factor-induced signaling pathway to 
mTORC1 are well-characterized, while the ones in the amino acid pathway have only 
recently started to be uncovered. The importance of amino acids in regulating 
mTORC1 has been substantiated by the fact that in cells deprived of amino acids, 
growth factor stimulation cannot induce mTORC1 activation (Hara et al., 1998). It is 
unclear how mammalian cells perceive variation of intracellular amino acid 
concentrations, determined by the extracellular amino acid supply and by rates of 
protein synthesis and degradation. But recently different molecules have been 
identified mediating the amino acid signal to mTORC1, including the Rag GTPases, 
MAP4K3 and hVps34 with its lipid product PtdIns(3)P (Byfield et al., 2005; Findlay et 
al., 2007; Nobukuni et al., 2005; Sancak et al., 2010; Sancak et al., 2008; Yan et al., 
2010). To our opinion the involvement of hVps34 in the amino acid sensing pathway 
to mTORC1 is controversial.  
 
Therefore as a first aim we re-analyzed the connection between hVps34 and 
mTORC1 by examining the effect of either ectopic expression of wild type and 
kinase-dead hVps34, or RNAi-induced deletion of hVps34 on amino acid-induced 
mTORC1 signaling. We could show that independently of the catalytic activity of 
hVps34 overexpression had no effect, while hVps34 deletion only partially affected 
mTORC1 activity, which is consistent with the observed PtdIns(3)P generation.  
 
Since both class II PI3K isoforms PI3K-C2α and PI3K-C2β have been shown to form 
PtdIns(3)P in vivo (Falasca and Maffucci, 2007; Maffucci et al., 2005) we aimed to 
investigate their role in mTORC1 signaling by RNAi knockdown. Surprisingly, while 
PI3K-C2α knockdown increased mTORC1 activity, PI3K-C2β caused only a modest 
decrease in mTORC1 activation. 
 
PtdIns(3)P has been proposed to be involved in mTORC1 regulation (Byfield et al., 
2005; Nobukuni et al., 2005). Despite targeting PtdIns(3)P-generating enzymes we 
were not able to observe a clear cut connection to mTORC1. Therefore we attempted 
to directly affecting intracellular PtdIns(3)Ps by either reducing the availability of free 
PtdIns(3)P or by acutely increasing PtdIns(3)P levels, which caused a strong 




PtdIns(3)P is phosphorylated by PIKfyve to form PtdIns(3,5)P2 (Ikonomov et al., 
2001; Sbrissa et al., 1999; Shisheva et al., 2001), and both phospholipids are 
involved in endosomal membrane transports (Michell et al., 2006; Odorizzi et al., 
2000). Moreover, mTORC1 signaling seems to be coordinated at endosomal 
compartments (Flinn et al., 2010; Sancak et al., 2010; Sancak et al., 2008). 
Collectively, this would suggest a possible implication of PIKfyve and its 
PtdIns(3,5)P2 in mTORC1 signaling. Therefore we subjected PIKfyve to 
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The mammalian target of rapamycin (mTOR) serine/threonine kinase is the catalytic 
component of two functional distinct complexes, mTOR complex 1 (mTORC1) and 
mTORC2. mTORC1 integrates signals emerging from growth factors and nutrients 
such as amino acids to regulate cell proliferation and cell growth. In contrary to the 
growth factor-initiated pathway, the components of the amino acid signaling pathway 
to mTORC1 are poorly characterized and only in recent years they have started to be 
uncovered. In this study we analyzed two different phosphoinositides (PIs), 
PtdIns(3)P and PtdIns(3,5)P2, in the regulation of mTORC1 signaling in response to 
amino acid stimulation. The role of PtdIns(3)P was analyzed by targeting PtdIns(3)P-
generating enzymes, human vacuolar protein sorting 34 (hVps34) and class II 
phosphatidylinositol 3-kinase (PI3K). In contrary to previous reports, we found that 
downregulation of hVps34 does not completely blunt mTORC1 signaling and that 
overexpression of hVps34 kinase-dead mutant affects mTORC1 activation similarly 
as wild type hVps34 does. Unexpectedly, silencing of class II PI3Ks results in an 
isoform-specific activation of mTORC1 where PI3K-C2α knockdown increases, while 
PI3K-C2β knockdown modestly decreases mTORC1 activity. Nevertheless, by 
affecting PtdIns(3)P directly either by masking or by acute treatment with synthetic 
PtdIns(3)P strongly inhibits or increases mTORC1 activity, respectively. Surprisingly, 
pharmacologic inhibition of the PtdIns(3,5)P2-synthesizing enzyme PIKfyve 
decreases mTORC1 signaling that is paralleled by diminished late endosomal 
localization of mTOR.  
Our data confirm a positive role of PtdIns(3)P in the mTORC1 pathway and 
demonstrate a novel role for PIKfyve and its phospholipid PtdIns(3,5)P2 in the 
regulation of mTORC1 signaling in response to amino acids, which is consistent with 






Mammalian target of rapamycin (mTOR) is a Ser/Thr kinase playing a central role in 
the regulation of cell metabolism, growth, proliferation and survival (Corradetti and 
Guan, 2006; Guertin and Sabatini, 2007; Wullschleger et al., 2006). mTOR is found 
in two functionally distinct and independently regulated complexes, termed mTOR 
complex 1 (mTORC1) and mTORC2 (Jacinto et al., 2004; Loewith et al., 2002; 
Sarbassov et al., 2004). mTORC1 consists of mTOR, raptor, mLST8, PRAS40 and 
DEPTOR and is sensitive to rapamycin (Hara et al., 2002; Kim et al., 2002; Kim et 
al., 2003; Loewith et al., 2002; Peterson et al., 2009; Sancak et al., 2007). mTORC2 
shares mTOR, mLST8 and DEPTOR with mTORC1, while rictor, mSIN1 and Protor 
are unique components (Frias et al., 2006; Jacinto et al., 2006; Jacinto et al., 2004; 
Pearce et al., 2007; Peterson et al., 2009; Sarbassov et al., 2004; Yang et al., 2006). 
In contrary to mTORC1, mTORC2 is insensitive to rapamycin, although long-term 
rapamycin treatment disrupts mTORC2 assembly in certain cell lines (Sarbassov et 
al., 2006). 
Different upstream signals such as growth factors, amino acid availability, 
intracellular energy levels and stress control mTORC1 activation (Hay and 
Sonenberg, 2004; Wullschleger et al., 2006). In responses to these signals, 
mTORC1 controls many cellular processes that contribute to cell growth, including 
protein synthesis, ribosome biogenesis, nutrient transport and autophagy (Hay and 
Sonenberg, 2004; Martin and Hall, 2005; Wullschleger et al., 2006). The two best-
characterized downstream targets of mTORC1 are S6K1 (p70 ribosomal S6 kinase 
1) and 4E-BP1 (eukaryotic initiation factor 4E binding protein 1) via which mTORC1 
controls protein synthesis (Burnett et al., 1998; Hay and Sonenberg, 2004; 
Wullschleger et al., 2006). The mechanism how growth factors regulate mTORC1 
downstream targets is well-characterized, while the amino acid signaling pathway to 
mTORC1 is at its infancy. It is known that amino acids regulate mTORC1-mediated 
S6K1 and 4E-BP1 phosphorylation (Hara et al., 1998; Kim et al., 2002). However, 
how amino acids are sensed and how this information is transmitted to mTORC1 is 
poorly understood.  
Intracellular molecules have recently been identified that may sense amino acid 
sufficiency to mTORC1. The class III phosphatidylinositol 3-kinase (PI3K), Vps34 
(vacuolar protein sorting 34), which was identified as a protein regulating vesicular 
trafficking (Herman and Emr, 1990; Stack et al., 1993) and autophagy (Simonsen 
and Tooze, 2009), has recently been proposed to mediate the amino acid signal to 
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mTORC1 (Byfield et al., 2005; Gulati et al., 2008; Nobukuni et al., 2005). Especially 
its phospholipid product phosphatidylinositol 3-phosphate [PtdIns(3)P] seems to be 
required in the amino acid-induced mTORC1 activation (Nobukuni et al., 2005; Yoon 
et al., 2011).  
An important step in the amino acid-dependent activation of mTORC1 is the 
recruitment of mTORC1 to late endosomal/lysosomal membranes, where it interacts 
with Rheb thereby promoting mTORC1 activation. This translocation is mediated by a 
complex composed of heterodimeric Rag GTPases and the p18-p14-MP1 complex 
(also termed Ragulator) that anchors the Rag GTPases on late 
endosomes/lysosomes (Sancak et al., 2010; Sancak et al., 2008). The Rag 
GTPases-Ragulator complex is constitutively localized on late endosomes/lysosomes 
(Sancak et al., 2010) and in response to amino acid stimulation Rag GTPases are 
activated allowing to interact with mTORC1 via raptor, thereby re-localizing mTORC1 
to late endosomes/lysosomes (Sancak et al., 2010; Sancak et al., 2008).  
There are evidences indicating that continuous intracellular trafficking is important for 
mTORC1 signaling. It is known that during early to late endosome maturation, Rab5 
is substituted for Rab7 and that either active Rab5 mutants or deletion of Rab7 GEF 
(guanine exchange factor) Vps39 block early to late endosomal conversion (Rink et 
al., 2005). Concerning mTORC1, overexpression of constitutive active Rab5 has 
been demonstrated to impair amino acid- and insulin-induced mTORC1 activation 
similarly to Vps39 knockdown (Flinn et al., 2010; Li et al., 2010). Because PtdIns(3)P 
and PtdIns(3,5)P2 contribute to the identity of early and late endosomes, respectively 
(Huotari and Helenius, 2011), early-to-late endosomal conversion might be paralleled 
by the PtdIns(3)P-to-PtdIns(3,5)P2 conversion implicating PIKfyve (mammalian 
homologue of yeast Fab1) in this process, as it is the PtdIns(3)P 5-kinase that 
generates PtdIns(3,5)P2 from PtdIns(3)P (Dove et al., 2009; Ikonomov et al., 2001; 
Sbrissa et al., 1999; Shisheva et al., 2001). 
In this present study we re-ananlyzed the role of hVps34 (human Vps34) and its 
phospholipid product PtdIns(3)P in the nutrient sensing pathway to mTORC1, 
especially because the Vps34-mTORC1 connection has been shown to be 
controversial (Juhasz et al., 2008). Additionally, the role of PtdIns(3)P and 
PtdIns(3,5)P2 were investigated in the amino acid sensing pathway to mTORC1. In 
contrary to recent reports (Byfield et al., 2005; Nobukuni et al., 2005) we were unable 
to reproduce a clear hVps34-mTORC1 connection. Nonetheless, we could 
demonstrate that PtdIns(3)P is important for mTORC1 activation. Surprisingly, 
pharmacologic inhibition of PIKfyve impairs mTORC1 activation and mTOR 
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localization to late endosomes. This is the first report demonstrating that PIKfyve and 




4.3 Materials and Methods 
 
Chemicals 
DMSO, phosphatidylserine (PS) and phosphatidylinositol (PI) were purchased from 
Sigma. Rapamycin and ZSTK474 were purchased from LC Laboratories. 
Wortmannin was purchased from Sandoz. NVP-BEZ235 was from Novartis Institutes 
for BioMedical research (Basel, Switzerland). PI-103 was purchased from Enzo. 
pp242 and YM201636 were purchased from Chemdea. PtdIns(3)P/AM was 
synthesized by D. Subramanian (EMBL Heidelberg, Germany). [γ-32P]-ATP was 
purchased from Perkin Elmer. 
 
Plasmids and plasmid generation 
pRK5-Myc-S6K1 was obtained from G. Thomas (Cincinnati, USA), pEGFP-
2xFYVEHRS wt and C215S mutant from H. Stenmark (Oslo, Norway), pRK5-HA-
Raptor and pEGFP-Rheb were from M. Hall (Basel, Switzerland), pEGFP-PHBtk from 
T. Balla (Bethesda, USA) and pEGFP-PHTAPP1 was from laboratory plasmid 
collection. pRK5-HA-Raptor-Rheb15 was generated by subcloning the C-terminal tail 
of pEGFP-Rheb containing the last 15 amino acids of Rheb (I-D-G-A-A-S-Q-G-K-S-
S-C-S-V-M) to the C-terminus of pRK5-HA-Raptor. Kinase-dead pcDNA3-GST-
hVps34K636R was cloned by introducing three point mutations into pcDNA3-GST-
hVps34wt (3587AAG3589 -> 3587CGC3589) by site-directed mutagenesis. pEGFP-Rab5a 
and pEGFP-Rab7 were generated by subcloning Rab5a and Rab7 cDNA (from 
Missoury S&T Resource Center) into pEGFP-C1 (Clontech), respectively.  
 
Cells, cell culture and transfection 
HEK293 and HER911 cells were cultured in DMEM containing 10% heat-inactivated 
fetal calf serum (HIFCS, Sigma), 2mM L-glutamine (L-Gln, Sigma) and 1% penicillin-
streptomycin solution (PEST, Sigma). The human melanoma cell line A375 was 
cultured in RPMI 1640 containing 10% HIFCS, 2mM L-Gln and 1% PEST at 37°C in 
5% CO2 atmosphere. shRNA mock and shRNA hVps34 HEK29 and A375 cells were 
cultured in complete medium as described before supplemented with 1µg/ml 
puromycin.  





Mammalian lentiviral shRNA and siRNA targeting sequences 
The sequences of shRNA targeting hVps34 (Sigma), siRNA targeting hVps34 
(Invitrogen), and PI3K-C2α and PI3K-C2β (Invitrogen) were as follows:  
 
shRNA hVps34: CCACGAGAGATCAGTTAAATA 
siRNA PI3K C2A#1: GGAAUAUGGUGUGACAGGAUCCUUU 
siRNA PI3K C2A#2: GGAUGUAGCAGAGUGUGAUCUUGUU 
siRNA PI3K C2A#3: UCAACUUGAGCAAAGAGACGGUUAA 
siRNA PI3K C2B#1: GAGAGAUGAGGAGGUUGCUGCAUUU 
siRNA PI3K C2B#2: UGGCUGAUGGAGACUUCCCACUGAA 
siRNA PI3K C2B#3: CAGCGCCCGUUGGAGUGCACCUAAU 
 
siRNA-mediated silencing of class II PI3K  
After Myc-S6K1 transfection, cells were transfected with siRNA using Lipofectamine 
RNAiMAX (Invitrogen) as described in the manufacturer’s guideline. Briefly, 180,000 
HEK293 cells were plated per well in 6-well culture plates in complete medium 
without antibiotics. Twenty-four hours later cells were transfected with 100 ng pRK5-
Myc-S6K1 using JetPEI and medium replaced 7 hours later with complete medium 
without antibiotics. The following day, cells were either transfected with 10 nM control 
siRNA, siRNA C2A#1-3 or siRNA C2B#1-3 and 5 hours later medium replaced. After 
48 h cells were O/N serum starved and subjected to amino acid starvation and amino 
acid stimulation as described below. 
 
Amino acid and serum starvation and stimulation of cells 
Cells were washed once with PBS and incubated O/N (16-18h) in serum-free culture 
medium supplemented with 2 mM L-glutamine. The following day cells were washed 
twice with PBS and incubated for 2h in amino acid free buffer (homemade: 1.8 mM 
CaCl2, 0.248 µM Fe(NO3)3, 810 µM MgSO4, 5.37 mM KCl, 44 mM NaHCO3, 109.5 
mM NaCl, 906 µM NaH2PO4, 25 mM Glucose, 4x MEM vitamins) followed by amino 
acid stimulation with serum-free culture medium supplemented with 2 mM L-
glutamine for 30 min.  
For IGF-II stimulation, cells were O/N serum starved in serum-free culture medium 




MTT-based cell proliferation assay 
For proliferation HEK293 or A375 cells were plated in quadruplicate at 3,000 or 1,000 
cells per well in 96-well tissue culture plates in 100 µl culture medium. At day 0, 24h 
after plating, inhibitors (1 µM BEZ235, 100 nM Rapamycin, 1 µM pp242, 1 µM 
ZSTK474, and 1 µM YM201636) were added to cells. To each well 11 µl MTT 
(Sigma, diluted in PBS to 5 mg/ml) was added and plate shaken carefully. After 
incubation for 2h at 37°C and 5% CO2, 100 µl solubilization solution (95% 
isopropanol, 5% formic acids) was added to each well and pipetted up and down 
several times to dissolve the formazan salt. After 10 min of gently mixing absorbance 
was measured at 570 nm and background absorbance at 690 nm.  
 
Lipid kinase assay 
GST-hVps34wt and GST-hVps34K636R were GST pulled down and resuspended in 
40µl kinase buffer (20 mM HEPES (pH 7.4)/5mM MnCl2) and pre-treated with either 
DMSO or 100nM wortmannin while vigorously shaking for 15 min at 37°C. 
Afterwards, 10 µl of PS/PtdIns (1µg/µl) vesicles and 10 µl [γ-32P]-ATP/ATP solution 
(2µCi [γ-32P]-ATP and 60 µM cold ATP) were added and mixed constantly for 10 min 
at 30°C. Reaction was stopped by the addition of 100 µl 1 M HCl and lipid extracted 
with 200 µl Chloroform:Methanol (1:1, v/v). PtdIns(3)Ps were resolved by thin layer 
chromatography and visualized by phosphoimager and autoradiography. 
 
Preparation of cell lysates 
Cells were washed twice with ice-cold PBS and scraped in ice-cold NP40-based lysis 
buffer (20 mM Tris-HCl pH 8.0, 138 mM NaCl, 2.7 mM KCl, 5% glycerol, 1% NP-40, 
40 mM NaF, 2mM Na3VO4, 20 µM Leupeptin, 18 µM Pepstatin, 5 µM Aprotinin, 1 mM 
PMSF, 1 mM MgCl2, 1 mM CaCl2, 5 mM EDTA). Cell lysates were cleared by 
centrifugation at 13,200 rpm for 15 min and denatured by the addition of 5x sample 
buffer and boiling for 6 min. 
 
Western blotting analysis and antibodies 
Equal amount of proteins were subjected to SDS-PAGE and transferred to Immobilon 
PVDF membranes (Millipore). Primary antibodies to pS6K Thr389 (1A5), S6K1, 
pPKB Ser473 (193H12), pPKB Thr308 (244F9) and Myc (9B11) were from Cell 
signaling Technology; primary antibodies to PI3-Kinase C2α and PI3-Kinase C2β 
were from BD Transduction Laboratories; primary antibody to PKB (19G7/C7) was a 
kind gift of E. Hirsch (Turin, Italy); primary antibody to GFP (clone 7.1 and 13.1) was 
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from Roche; primary antibody to Tubulin (DM1A) was from Sigma; primary antibody 
to hVps34 was from Zymed Laboratories/Invitrogen; and primary antibody to HA 
(HA.11) was from Lucerna Chem. Secondary antibodies such as horseradish 
peroxidase (HRP)-conjugated goat anti-mouse IgG and goat anti-rabbit IgG (Sigma) 
were visualized using enhanced chemiluminescence (Millipore). 
 
Immunofluorescence of cells and quantification of colocalization 
For staining, cells were grown in a 12-well plate on glass coverslips. After 
transfection with appropriate plasmids (total 1 µg), starvation and stimulation, cells 
were washed twice with PBS and fixed with 3% paraformaldehyde for 10 min at 
37°C. After two times washing with PBS cells were quenched with 100 mM Glycine in 
PBS for 5min and washed an additional time with PBS. For intracellular staining, cells 
were permeabilized with 0.1% (w/v) saponin (Sigma) in PBS for 20 min at RT, and 
washed once with PBS and blocked with 5% goat serum in PBS (5% GS/PBS) for 20 
min at RT. Cells were incubated with primary antibody (anti-HA (HA.11, Lucerna 
Chem); anti-TOR (7C10) (Cell Signaling Technology)) diluted in 5% GS/PBS for 1h at 
RT, washed twice with PBS and incubated with secondary antibody (AlexaFluor568 
goat anti-rabbit IgG (H+L) and AlexaFluor568 goat anti-mouse IgG (H+L) from 
Molecular Probes) diluted in 5% GS/PBS for 1h at RT in dark. After two times wash 
with PBS, nuclei were stained with 1 µM Hoechst 33342 (Juro supply) diluted in PBS 
for 15 min at RT in dark. After washing twice with PBS, glass coverslips were 
mounted with Mowiol and cells imaged on a Zeiss LSM 510 Meta confocal laser 
scanning microscope attached to an Axiovert 200 inverted microscope using an oil-
immersed 63x/1.40 numerical aperture objective (Carl Zeiss). 
All images were analyzed with ImageJ except for Pearson’s correlation coefficient 
analysis where colocalization threshold plugin of FiJi was used. For colocalization 
analysis, ROI (region of interest) of individual cells was selected and Pearson’s 
coefficient correlation performed from at least 10 cells. 
 
Statistical analysis 
Data are shown as means and error bars indicate standard error of the mean (SEM). 
Data analysis was carried out using a two-tailed Student’s t-test and are considered 







Implication of hVps34 in the amino acid-dependent activation of mTORC1 
The Vps34 is the sole class III phosphatidylinositol 3-kinase (PI3K) and exclusively 
synthesizes PtdIns(3)P from PtdIns (Stack and Emr, 1994; Volinia et al., 1995). In 
addition in regulating autophagy and vesicular transport such as homotypic early 
endosomal fusion, formation of internal vesicles in multivesicular bodies and 
transport of the PDGF receptor through the early endosome (Christoforidis et al., 
1999; Futter et al., 2001; Siddhanta et al., 1998; Simonsen and Tooze, 2009; Stein et 
al., 2003), Vps34 has been demonstrated to be involved in the activation of mTORC1 
by amino acids, and in particular its lipid product PtdIns(3)P seems to positively 
regulate mTORC1 (Byfield et al., 2005; Nobukuni et al., 2005; Yoon et al., 2011). To 
investigate the role of PtdIns(3)P in the amino acid sensing pathway to mTORC1, we 
first re-examined the connection between the PtdIns(3)P-generating Vps34 and 
mTORC1. GST-tagged human Vps34 (hVps34) wild type and kinase-dead mutant 
(K636R) were ectopically expressed in HEK293 cells in increasing amounts and 
Thr389 phosphorylation of Myc-S6K1 was measured as a readout for mTORC1 
activation (Fig. 1). Amino acid stimulation resulted in an increase in Thr389 
phosphorylation, but no concentration dependence was observed as evidenced in 
the western blotting and from the quantification (Fig. 1A and 1B). Intriguingly, cells 
expressing the hVps34 KR mutant, that is devoid of kinase activity (Fig. 1C), also 
resulted in S6K1 Thr389 phosphorylation by amino acid stimulation (Fig. 1A and 1B). 
Probably, the PtdIns(3)P that is generated by the endogenous hVps34 (Fig. 1A) is 
most likely enough to induce mTORC1-mediated S6K1 phosphorylation. 
Furthermore, it is known that membrane targeting of hVps34 is accomplished by its 
adaptor protein hVps15 (also called p150) (Christoforidis et al., 1999; Murray et al., 
2002; Stack et al., 1993; Stein et al., 2003) and that coexpression of hVps34 with 
hVps15 increases the activity of hVps34 (Yan et al., 2009). Therefore, it is 
conceivable that overexpression of Vps34 alone results in its mislocalization, from 






Fig. 1: Ectopic expression of GST-hVps34 wild type or kinase-dead does not influence mTORC1 
activity.  
(A) HEK293 cells ectopically co-expressing Myc-S6K1 and increasing amounts of wild type (wt) or 
kinase-dead (KR) GST-hVps34 were serum starved over night, amino acid deprived for 2h (-AA) and 
stimulated with amino acids (+AA) for 30min. Cell lysates were subjected to SDS-PAGE and indicated 
proteins were analyzed by western blotting. Phosphorylated Thr389 S6K1 was assessed for mTORC1 
activity and amount of hVps34 determined with anti-hVps34. Anti-α-Tubulin was used as loading control.  
(B) Levels of phosphorylated S6K1 Thr389 from experiment described in (B) were densitometric 
quantified using ImageJ and normalized to the levels of S6K1. Data represented as mean ± SEM of n = 
3 experiments.  
(C) In vitro PI3K lipid kinase assay. GST pulldowns were prepared from HEK293 cells ectopically 
expressing GST-tagged wild type (wt) or kinase-dead mutant (KR) hVps34 and analyzed for kinase 
activity in an in vitro lipid kinase assay. GST pulldowns were pre-treated either with DMSO or 100 nM 
wortmannin for 15 min at 30°C, followed by the kinase assay in the presence of 2 µCi [γ-
32
P] ATP/10 µM 
cold ATP and 10 µg PtdIns/PS vesicles for 10 min at 30°C. Extracted lipids were separated on TLC and 
analyzed by phosphoimager. 
 
 
To further investigate the connection between hVps34 and mTORC1, we depleted 
hVps34 by RNA interference (RNAi) in two completely different cell lines, HEK293 
and A375 (a human melanoma cell line) (Figs. 2A-2D and 2E-2H, respectively). 
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Silencing of hVps34 markedly decreased the expression of hVps34 in both cell lines 
(reduced to 6.7 % in HEK293 and 3.4% in A375 cells) (Figs. 2A and 2E) and 
decreased amino acid-stimulated S6K1 Thr389 phosphorylation (Figs. 2B and 2F). In 
HEK293 cells Thr389 phosphorylation decreased significantly to 55% (Fig. 2C), while 
in A375 decreased to 67% (Fig. 2G). In contrary to hVps34 silencing, pharmacologic 
inhibition of PtdIns(3)P synthesis by wortmannin treatment, a pan PI3K inhibitor, 
completely abrogated S6K1 Thr389 phosphorylation (Figs. 2B-2C and 2F-2G). To 
find an explanation why hVps34 silencing did not completely abrogate mTORC1 
activity and considering that PtdIns(3)P is most likely required for mTORC1 activation 
(Byfield et al., 2005; Nobukuni et al., 2005; Yoon et al., 2011), we examined whether 
PtdIns(3)P generation is abrogated in hVps34 deleted cells (Fig. S1). To visualize 
PtdIns(3)P by microscopy, we ectopically expressed EGFP-tagged tandem FYVE 
domain (named after the first four proteins in which it was identified: 
Fab1/YOTB/Vac1/EEA1) of HRS (hepatocyte growth factor-regulated tyrosine kinase 
substrate) (EGFP-2xFYVEHRS), which is known to specifically bind to PtdIns(3)P 
(Gillooly et al., 2000) (Fig. S1). In both control and hVps34 depleted A375 cells, 
EGFP-2xFYVEHRS localized on intracellular vesicles indicating that in hVps34 
knockdown cells PtdIns(3)P is still formed, whereas treatment with wortmannin 
resulted into a diffused cytoplasmic distribution (Fig. S1). This is consistent with a 
previous report, where suppression of hVps34 by RNAi did not disrupt the 
PtdIns(3)P-dependent localization of the early endosomal antigene 1 (EEA1) in U-
251 glioblastoma (Johnson et al., 2006). This explains, why in the hVps34 
knockdown cells mTORC1 was still able to phosphorylate S6K1 (Figs. 2B and 2F), 
although hVps34 expression was almost completely suppressed (Figs. 2A and 2E). 
Therefore, it is possible that another PI3K can compensate for the loss of hVps34 to 
generate PtdIns(3)P.  
Consistent with the remaining S6K1 Thr389 phosphorylation signal, knockdown of 
hVps34 did not affect cell proliferation in HEK293 and A375 cells (Figs. 2D and 2H), 
while pharmacological inhibition of the mTOR kinase by BEZ235, rapamycin and 
pp242 treatment completely blocked proliferation (Figs. 2D and 2H). Together, 
hVps34 knockdown negatively, but not completely, affects mTORC1 activation in 







Fig. 2: Implication of hVps34 knockdown on amino acid-stimulated mTORC1 signaling. 
(A and E) Degree of hVps34 knockdown. HEK293 (A) and A375 (E) cells were transduced with 
lentivirus expressing shRNA against hVps34 (shRNA hVps34) or empty vector (shRNA mock) as control 
and selected with puromycin. Cell lysates were subjected to SDS-PAGE and hVps34 levels determined 
by western blotting with anti-hVps34 and quantified using ImageJ. Anti-α-Tubulin was used as loading 
control. Data represented as mean ± SEM of n > 3 experiments. *** P<0.001. 
(B and F) Effect of hVps34 silencing on mTORC1 by amino acid stimulation. HEK293 (B) and A375 (F) 
cells were transduced with lentivirus as described above and transiently transfected with Myc-S6K1. 
Cells were kept either in complete medium (DMEM
C
 for HEK293 and RPMI
C
 for A375; DMEM or RPMI 
medium supplemented with 2 mM L-glutamine and 10% FCS) or serum starved over night, amino acids 
deprived  for  2h  (-AA)  and  re-stimulated  with amino  acids  (+AA)  for  30 min.  Prior  to  amino  acid  
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(Fig. 2 continued) 
stimulation cells were pre-treated with 1 µM wortmannin, where indicated. Cell lysates were subjected to 
SDS-PAGE and indicated proteins were analyzed by western blotting. Phosphorylated Thr389 S6K1 
was assessed for mTORC1 activity and abundance of hVps34 was determined with anti-Vps34. Anti-α-
Tubulin was used as loading control. 
(C and G) Levels of phosphorylated S6K1 Thr389 from experiments described in (B) and (F) were 
quantified using ImageJ and data represented as mean ± SEM of n = 3 experiments. ** P<0.01. 
(D and H) MTT-based proliferation assay. Lentivirus transduced HEK293 (D) and A375 (H) cells 
expressing shRNA against hVps34 (shRNA hVps34) or empty vector (shRNA mock) were treated with 
either DMSO, 1 µM BEZ235, 100 nM rapamycin or 1 µM pp242 and proliferation monitored for 4 days. 
Data represented as mean ± SEM of n = 4 experiments. 
 
 
Class II PI3K isoforms differentially affect mTORC1 signaling by amino acid 
treatment 
Since hVps34 silencing did not affect endomembrane localization of EGFP-
2xFYVEHRS (Fig. S1) and cell proliferation (Figs. 2D and 2H) and only partially 
decreased amino acid-stimulated S6K1 Thr389 phosphorylation (Figs. 2B and 2F), 
we wondered whether another PI3K might generate PtdIns(3)P that can contribute to 
mTORC1 activity. A possible candidate could be class II PI3K, which consists of 
three isoforms; PI3K-C2α, PI3K-Cβ and PI3K-C2γ. While PI3K-C2α and PI3K-Cβ are 
ubiquitously expressed, PI3K-C2γ expression is tissue restricted mostly in the liver, 
breast, prostate and salivary glands (Kok et al., 2009). They phosphorylate in vitro 
PtdIns and PtdIns(4)P to generate PtdIns(3)P and PtdIns(3,4)P2, respectively, but 
evidences suggest that in vivo they synthesize PtdIns(3)P (Falasca and Maffucci, 
2007; Maffucci et al., 2005; Wen et al., 2008). Furthermore, class II PI3Ks seem to 
be associated with intracellular membranes (Arcaro et al., 1998; Domin et al., 2000; 
Prior and Clague, 1999). Therefore, we hypothesize that class II PI3Ks can 
compensate for the loss of hVps34 and generate PtdIns(3)P, which will then be 
required for mTORC1 activation. Hence, we targeted PI3K-C2α and PI3K-C2β by 
small interference RNA (siRNA) in HEK293 cells and analyzed Myc-S6K1 Thr389 
phosphorylation by western blotting (Fig. 3). Interestingly, knockdown of PI3K-C2α 
(Fig. 3A) and PI3K-C2β (Fig. 3B), respectively, had an isoform specific effect on 
mTORC1 activity. In the presence of amino acids, knockdown of PI3K-C2α caused 
an increase in S6K1 Thr389 phosphorylation (Fig. 3A), while loss of PI3K-C2β, in 
particular targeting sequences C2B#1 and C2B#2, decreased S6K1 Thr389 
phosphorylation to approximate 50% (Fig. 3B). The observed increase in Thr389 
phosphorylation by PI3K-C2α deletion could be due to a defect in the endocytosis of 
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amino acid transporters. PI3K-C2α is known to be a component of the clathrin-
mediated transport machinery at the plasma membrane and in the trans-Golgi 
network (Domin et al., 2000) and therefore one can speculate that PI3K-C2α might 
be involved in endocytosis. In Drosophila increased levels of Slimfast, a cationic-
dependent amino acid transporter, at the cell surface correlates with increased TOR 
activity, while reduction in TOR activity results in decreased levels of Simfast (Hennig 
et al., 2006). Therefore, it is conceivable that upon PI3K-C2α deletion, amino acid 




Fig. 3: Silencing of PI3K-C2α and PI3K-C2β has an isoform specific effect on mTORC1 signaling. 
Twenty-four hours after Myc-S6K1 transfection, HEK293 cells were transfected with three different 
siRNA duplexes against either PI3K-C2α (A) or PI3KC-2β (B). 48 h later cells were serum starved over 
night, amino acids deprived for 2h (-AA) and stimulated with amino acids (+AA) for 30 min. Cell lysates 
were subjected to SDS-PAGE and indicated proteins were analyzed by western blotting. PI3K-C2α (A) 
and PI3K-C2β (B) knockdown were assessed with anti-PI3KC2α and anti PI3KC2β and anti-α-Tubulin 
used as loading control. mTORC1 activity was measured by Thr389 S6K1 phosphorylation. Thr389 
levels were quantified using ImageJ and normalized to the levels of Myc-S6K1. Data represented as 
mean ± SEM of n = 9 for PI3K-C2α and n = 6 for PI3K-C2β experiments. *P<0.05; **P<0.01. 
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In contrary to amino acid treatment, IGF-II stimulation of serum-starved cells did not 
markedly affect S6K1 Thr389 phosphorylation by either PI3K-C2α (Fig. S2A) or 
PI3K-C2β (Fig. S2B) silencing indicating that IGF-II stimulation goes via the 
canonical PI3K/PKB pathway to mTORC1, which is consistent with the unaltered 
PKB/Akt Thr308 and Ser473 phosphorylations (Figs. S2).  
Together, it is still enigmatic which PI3K is responsible for the PtdIns(3)P generation 
that is required for mTORC1 activity. The modest decrease in mTORC1 activity 
induced through the RNAi-mediated deletion of hVps34 or PI3K-C2β suggests that 
loss of one PI3K can probably be complemented by another PI3K class.  
 
 
PtdIns(3)P-dependent activation of mTORC1 
Since targeting of hVps34 and PI3K-C2β did not markedly affect S6K1 Thr389 
phosphorylation (Fig. 1B and Fig. 2B) we chose another approach to investigate the 
role of PtdIns(3)P in the amino acid sensing pathway to mTORC1. PtdIns(3)P is 
highly enriched on early endosomes and is involved in recruiting proteins containing 
FYVE or phox (PX) homology domains to endosomal membranes. FYVE domain 
containing proteins as hepatocyte growth factor-regulated tyrosine kinase substrate 
(HRS) and early endosomal antigen 1 (EEA1) are used as PtdIns(3)P sensors 
(Gillooly et al., 2000; Lemmon, 2003). However, we utilized the FYVE domain to 
mask PtdIns(3)P in order to disrupt PtdIns(3)P-dependent signaling (Byfield et al., 
2005; Nobukuni et al., 2005; Yoon et al., 2011). Ectopic expression of EGFP-
2xFYVEHRS decreased amino acid-induced Thr389 phosphorylation in a 
concentration-dependent manner in two different cell lines, HEK293 (Fig. 4A) and 
HER911 cells (Fig. S3A). Unlike EGFP-2xFYVEHRS wild type, the PtdIns(3)P binding-
deficient mutant EGFP-2xFYVEHRS C215S did not impair amino acid-induced S6K1 
Thr389 phosphorylation in HEK293 (Fig. 4B) and HER911 cells (Fig. S3B). Together, 
this confirms a PtdIns(3)P-dependent mechanism in the activation of mTORC1 by 
amino acid treatment. To exclude that other 3-phosphorylated phosphoinositides 
might be involved in mTORC1 signaling, the PH domain of TAPP1 (tandem PH 
domain containing protein 1) and Btk (Bruton’s tyrosine kinase), which specifically 
binds to PtdIns(3,4)P2 and PtdIns(3,4,5)P3 (Lemmon, 2003), respectively, were 
overexpressed in HEK293 cells (Fig. 4C). Both PH domains, unlike the tandem FYVE 
domain, were not able to ablate S6K1 Thr389 phosphorylation induced by amino acid 
treatment. The requirement of PtdIns(3)P for mTORC1 signaling is also necessary 
during growth factor such as IGF-II stimulation and at steady-state conditions (cells 
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maintained in complete medium) (Fig. 4D). Interestingly, PKB/Akt Thr308 
phosphorylation was not affected by masking PtdIns(3)P (Fig. 4D), indicating that the 
canonical PI3K/PKB pathway was not influenced. Consequently, PtdIns(3)P is an 
important phospholipid in the regulation of mTORC1 and it regulates mTORC1 




Fig. 4: PtdIns(3)P-dependent activation of mTORC1. 
(A) Concentration-dependent sequester of PtdIns(3)P inhibits amino acid-induced mTORC1 activation in 
a concentration-dependent manner. HEK293 cells were co-transfected with Myc-S6K1 and increasing 
amounts of  EGFP-2xFYVE
HRS
.  Thirty  hours  later  cells  were  serum  starved  over  night, amino acid  
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(Fig. 4. continued) 
depleted for 2h and re-stimulated with amino acids for 30 min. Cell lysates were processed for SDS-
PAGE and the indicated proteins were analyzed by western blotting. Anti-α-Tubulin was used as loading 
control and mTORC1 activity measured by S6K1 Thr389 phosphorylation. Levels of phosphorylated 
Thr389 were quantified using ImageJ and normalized to the levels of Myc-S6K1. Data represented as 
mean ± SEM of n = 3 experiments. 
(B) Masking PtdIns(3)P negatively affects mTORC1 activity. EGFP-2xFYVE
HRS
 wild type (wt) and lipid-
binding deficient mutant (CS) were co-transfected with Myc-S6K1 in HEK293 cells. Cells were starved 
and stimulated as described in (A). Where indicated, cells were pre-treated with 100nM rapamycin for 
15 min prior to amino acid stimulation. Cells and western blotting were processed and analyzed as 
described in (A). Data represented as mean ± SEM of n = 3 experiments. **P<0.01. 
(C) Masking different 3-phosphorylated phosphoinositides other than PtdIns(3)P does not affect 
mTORC1 signaling by amino acid stimulation. HEK293 cells were co-transfected with Myc-S6K1 and 





 (PtdIns(3,4)P2 binding) and EGFP-PH
Btk
 (PtdIns(3,4,5)P3 binding). 
Thirty hours later, cells were serum starved over night, amino acid depleted for 2h and stimulated with 
amino acids for 30 min. Cell lysates and western blotting were processed as described above. One 
representative experiment of three is shown. 
(D) Sequester of PtdIns(3)P affects mTORC1 signaling by IGF-II stimulation and at steady-state 
condition. EGFP-2xFYVE
HRS
 wild type (wt), lipid-binding deficient mutant (CS) or empty vector were co-
transfected with Myc-S6K1 in HEK293 cells and 30h later cells were either serum starved over night (-
serum) and stimulated with 50 ng/ml IGF-II for 5 min (on the left) or maintained in complete medium 
(DMEM
C
; on the right). Cell lysates were processed as described above. mTORC1 activity was 
measured by S6K1 Thr389 phosphorylation and PI3K activity by PKB/Akt Thr308 phosphorylation. Anti-
α-Tubulin was used as loading control. One representative experiment of three is shown. 
 
 
To further prove the connection between PtdIns(3)P and mTORC1, we acutely 
increased intracellular PtdIns(3)P levels by using a synthetic membrane-permeant 
PtdIns(3)P/AM (Subramanian et al., 2010), which chemical structure is depicted in 
figure 5A. The mode of action of the synthetic phospholipid is as follows: The 
negative charged phosphate groups of PtdIns(3)P/AM are masked with 
acetoxymethyl ester (AM) groups and the hydroxyl groups by butyrates that allow the 
uncharged lipid to pass the lipid membrane. Once inside the cell, the negative 
charges are regenerated by the action of endogenous esterases and lipases that 
remove the AM esters and butyrates and therefore making the lipid biological active 
(Subramanian et al., 2010). Treatment with synthetic PtdIns(3)P/AM increased 
almost 2-fold S6K1 Thr389 phosphorylation by amino acid stimulation, while in the 
absence of amino acids PtdIns(3)P/AM treatment could not induce Thr389 
phosphorylation as evidenced by western blotting (Figs. 5B and 5C). Collectively, an 
amino acid input has to exist in order that PtdIns(3)P can activate mTORC1. 
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Moreover, the positive effect of synthetic PtdIns(3)P/AM on Thr389 phosphorylation 
was blocked by the overexpression of EGFP-2xFYVEHRS (Figs. 5B and 5C) further 
confirming that 2xFYVEHRS specifically binds to PtdIns(3)P and negatively affects 




Fig. 5: Acute treatment with PtdIns(3)P increases mTORC1 signaling in response to amino acid 
stimulation.  
(A) Chemical structure of synthetic, membrane-permeant PtdIns(3)P/AM. 
(B) Treatment with PtdIns(3)P/AM positively affects mTORC1. HEK293 cells were co-transfected with 
EGFP-2xFYVE
HRS
 or empty vector together with Myc-S6K1. Thirty hours later, cells were serum starved 
over night, amino acids depleted for 1 ½ h, pre-treated with either 50 µM PtdIns(3)P/AM or carrier for 30 
min and subsequently stimulated with amino acids for 30 min. Cell lysates were processed for SDS-
PAGE and the indicated proteins analyzed by western blotting. mTORC1 activity was assessed by 
S6K1 Thr389 phosphorylation and anti-α-Tubulin used as loading control. 
(C) Thr389 phosphorylation levels were quantified using ImageJ. Data are represented as mean ± SEM 
of n = 4 experiments, except 2xFYVE
HRS
 experiments that were done n = 3. A one tailed t-test was 





Positioning mTORC1 to endosomal membranes renders its activation 
independent of PtdIns(3)P 
Recent studies have demonstrated that by amino acid stimulation, mTORC1 is 
translocated from an unknown compartment to late endosomes/lysosomes, where 
mTORC1 can interact with and be activated by Rheb (Sancak et al., 2010; Sancak et 
al., 2008). To confirm the translocation, we analyzed the localization of mTOR in 
respect to Rab5a and Rab7 in amino acid-starved and amino acid-stimulated cells, 
with or without treatment by rapamycin or wortmannin (Fig. 6A and Fig. S4). For that 
purpose, A375 cells expressing EGFP-tagged Rab5a and Rab7 were stained for 
endogenous mTOR by anti-mTOR and colocalization between mTOR and EGFP-
Rab5a or Rab7 analyzed by confocal microscopy (Fig. 6A and Fig. S4 showing 
representative microscopy pictures). As summarized in the ∆ Pearson’s correlation 
coefficient, mTOR localized to both Rab5a- and Rab7-positive endosomes in amino 
acid-starved, amino acid-stimulated conditions as well as at steady-state conditions 
(Fig. 6A). However, independently of the stimulation, the degree of mTOR 
localization on Rab7-positive late endosomes was significantly higher than on 
Rab5a-positive early endosomes. Moreover, upon amino acid stimulation mTOR 
localization on Rab7 endosomes significantly increased compared to amino acid-
starved cells, while on Rab5a endosomes the degree of mTOR localization remained 
unchanged (Fig. 6A). Interestingly, rapamycin or wortmannin treatment did not affect 
mTOR translocation to Rab7 endosomes by amino acid stimulation (Fig. 6A) 
indicating that the translocation process is mTORC1 and PI3K independent. 
Together these data confirm that late endosomes are the cellular compartments, 
where mTOR translocates upon amino acid stimulation.  
 
With in mind that PtdIns(3)P (this work; Nobukuni et al., 2005; Yoon et al., 2011) and 
that late endosomal translocation of mTOR (Sancak et al., 2010; Sancak et al., 2008) 
are required for mTORC1 signaling, we wondered whether mTORC1 activation can 
be made independent of PtdIns(3)P. For that purpose we made use of a system 
developed in Sabatini’s lab (Sancak et al., 2010), where they artificially targeted 
raptor to late endosomal/lysosomal membranes thereby rendering mTORC1 
constitutive active and resistant to amino acid starvation. Therefore, we generated 
HA-tagged raptor fusion protein containing at its C-terminus the last 15 amino acids 
of Rheb, which confers membrane targeting. For simplicity and in analogy to Sancak 
et al. we named this construct HA-Raptor-Rheb15 (Sancak et al., 2010). To 
investigate whether HA-Raptor-Rheb15, and therefore mTORC1, was localized on 
late endosomes we ectopically expressed EGFP-Rab5a or EGPF-Rab7 together with 
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HA-Raptor-Rheb15 or HA-Raptor in HEK293 and A375 cells and analyzed their 
colocalization to EGFP-Rab5a or EGPF-Rab7 by anti-HA staining and confocal 
microscopy (Fig. 6B and Fig. S5). As evidenced in the ∆ Pearson’s correlation 
coefficient summarizing the colocalization analysis, both HA-Raptor-Rheb15 and HA-
Raptor localized on Rab5a early and Rab7 late endosomes in both cell lines (Fig. 6B; 
representative microscopy pictures are shown in Fig. S5). Nonetheless, HA-Raptor-
Rheb15 was significantly more abundant on these endosomal membranes than HA-
Raptor (Fig. 6B). Intriguingly, the targeting sequence of Rheb guided raptor on both 
early and late endosomes. So far, it was assumed that the C-terminus of Rheb is a 
late endosome/lysosome targeting sequence (Sancak et al., 2010). Considering 
mTORC1 signaling, ectopic expression of HA-Raptor-Rheb15 in HEK293 cells, unlike 
control samples (empty vector and HA-Raptor), resulted in S6K1 Thr389 
phosphorylation in the absence of amino acids (Fig. 6C), thereby confirming that 
endosomal targeted raptor renders mTORC1 constitutive active and resistant to 
amino acid starvation. Interestingly, in HA-Raptor-Rheb15 expressing cells amino 
acid stimulation significantly increased Thr389 phosphorylation compared to amino 
acid starved cells, indicating that besides being constitutive active mTORC1 is still 
sensitive to amino acid stimulation (Fig. 6C).  
Simultaneous expression of HA-Raptor-Rheb15 and sequester of PtdIns(3)P by 
ectopic expression of EGFP-2xFYVEHRS significantly increased S6K1 Thr389 
phosphorylation by amino acid stimulation compared to cells expressing HA-Raptor-
Rheb15 alone or HA-Raptor/EGFP-2xFYVEHRS (Fig. 6C). These data suggest that, 
when mTORC1 is guided artificially to endosomal membranes, PtdIns(3)P becomes 
dispensable for mTORC1 activation. Interestingly, by simultaneous masking of 
PtdIns(3)P by 2xFYVEHRS and by HA-Raptor-Rheb15 expression S6K1 Thr389 
phosphorylation increased, probably because either an inhibitory effect of PtdIns(3)P 
on mTORC1 was relieved or because due to complete shielding of early endosomes 
by 2xFYVEHRS more HA-Raptor-Rheb15 and therefore more mTORC1 was targeted 
to late endosomes, where mTORC1 is believed to interact with Rheb (Sancak et al., 
2010; Sancak et al., 2008).  
In contrary to EGFP-2xFYVEHRS/HA-Raptor-Rheb15 expression, EGFP-2xFYVEHRS 
alone is inhibitory to mTORC1 signaling (Fig. 4) probably because either early 
endosomes are not able to mature into late endosomes when PtdIns(3)P is masked 
by 2xFYVEHRS and therefore preventing mTORC1 to interact with and be activated by 
Rheb, or because mTORC1 needs PtdIns(3)P as a docking platform to associate 






Fig. 6: Positioning mTORC1 on endosomes renders mTORC1 signaling independent of 
PtdIns(3)P. 
(A) Amino acid stimulation induces translocation of mTOR to late endosomes. A375 cells were 
transfected with either EGFP-Rab5a or EGFP-Rab7 and 30h later, cells were either serum starved over 
night, depleted of amino acids for 2h (-AA) and re-stimulated with amino acids for 30min (+AA) or 
maintained in complete medium (RPMI
c
). Where indicated, prior to amino acid stimulation cells were 
pre-treated with 100 nM rapamycin (Rapa) or 1 µM wortmannin (Wm) for 15 min and included during 
amino acid stimulation. Following fixation, cells were immunostained for endogenous mTOR followed by 
AlexaFluor568-coupled secondary antibody. Images were acquired with a Zeiss confocal microscope 
and degree of mTOR colocalization to either EGFP-Rab5a (Rab5a) or EGFP-Rab7 (Rab7) was 
determined by ∆ Pearson’s correlation coefficient of at least 10 different cells. Representative pictures 
for each treatment used for quantification are depicted in the supplementary figures (Fig. S4). Data are 
represented as mean ± SEM. Horizontal grey lines demarcate the levels amino acid-starved Rab5a- or 
Rab7-positive cells from the other stimulated cells. *P<0.05, **P<0.01, ***P<0.001. 
(B) HA-Raptor-Rheb15 targets mTOR to endosomal membranes. Both HEK293 and A375 cells were 
co-transfected with HA-Raptor and HA-Raptor-Rheb15 with either EGFP-Rab5a or EGFP-Rab7. Thirty 
hours later, cells were serum starved over night, amino acids depleted for 2h and cells were fixed and 
immunostained for HA followed by AlexaFluor568-coupled secondary antibody. Images were acquired 
with a Zeiss confocal microscope and degree of colocalization of either HA-Raptor-Rheb15 or HA-
Raptor to EGFP-Rab5a (Rab5a) and EGFP-Rab7 (Rab7) was determined by ∆ Pearson’s correlation 
coefficient of at least 10 different cells. Representative pictures used for quantification are depicted in 
the supplementary figures (Fig. S5). Data represented as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001. 
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(Fig. 6 continued) 
(C) Endosomal targeting renders mTORC1 activity independent of PtdIns(3)P. HEK293 cells were co-
transfected with empty vector, HA-Raptor, HA-Raptor-Rheb15 and Myc-S6K1 together with or without 
EGFP-2xFYVE
HRS
. Thirty hours later cells were serum starved over night, amino acids depleted for 2h 
and re-stimulated with amino acids for 30 min. Cell lysates were processed for SDS-PAGE and the 
indicated proteins were analyzed by western blotting. S6K1 Thr389 phosphorylation was assessed for 
mTORC1 activity and anti-α-Tubulin used as loading control. Levels of phosphorylated Thr389 were 
quantified using ImageJ and normalized to Myc-S6K1. Data represented as mean ± SEM of n = 4 
experiments. *P<0.05, **P<0.01. 
 
 
Inhibiting PtIns(3,5)P2 synthesis by treatment with the PIKfyve inhibitor 
YM201636, impairs amino acid-induced mTORC1 activation and late endosomal 
mTOR localization 
PtdIns(3,5)P2 along with PtdIns(3)P are fundamental for endomembrane sorting and 
endomembrane homeostasis (Michell et al., 2006). PtdIns(3,5)P2 is synthesized by 
the PtdIns(3)P 5-kinase PIKfyve (Fab1 in yeast) that catalyzes the 5-phosphorylation 
of PtdIns(3)P (Dove et al., 2009; Ikonomov et al., 2001; Sbrissa et al., 1999; 
Shisheva et al., 2001). PIKfyve is a fundamental kinase as genetic deletion in mice 
and C. elegans is embryonic lethal (Ikonomov et al., 2011; Nicot et al., 2006). 
Furthermore, cells having a defective PIKfyve kinase display a characteristic vacuolar 
phenotype. Overexpression of a catalytic inactive PIKfyve mutant or knockdown of 
PIKfyve results in swollen cytoplasmic vacuoles in many cell types and decreased 
PtdIns(3,5)P2 levels (Ikonomov et al., 2003; Ikonomov et al., 2006; Jefferies et al., 
2008; Rutherford et al., 2006). Enlarged vacuoles and decreased PtdIns(3,5)P2 have 
also been observed in different cell lines by pharmacologic inhibition of PIKfyve with 
the pyridofuropyrimidine compound YM201636, a specific PIKfyve inhibitor (Jefferies 
et al., 2008). The generation of these large vacuoles is regarded as a functional 
indication of reduced PtdIns(3,5)P2 levels or lost PIKfyve activity (Ikonomov et al., 
2011). Treatment of HEK293 and A375 cells with YM201636 for different times led to 
the formation of the well-characterized vacuolization phenotype (Fig. S6, see 
transmission pictures) thereby indicating a loss of PIKfyve activity. To investigate 
whether PtdIns(3,5)P2 might be required for amino acid-induced mTORC1 signaling, 
HEK293 and A375 cells were treated with different concentrations of YM201636 and 
Myc-S6K1 Thr389 phosphorylation analyzed by western blotting (Figs. 7A and Fig. 
7B). Already a low dose of 0.5 µM YM201636 almost completely blocked amino acid-
induced S6K1 Thr389 phosphorylation in HEK293 cells (Fig. 7A), while in A375 cells 
treatment with 1 µM YM201636 significantly decreased Thr389 phosphorylation to 
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50% (Fig. 7B). Over night treatment with 1 µM YM201636 in A375 could not further 
decrease Thr389 phosphorylation (Fig. 7B). The differential behavior in S6K1 Thr389 
phosphorylation observed between A375 and HEK293 cells is probably dependent 
on the constitutive active MAPK pathway in A375 cells due to V600E mutation in B-
Raf. It is known that active ERK and RSK either indirectly, via inhibition of the 
TSC1/TSC2 complex, or directly, via phosphorylation of raptor, activate mTORC1 
signaling (Carriere et al., 2008; Carriere et al., 2011; Langlais et al., 2011; Roux et 
al., 2004). Collectively, YM201636 almost completely blocks mTORC1-mediated 
S6K1 Thr389 phosphorylation in amino acid-stimulated HEK293 cells, while in A375 
cells the suppression is less pronounced probably due to the constitutive active 
MAPK pathway.  
 
Consistent with mTOR translocation to late endosomes being required for mTORC1 
signaling (Sancak et al., 2010; Sancak et al., 2008), we investigated whether 
YM201636 treatment affected the localization of mTOR in respect to Rab7. EGFP-
Rab7 was ectopically expressed in A375 cells and localization of endogenous mTOR 
examined by anti-mTOR antibody and by confocal microscopy (Fig. 7C). 
Interestingly, mTOR localization to Rab7 endosomes was significantly reduced by 
YM201636 treatment in amino acid stimulated cells compared to vehicle treated cells 
as evidenced in the ∆ Pearson’s correlation coefficient (Fig. 7C; representative 
microscopy pictures are shown in Fig. S7). The colocalization between mTOR and 
Rab7 after YM201636 treatment resembled that of amino acid starved cells (Fig. 7C). 
Together, PtdIns(3,5)P2 regulates mTORC1 signaling either by serving as a docking 
platform for mTORC1 association on late endosomes or as an important 
phospholipid involved in the maturation of early to late endosomes. Concerning 
endosome maturation, Flinn et al. claimed that when maturation from early to late 
endosome is blocked by constitutive active Rab5 or by deleting the Rab7 GEF 
(guanine exchange factor) Vps39, mTORC1 signaling is negatively affected (Flinn et 
al., 2010). PIKfyve has been shown to be required in the early-to-late endosome 
traffic and is essential for the organization of late endosomal/lysosomal compartment 
(Ikonomov et al., 2003; Ikonomov et al., 2006) consequently favoring the maturation 






Fig. 7: Inhibiting PtIns(3,5)P2 generation by treatment with the PIKfyve inhibitor YM201636, 
impairs amino acid-induced mTORC1 activation and late endosomal mTOR localization.  
(A and B) PIKfyve inhibition by YM201636 negatively affects amino acid-induced mTORC1 activation. 
Following 30h of Myc-S6K1 transfection, HEK293 (A) and A375 (B) cells were serum starved over night, 
amino acid depleted for 2h and re-stimulated with amino acids for 30 min. Where indicated, cells were 
either pre-treated with DMSO, different concentrations of YM201636 (0.1 µM, 0.5 µM and 1 µM), 100nM 
rapamycin (Rapa) or 1µM wortmannin (Wm) for 15 min prior to amino acid stimulation and inhibitors 
were re-added during amino acid stimulation. For over night (O/N) YM201636 treatment, 1 µM 
YM201636 was added each time to the cells when medium condition was changed. Cell lysates were 
processed for SDS-PAGE and indicated proteins analyzed by western blotting. Anti-α-Tubulin was used 
as loading control. S6K1 Thr389 phosphorylation was assessed for mTORC1 activity and Thr389 levels 
quantified using ImageJ and normalized to Myc-S6K1. Data are represented as mean ± SEM of n = 3 
experiments, exception O/N YM201636 treatment done n = 1 in HEK293 (A) and n = 2 in A375 (B) cells. 
*P<0.05, **P<0.01, ***P<0.001. 
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(Fig. 7 continued) 
(C) PIKfyve inhibition by YM201636 treatment affects mTOR localization on late endosomes. A375 cells 
were transfected with EGFP-Rab7 and 30h later cells were serum starved over night, amino acids 
depleted for 2h (-AA) and stimulated with amino acids for 30min (+AA). Prior to amino acid stimulation 
cells were pre-treated with 1 µM YM201636 for 15 min and re-added during amino acid stimulation, 
where indicated. After fixation, cells were immunostained for endogenous mTOR followed by 
AlexaFluor568-coupled secondary antibody. Images were acquired with a Zeiss confocal microscope 
and degree of mTOR colocalization to EGFP-Rab7 was determined by ∆ Pearson’s correlation 
coefficient of at least 16 different cells. Data are represented as mean ± SEM (*P<0.05, **P<0.01). 
Horizontal line demarcates the level of amino acid-starved cells from amino acid-stimulated cells treated 
with or without YM201636. Representative pictures used for quantification are depicted in 
supplementary figures (Fig. S7).  
(D) YM201636 is not an mTOR kinase inhibitor. HEK293 cells were co-transfected with HA-Raptor-
Rheb15 and Myc-S6K1 and 30 h later cells were over night serum starved and amino acid depleted for 
2h. Where indicated 1µM YM201636, 1µM PI-103 and 1µM pp242 were included during the last 45 min 
of amino acid depletion. Cell lysates and western blotting were processed as described above. Data are 
represented as mean ± SEM of n = 3 experiments, exception PI-103 and amino acid starved 
experiments done n = 2. **P<0.01, ***P<0.001. 
E) Chemical structures of YM201636 and PI-103. 
 
 
Because of the negative effect of YM201636 treatment on mTORC1 signaling and 
late endosomal mTOR localization (Figs. 7A-7C), we wondered whether these effects 
were due to the inhibition of the catalytic activity of mTOR. For that purpose we 
tested YM201636 in the absence of amino acids on constitutive active mTORC1, 
induced through the expression of HA-Raptor-Rheb15 in HEK293 cells (Fig. 7D). 
S6K1 Thr389 phosphorylation was completely blocked by two mTOR kinase 
inhibitors, pp242 and PI-103, the latter one being structurally related to YM201636 
(Fig. 7E), while YM201636 had no effect on mTORC1 activity (Fig. 7D). 
Consequently, YM201636 inhibits mTORC1 signaling by preventing the translocation 
of mTOR to late endosomes but not by inhibiting the kinase activity of mTOR.  
To exclude any effect of YM201636 treatment on PtdIns(3)P generation, we 
examined the intracellular distribution of EGFP-2xFYVEHRS in HEK293 and A375 
cells by confocal microscopy (Fig. S6). YM201636 did not affect endosomal 
localization of EGFP-2xFYVEHRS in both cells lines, while wortmannin treatment 
resulted in a diffused cytoplasmic localization of EGFP-2xFYVEHRS due to the 
inhibition of PtdIns(3)P synthesis (Fig S6). Interestingly, EGFP-2xFYVEHRS positive 
endosomes increased in size over time of YM201636 treatment either due to 
increased homotypic early endosome fusion or due to a block in forward membrane 
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transport from early to late endosomes. The latter would be consistent with a defect 
in membrane transport (Ikonomov et al., 2003; Ikonomov et al., 2006).  
Together, PIKfyve inhibition by YM201636 treatment negatively affects amino acid-
induced mTORC1 signaling by preventing the amino acid-induced translocation of 
mTOR on late endosomes rather than by blocking mTOR kinase activity or 
PtdIns(3)P synthesis. However, YM201636 is less effective in A375 cells than in 






In this study, we have characterized the role of PtdIns(3)P and PtdIns(3,5)P2 in the 
amino acid-dependent activation of mTORC1 and described how targeting 
PtdIns(3)P- and PtdIns(3,5)P2-generating kinases or changing intracellular levels of 
freely available PtdIns(3)P affects mTORC1 activity. 
We provide evidence that PIKfyve, the sole PtdIns(3)P 5-kinase, that synthesizes 
PtdIns(3,5)P2 from PtdIns(3)P (Dove et al., 2009; Ikonomov et al., 2001; Sbrissa et 
al., 1999; Shisheva et al., 2001), is implicated in the amino acid signaling pathway to 
mTORC1. PIKfyve and its phospholipid product PtdIns(3,5)P2 are mostly found on 
late endocytic compartments (Sbrissa et al., 2002; Shisheva et al., 2001). PIKfyve is 
necessary for several membrane trafficking pathways as retrograde transport from 
early/late endosomes to the trans-Golgi network (TGN) (Ikonomov et al., 2003b), 
morphogenesis of multivesicular bodies (Ikonomov et al., 2003), insulin-regulated 
GLUT4 vesicle transport (Berwick et al., 2004) and early-to-late endosome traffic 
(Ikonomov et al., 2003; Ikonomov et al., 2006). Here, we have assessed that PIKfyve 
is also involved in mTORC1 signaling. Inhibition of PIKfyve by YM201636 treatment, 
a PIKfyve inhibitor that specifically blocks PtdIns(3,5)P2 synthesis (Jefferies et al., 
2008), blunts amino acid-induced mTORC1 activation by preventing mTOR 
translocation to late endosomes, but without affecting mTOR kinase activity and 
PtdIns(3)P generation. Previous reports have shown that recruitment of mTOR to late 
endosomes/lysosomes by amino acid stimulation is important for mTORC1 activation 
(Sancak et al., 2010; Sancak et al., 2008). Conceivably, PtdIns(3,5)P2 might serve as 
a docking platform for mTORC1 association on late endocytic compartments. On the 
other hand intracellular trafficking, especially maturation of early to late endosomes 
also impinges on mTORC1 activation (Flinn et al., 2010; Li et al., 2010). When early 
to late endosome conversion is blocked by ectopic expression of constitutive active 
Rab5 or by knockdown of Rab7 GEF hVps39 mTORC1 activation is blunted, 
probably due to the formation of a hybrid endosome that contain both markers for 
both early and late endosomes (Flinn et al., 2010). PIKfyve regulated PtdIns(3)P-to-
PtdIns(3,5)P2 transition has been shown to be important for the organization of late 
endosomes/lysosomes (Ikonomov et al., 2006), therefore it might be possible that 
PIKfyve is involved in the early-to-late endosome maturation process. Consistently, 
by inhibiting PIKfyve, increased EGFP-2xFYVEHRS-positive endosomes have been 
observed that were generated probably due to a defect in membrane transport. This 
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would explain why inhibition of PIKfyve impairs amino acid-induced mTORC1 
activation.  
 
Similarly to PIKfyve inhibition, masking PtdIns(3)P by EGFP-FYVEHRS expression 
inhibits mTORC1 activation possibly by affecting membrane transport. Consistently, it 
has been demonstrated that EGFR (epidermal growth factor receptor) stays trapped 
in early endosomes by EGFP-2FYVEHRS overexpression (Petiot et al., 2003). 
Moreover, PIKfyve uses PtdIns(3)P as a substrate for the formation of PtdIns(3,5)P2 
(Sbrissa et al., 1999; Shisheva et al., 1999) and as a membrane docking through its 
FYVE finger domain (Sbrissa et al., 2002; Shisheva et al., 1999). Masking PtdIns(3)P 
by 2xFYVEHRS deprives PIKfyve of its substrate and displaces PIKfyve from its 
membrane localization and consequently PtdIns(3,5)P2 production is lost.  
Interestingly, we demonstrated that acute treatment with the membrane permeant 
PtdIns(3)P/AM increases almost 2-fold amino acid-induced S6K1 Th389 
phosphorylation compared to control. Cell fractionation studies have demonstrated 
that PIKfyve is to 70% cytosolic (Sbrissa et al., 2002), therefore acute PtdIns(3)P/AM 
treatment can lead to higher mobilization of PIKfyve to endomembrane 
compartments and therefore to increased PtdIns(3,5)P2 formation and consequently 
to increased mTORC1 activation.  
 
PtdIns(3,5)P2 is derived from the sequential phosphorylation of PtdIns. hVps34 
catalyzes the 3-phosphorylation of PtdIns to form PtdIns(3)P that is eventually used 
for 5-phosphorylation catalyzed by PIKfyve resulting in PtdIns(3,5)P2 formation. 
Therefore, manipulation of PtdIns(3)P levels by deleting the expression of hVp34 is 
expected to have a negative effect on mTORC1 activation as has been demonstrated 
previously (Byfield et al., 2005; Nobukuni et al., 2005; Yoon et al., 2011). However, 
unlike to these reports, we were unable to see a complete decrease in amino acid-
induced mTORC1 activation by depleting hVps34 expression in HEK293 and A375 
melanoma cells. Similarly, Xu et al were not able to see a significant reduction in 
amino acid-induced S6K1 Thr389 phosphorylation by hVps34 knockdown in T24 
bladder cancer cells, but only by deleting hVps15/p150, the adaptor of hVps34, a 
marked reduction in mTORC1 activation was observed (Xu et al., 2011). Elimination 
of hVps34 is expected to deplete intracellular PtdIns(3)P similar to wortmannin 
treatment. Despite hVps34 knockdown, PtdIns(3)P was still formed as demonstrated 
by the endosomal localization of EGFP-2xFYVEHRS. This result might explain why 
mTORC1 activity was still present in the Vps34 depleted cells. Moreover, hVps34 
knockdown cells proliferated similarly to control cells.  
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The connection between hVps34 and mTORC1 in the amino acid pathway has been 
shown to be controversial. Genetic elimination of Vps34 in Drosophila has no impact 
on dTORC1 signaling, while autophagy and endocytosis are affected (Juhasz et al., 
2008). Recently, Vps34 knock out mice have been generated, where homozygous 
Vps34 null mice are embryonic lethal and die between E7.5 and E8.5 of 
embryogenesis due to severely reduced cell proliferation (Zhou et al., 2011). 
Additionally, phospho-S6 staining in E6.5 Vps34 null embryos is drastically reduced 
compared to control embryos thereby providing evidence that mTORC1 signaling is 
reduced in Vps34 mutant embryos (Zhou et al., 2011). This result suggests that in 
mammalian cells, Vps34 is implicated in the mTORC1 signaling. However, during 
early stages of development the embryo is dependent on branched chain amino 
acids and glucose (Martin and Sutherland, 2001). During these early stages 
autophagy provides the embryo with the required nutrients. Since Vps34 is involved 
in the autophagic process (Simonsen and Tooze, 2009), it is conceivable that the 
phospho-S6 phenotype observed in Vps34 null embryos is a consequence of nutrient 
shortage due to the disrupted autophagy rather than a direct involvement of Vps34 in 
the nutrient regulation to mTORC1.  
 
In cells, PtdIns(3)P generation is not exclusively dependent on hVps34. In C. elegans 
RNAi-mediated deletion of myotubularin 6 (MTM6), a PtdIns(3)P phosphatase, in 
Vps34 knockout larvae (let-512 mutants) restored PtdIns(3)P levels and rescued 
lethality of the let-512 mutants (Xue et al., 2003). Interestingly, the kinase responsible 
for the generation of PtdIns(3)P in the let-512 mutants has been shown to be class II 
PI3K (Xue et al., 2003). Therefore, it is possible that the class II PI3K might 
compensate for the loss of hVps34 in the amino acid signaling pathway to mTORC1. 
Class II PI3Ks are poorly understood kinases, but there are some evidences that 
they preferentially generate PtdIns(3)P in vivo (Falasca and Maffucci, 2007; Maffucci 
et al., 2005; Wen et al., 2008). To our surprise depletion of PI3K-C2α and PI3K-C2β 
resulted in an isoform specific effect on amino acid-dependent mTORC1 activation. 
While knockdown of PI3K-C2α increased mTORC1 activation, knockdown of PI3K-
C2β decreased it to approximate 50% similar to the result obtained by silencing 
hVps34. However, when performing a double PI3K-C2β/hVps34 knockdown no 
additional decrease in amino acid-induced mTORC1 activation could be observed 
(unpublished data).  
There are alternative pathways for the generation of PtdIns(3)P that do not require 
the direct 3-phosphorylation of PtdIns, which might have an impact on mTORC1. It 
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has been shown that PtdIns(3,4,5)P3 generated by class IA PI3Kβ, p110β, is 
sequentially dephosphorylated by phosphoinositide 4- and 5-phosphatases (Shin et 
al., 2005). Alternatively, type I alpha inositol polyphosphate 4-phosphatase has been 
found to be localized on early and recycling endosomes and forms PtdIns(3)P by 
dephosphorylating PtdIns(3,4)P2 (Ivetac et al., 2005). 
 
In these report we show a mechanistic role of PtdIns(3)P and PtdIns(3,5)P2 in the 
regulation of mTORC1 by amino acid stimulation. With in mind that progression of 
early endosomes to late endosome is involved in amino acids signaling to mTORC1 
(Flinn et al., 2010), the PtdIns(3)P-to-PtdIns(3,5)P2 transition might be involved in the 
same process. 
 
PtdIns(3)P and PtdIns(3,5)P2 do not directly affect mTORC1 activation rather they 
are involved in the formation of late endosomes that might serve as a signaling 
platform for mTORC1. However, when HA-Raptor-Rheb15 is ectopically expressed, 
mTORC1 activity is independent of PtdIns(3)P and PtdIns(3,5)P2, probably because 
the targeting sequence of Rheb fused to raptor guides mTORC1 to Rheb-containing 
endosomal compartments allowing mTORC1 to be activated by Rheb.  
 
We are the first to show that the PIKfyve inhibitor YM201636 blocks amino acid-
induced mTORC1 activation but without affecting the mTOR kinase activity. Our 
preliminary data further show that YM201636 negatively affects proliferation in 
HEK293 cells without affecting the canonical PI3K/PKB pathway (data not shown). 
The implication of PIKfyve in cell proliferative capacity has also been demonstrated in 
PIKfyve null MEFs, where they have a profound arrest in DNA synthesis (Ikonomov 
et al., 2011). However, PIKfyve is likely not suitable as a cancer target. In A375 
melanoma cells, that have a constitutive active MAPK kinase pathway, the effect of 
YM201636 treatment on mTORC1 activity is less pronounced. Additionally, A375 
cells proliferate undisturbed by YM20636 treatment (data not shown). A 
combinatorial treatment of YM201636 with a MAPK kinase inhibitor might be more 
effective in blocking mTORC1 activity and proliferation.  
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4.6 Supplementary figures 
 
Suppl. Fig. 1 
 
 
Fig. S1 (related to Fig. 2): Silencing of hVps34 does not affect PtdIns(3)P generation.  
A375 cells were transduced with lentivirus with shRNA against hVps34 (shRNA hVps34) and empty 
vector (shRNA mock) and selected with puromycin followed by EGFP-2xFYVE
HRS
 transfection in order 
to visualize PtdIns(3)P-containing endosomes. Cells were maintained in complete medium (RPMI 
supplemented with 2 mM L-glutamine and 10% FCS) and 48h later cells were either treated with 
DMSO or 100nM wortmannin for 30min. After fixation, nuclei were stained with Hoechst and cells 




Suppl. Fig. 2 
 
 
Fig. S2 (related to Fig. 3): PI3K-C2α and PI3K-C2β are not involved in the growth factor-induced 
mTORC1 and PI3K activation.  
HEK293 cells were transfected with Myc-S6K1 followed 24h later by siRNA transfection with three 
different siRNA duplexes against either PI3K-C2α (siRNA C2α #1, #2 and #3) (A) or PI3K-C2β (siRNA 
C2β #1, #2 and #3) (B) and siRNA control duplex was included as negative control (control siRNA). 
After 48h, cells were over night serum starved (-serum) and stimulated with 50 ng/ml IGF-II for 5 min 
(+IGF-II). Cell lysates were processed for SDS-PAGE and indicated proteins analyzed by western 
blotting. Anti-α-Tubulin was used as loading control. mTORC1 activity was assessed by S6K1 Thr389 
phosphorylation and PI3K activity by PKB Thr308 and Ser473 phosphorylation. Levels of 
phosphorylated Thr389 were quantified using ImageJ and normalized to Myc-S6K1. Data are 




Suppl. Fig. 3 
 
 
Fig. S3 (related to Fig. 4): PtdIns(3)P-dependent activation of mTORC1 in HER911 cells. 
(A) Concentration-dependent sequester of PtdIns(3)P inhibits amino acid-induced mTORC1 activation in 
a concentration-dependent manner. HER911 cells were co-transfected with Myc-S6K1 and increasing 
amounts of EGFP-2xFYVE
HRS
. Thirty hours later cells were serum starved over night, amino acid 
depleted for 2h and re-stimulated with amino acids for 30 min. Cell lysates were processed for SDS-
PAGE and the indicated proteins were analyzed by western blotting. Anti-α-Tubulin was used as loading 
control and mTORC1 activity measured by S6K1 Thr389 phosphorylation. Levels of phosphorylated 
Thr389 were quantified using ImageJ and normalized to the levels of Myc-S6K1. Data represented as 
mean ± SEM of n = 3 experiments. 
(B) Masking PtdIns(3)P negatively affects mTORC1 activity. HER911 cells were co-transfected with 
Myc-S6K together either EGFP-2xFYVE
HRS
 wild type (wt), EGFP-2xFYVE
HRS
 lipid-binding deficient 
mutant (CS) or empty vector. Cells were starved and stimulated as described in (A). Where indicated, 
cells were pre-treated with 100nM rapamycin for 15 min prior to amino acid stimulation. Cells and 
western blotting were processed and analyzed as described in (A). Data represented as mean ± SEM of 




Suppl. Fig. 4 
 
 
Fig. S4 (related to Fig. 6A): Translocation of mTOR to late endosomes by amino acid 
stimulation.  
A375 cells were transfected and processed as described in Fig. 6A. Images of A375 cells expressing 
EGFP-Rab5a (green) or EGFP-Rab7 (green) immunostained for endogenous mTOR (red) after amino 
acid starvation, amino acid stimulation with or without treatment with 100 nM rapamycin or 1 µM 
wortmannin and maintained in complete medium (RPMI
C
). Nuclei were stained with Hoechst and 
colocalization depicted in the merge pictures. Scale bars represent 10 µm. 
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Suppl. Fig. 5 
 
 
Fig. S5 (related to Fig. 6B): HA-Raptor-Rheb15 targets mTOR to endosomal membranes.  
(A and B) HEK293 (A) and A375 (B) cells were transfected and processed as described in Fig. 6B. 
Images of HEK293 (A) and A375 (B) cells co-expressing EGFP-Rab5a (green) and EGFP-Rab7 (green) 
with HA-Raptor or HA-Raptor-Rheb15 immunostained for HA (red) after amino acid starvation. Nuclei 





Suppl. Fig. 6 
 
 
Fig. S6 (related to Fig. 7): PIKfyve inhibition by YM201636 treatment does not block PtdIns(3)P 
generation  
HEK293 (A) and A375 (B) cells were transfected with the PtdIns(3)P probe EGFP-2xFYVE
HRS
 and 
maintained in complete medium (DMEM
C
 for HEK293 and RPMI
C
 for A375 cells supplemented with 2 
mM L-glutamine and 10% FCS). After 48h, cells were incubated with 1 µM YM201636 for different time 
points (0, 1 and 20h) followed by a 30 min treatment with either DMSO or 1 µM wortmannin. Cells were 
fixed and nuclei stained with Hoechst. Images were acquired with a Zeiss confocal microscope. Arrows 
indicate swollen vacuoles in the transmission figure. Scale bars represent 10 µm. 
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Suppl. Fig. 7 
 
 
Fig. S7 (related to Fig. 7C): PIKfyve inhibition by YM201636 treatment affects mTOR localization 
on late endosomes. 
A375 cells were transfected and processed as described in Fig. 7C. Images of A375 cells expressing 
EGFP-Rab7 (green) immunostained for endogenous mTOR (red) after amino acid starvation and amino 
acid re-stimulation with DMSO or 1 µM YM201636. Nuclei were stained with Hoechst and colocalization 
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5 General discussion and conclusion 
 
In mammalian cells, mTORC1 senses intracellular amino acid status through a still 
undefined mechanism and regulates translation by phosphorylating key regulatory 
proteins such as S6K1 and 4E-BP1. Cultured cells can be easily manipulated and by 
withdrawing amino acids from the culture medium, mTORC1 signaling is completely 
inhibited thereby blocking cell growth and activating the catabolic process autophagy 
in order to produce energy during this period of stress. However, in higher organism 
such as humans, the bloodstream supplies the body constantly with nutrients. There 
are fluctuations in nutrient levels during food intake, but the organism will never suffer 
from complete nutrient deprivation. Nonetheless, it is important to elucidate in a 
cellular context how amino acid sufficiency is sensed, especially with in mind that 
cancers/tumors increase amino acids uptake via upregulating the expression of 
amino acid transporters (Fuchs and Bode, 2005) presumably to sustain their 
continuous growth. Elevated expression of the system L transporter LAT1 is 
associated with advanced glioblastoma and poorer prognosis (reviewed in Edinger, 
2007). Pharmacologic inhibition of LAT1 leads to inhibition of cancer cell growth 
thereby defining amino acid transporters as drug targets for cancer chemotherapy 
(Ganapathy et al., 2009). Alternatively, the intracellular amino acid sensor might also 
be a good candidate as a cancer drug target. However, an amino acid sensor has not 
been characterized yet. But it is known that cells somehow sense amino acid 
sufficiency and transmit the signal to mTORC1 (Beugnet et al., 2003; Christie et al., 
2002). In the recent years, proteins mediating the amino acid input to mTORC1 have 
started to be uncovered. Of great interest are the recently identified Rag GTPases 
and their role in translocating mTORC1 from an unknown compartment to late 
endosomes/lysosomes in response to amino acid stimulation, thereby bringing 
mTORC1 close to its activator Rheb (Sancak et al., 2010; Sancak et al., 2008). Other 
potential amino acid mediators such as MAP4K3, hVps34 and PLD1 have also been 
identified to be implicated in mTORC1 activation (Byfield et al., 2005; Findlay et al., 
2007; Nobukuni et al., 2005; Xu et al., 2011; Yan et al., 2010; Yoon et al., 2011). It is 
unknown whether a relationship between these proteins and Rag GTPases exist, or 
whether they function in a parallel pathway to the Rag GTPase as it was recently 
proposed for PLD1 (Yoon et al., 2011).  
 
The role of hVps34 in mediating the amino acid signal to mTORC1 is in my opinion 
still unclear. Experimental evidences demonstrate that PtdIns(3)P, which is formed 
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by hVps34 (Stack and Emr, 1994; Volinia et al., 1995), is important in the activation 
of mTORC1 (this present study; Nobukuni et al., 2005; Yoon et al., 2011). However, 
deletion of either hVps34 or class II PI3K isoforms, which might also generate 
PtdIns(3)P in vivo (Falasca and Maffucci, 2007; Maffucci et al., 2005; Wen et al., 
2008), do not completely abrogate mTORC1 signaling, probably because cells find 
alternative pathways in synthesizing PtdIns(3)P to compensate for the loss of 
PtdIns(3)P (Ivetac et al., 2005; Shin et al., 2005). Indeed, confocal microscopy 
analyses revealed that in hVps34 knockdown cells the PtdIns(3)P sensor EGFP-
2FYVEHRS still localizes to endomembrane compartments as in control cells. 
However, the importance of PtdIns(3)P in regulating amino acid-induced mTORC1 
activation is demonstrated by the sequester of PtdIns(3)P using 2xFYVEHRS. The 
specificity of PtdIns(3)P in regulating mTORC1 is further underscored by the finding 
that masking other 3-phosphorylated PIs such as PtdIns(3,4)P2 and PtdIns(3,4,5)P3 
does not affect mTORC1 signaling. Interestingly, the role of PtdIns(3)P in regulating 
mTORC1 activation is not only restricted to amino acid stimulation, but is also 
needed during IGF-II stimulation of serum starved cells and at steady-state 
conditions. Conceivably, PtdIns(3)P does not function as a amino acid mediator but 
owing to its role in endosomal membrane transport (Odorizzi et al., 2000; Reaves et 
al., 1996) might be involved in regulating the intracellular localization of mTORC1. On 
the other hand, PtdIns(3)P might be required to recruit effector proteins that 
somehow are involved in the regulation of mTORC1.  
 
Another phosphoinositide involved in membrane transport is PtdIns(3,5)P2 (Ikonomov 
et al., 2003; Ikonomov et al., 2006), and similarly to PtdIns(3)P might also affect 
mTORC1 signaling. Indeed, blocking PtdIns(3,5)P2 formation by pharmacologic 
inhibition of PIKfyve blunts amino acid-induced mTORC1 activation by diminishing 
the degree of late endosomal localization of mTOR rather than by blocking mTOR 
kinase activity. From our experiments, however, it is not obvious whether PIKfyve 
inhibition blocks translocation of mTOR to late endosomes or formation of late 
endosomes, where mTOR should translocate to. The formation of increased EGFP-
2xFYVEHRS positive vesicles indicates a block in membrane transport at the early 
endosomal level and therefore in a possible block of late endosome formation. In this 
respect, blocking the maturation of early endosome to late endosome prevents 
mTORC1 activation by amino acid or insulin stimulation (Flinn et al., 2010). However, 
it is not clear how formation of late endosomes might facilitate mTORC1 activation. 
Since endogenous farnesylated Rheb is believed to localize on late 
endosmes/lysosomes (Buerger et al., 2006; Sancak et al., 2008), the formation of 
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late endosomes increases the ability of Rheb to interact with mTORC1. This would 
explain why overexpression of Rheb activates mTORC1 in the absence of amino 
acids. Presumably due to overexpression, Rheb overflows the cell and randomly 
interacts with and activates mTORC1 without the requirement of amino acid-
stimulated translocation of mTORC1 to late endosomes. Similarly, artificial 
positioning of mTORC1 to late endosomes/lysosomes, induced through the 
expression of HA-Raptor-Rheb15, renders mTORC1 resistant to amino acid 
starvation or to treatment with the PIKfyve inhibitor. 
 
Concern exists in using YM201636 (PIKfyve inhibitor) as a cancer drug. While 
PIKfyve inhibition in HEK293 cells almost completely blocks amino acid-induced 
mTORC1 activation, in A375 melanoma cell line, which has a constitutive active 
MAPK kinase pathway, the effect on mTORC1 signaling is less pronounced. A 
combination of YM201636 and a MAPK or B-Raf inhibitor would most probably blunt 
mTORC1 activation. Therefore YM201636 cannot be regarded as an exclusive drug 
against cancer.  
 
With in mind that PIKfyve inhibition most probably affects early to late endosome 
maturation, it might also affect early to late phagosome maturation. This is of special 
interest in cells of the innate immune system that take up invading microorganisms 
through phagocytosis into a so-called phagosome, which through maturation 
becomes competent to fuse with lysosomes where microorganisms will eventually be 
degraded (Pieters, 2001). Microorganisms, such as Mycobacterium tuberculosis, 
once inside a phagosome have developed means to circumvent this maturation 
process thereby becoming intracellular parasites (Sundaramurthy and Pieters, 2007). 
Therefore, treatment with YM201636 would favor the survival of engulfed 
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AccuGel 29:1, ultra pure (40 % acrylamide stock) National Diagnostics 
Acetic acid Scharlau 
Acetone, analytical grade Scharlau 
Adenosine-5’-triphosphate (ATP) Roche 
32P-γ Adenosine-5’-triphosphate (32P-γ-ATP) Perkin Elmer 
Agar, technical grade Difco 
Agarose, standard Eurobio 
Albumin from bovine serum, BioChemika fraction V Fluka 
Ammonia solution 25 % Merck 
Ammonium persulfate (APS) Bio-Rad 
Ampicillin trihydrate Fluka 
Aprotinin Fluka 
Bacto-Tryptone BD 
Bacto-Yeast Extract BD 
Bromophenole blue sodium salt Riedel-de Haen 
Calcium chloride (CaCl2 x 2H2O) Fluka 
Chloroform Scharlau 
Coomaasie brilliant blue R-250 Serva 
Deoxynucleotides (dNTPs) Sigma 
Dimethylsulfoxide (DMSO) Sigma 
Dithiothreitol (DTT) Eurobio 
DNA AluI marker (low range) Fermentas 
DNA Lambda molecular weight marker (high range) LabForce 
T4 DNA ligase NEB 
Ethanol, absolute, HPLC grade Scharlau 
Ethidium bromide Sigma 
Ethylene diamine tetraacetate (EDTA) Fluka 
Fetal calf serum Sigma 
D (+)-glucose-monohydrate Fluka 
L-Glutamine, 200mM Sigma 
Glycerol, anhydrous Fluka 




HOECHST 33342 Juro Supply 
Hydrochloric acid (HCl) Merck 
Iron(III)nitrate nonahydrate (FeN3O9 x 9H2O) Fluka 
Isopropanol, analytical grade Scharlau 
Kanamycin sulfate Fluka 
Leupeptin Alexis Corporation 
Lithium chloride, anhydrous Fluka 
Magnesium chloride hexahydrate (MgCl2 x 6H2O) Fluka 
Magnesium sulphate heptahydrate (MgSO4 x 7H2O) Fluka 
Manganese chloride tetrahydrate (MnCl2 x 4H2O) Merck 
MEM Vitamin solution Amimed 
β-mercaptoethanol Sigma 
Methanol, HPLC grade Scharlau 
3-Methyladenine Fluka 
Milk powder (non-fat) Migros 
Mowiol Clariant 
Nonidet P40 (NP-40) Fluka 
Paraffin Richard-Allan Scientific 
Paraformaldehyde, powder, 95% pure Sigma 
PCR primers Microsynth 
Penicillin-Streptomycin solution Sigma 
Pepstatin A Alexis Corporation 
Phenylmethylsulfonylfluoride (PMSF) Fluka 
L-α-Phosphatidylinositol (PI) Sigma 
Phosphatidyl-L-Serine (PS) Sigma 
Potassium chloride (KCl) Fluka 
Potassium dihydrogen phosphate (KH2PO4) Fluka 
Potassium hydroxide (KOH) Merck 
Pwo DNA Polymerase  Roche 
Restriction Enzymes New England Biolabs 
Saponin (from Quillaja bark) Sigma 
SDS-PAGE prestained molecular weight marker (27 kDa-180 kDa) Sigma 
Sodium acetate (CH3COONa) Fluka 
Sodium azide (NaN3) Sigma 
Sodium chloride (NaCl) Fluka 
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Sodium dihydrogen phosphate dihydrate (NaH2PO4 x 2H2O) Fluka 
Sodium dodecyl sulfate (SDS) Fluka 
Sodium fluoride (NaF) Fluka 
Sodium hydrogen carbonate (NaHCO3) Fluka 
Sodium hydroxide (NaOH) Merck 
Sodium orthovanadate (Na3VO4) Sigma 
N,N,N’,N’tetramethylenethylenediamine (TEMED) Bio-Rad 
Triton X-100 Fluka 
Trizma Base (Tris) Sigma 
Trypsin-EDTA solution (10x) Sigma 
Tween 20 Fluka 
Water, endotoxin-free Sigma 






NVP-BAG956 Novartis, Basel 
NVP-BBD130 Novartis, Basel 
NVP-BEZ235 Novartis, Basel 
NVP-BGT226 Novartis Basel 
PI-103 Enzo 
pp242 Chemdea 
Rapamycin LC Laboratories 
Wortmannin Sandoz 
YM201636 Chemdea 




Bio-Rad Protein Assay Bio-Rad 
Protein G Sepharose 4 Fast Flow GE Healthcare GE Healthcare 
GenElute Gel Extraction Kit Sigma 
GenElute HP Endotoxin-Free Plasmid Maxiprep Kit Sigma 
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GenElute Plasmid Miniprep Kit Sigma 
Glutathione Sepharose 4B beads Amersham Biosciences 
Immobilon Western, Chemiluminescent HRP Substrate Millipore 
JetPEI DNA transfection agent Polyplus 
Min Elute PCR purification Kit Qiagen 
Pwo DNA Polymerase and PCR buffer Roche 
QIAGEN Plasmid Maxi Kit Qiagen 
QIAGEN Spin, Miniprep Kit Qiagen 
QIAquick Gel Extraction Kit Qiagen 
Taq DNA polymerase and PCR buffer New England Biolabs 
 
6.4 General buffers and solutions 
 
Blue Juice (10x) 80% glycerol 
(DNA loading buffer) 20% EDTA of 0.5M pH 8.0 
 1 spatula Bromophenole blue 
 1 spatula Xylene Cyanol FF 
 
Coomassie blue staining solution  0.1% Coomassie blue R-250 
 50% methanol 
 7% acetic acid 
 43% ddH2O 
 
Destaining solution for membrane 90% ethanol 
 2% acetic acid 
 8% ddH2O 
 
Stripping buffer 62.5mM Tris-HCl pH 6.7 
 2% SDS 
 100 mM β-Mercaptoethanol 
 
10x PBS 28.4 g Na2HPO4 x 2H2O 
 3.8 g KH2PO4 
 3.8 g KCl 
 159 g NaCl 
 pH adjusted to 7.4 
 filled up to 2 liters with ddH2O 
 sterilized by autoclaving 
 
10x TBS 24.2 g Trizma Base 
 80 g NaCl 
 pH adjusted to 7.6 with HCl 
 filled up to 1 liter with ddH2O 
 
1x TBS-T 1x TBS + 0.1% (v/v) Tween 20 
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5x sample buffer 2.5 ml of 1.25 M Tris-HCl pH 6.8 
 1 g SDS 
 2.5 ml β-Mercaptoethanol 
 5.8 ml of 87% glycerol 
 5 mg bromophenol blue 
 35 ml ddH2O 
 stirred until SDS and bromophenol  
 blue had dissolved and filled up to  
 50 ml with ddH2O. Stored at -20°C 
 
1M Tris-HCl 121.14 g Trizma Base  
 dissolved in 800 ml ddH2O and  
 pH adjusted to the desired value by  
 adding HCl. Volume adjusted to  
 1 l with ddH2O.  
 Sterilized by autoclaving. 
 
Standard lysis buffer 20 mM Tris-HCl pH 8.0 
 138 mM NaCl 
 2.7 mM KCl 
 5% glycerol 
 1% NP-40 
 
100x Leupeptin (2mM) dissolved in ddH2O 
 
100x Pepstatin (1.8mM) dissolved in methanol 
 
100x PMSF (100mM) dissolved in ethanol 
 
1000x Aprotinin (1 mg/ml) dissolved in ddH2O 
 
500 mM NaF  dissolved in ddH2O 
 
100 mM Na3VO4  dissolved in ddH2O 
 
10x electrode buffer (Tris-Glycine) 30.3 g Tris-HCl (250mM Tris-HCl) 
 144.2 g glycine (1.92 M glycine) 
 10 g SDS (1% SDS) 
 dissolved in 800 µl dH2O and filled up  
 to 1 l with ddH2O (pH approx. 8.3) 
 
10x transfer buffer 250 mM Tris-HCl 
 1.92 M glycine 
 For 1x transfer buffer, methanol  
 added to a final concentration  
 of 20% (v/v)  
 
50x TAE (5 liters) 1.21 kg Trizma base dissolved in H2O, 
 500ml 500 mM EDTA pH 8.0 and  
 285.5 ml glacial acetic acid added,  
 volume adjusted to 5 l with ddH2O 
 
10x TE pH 7.5 100 mM Tris-HCl pH 7.5 
 10 mM EDTA pH 8.0 
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3% paraformaldehyde (PFA) in PBS (20 ml) 18 ml ddH2O and 7.5 µl 1 M NaOH  
 added to 600 mg PFA, stirring on a  
 hot plate until PFA is dissolved,  
 2ml 10x PBS pH 6.55 added, mixed,  
 cooled to 37°C and pH adjusted to  
 pH 7.2 
 
6.5 Bacterial media and supplements 
 
LB Miller 10 g NaCl 
 5 g yeast extract 
 10 g Bacto-Tryptone 
 5 ml 1 M NaOH 
 filled up to 1 l with ddH2O and  
 sterilized by autoclaving. 
 
LB Miller agar LB Miller + 12.5 g agar 
 after autoclaving, medium cooled  
 down to 60°C, appropriate antibiotics  
 added, plate poured and stored at 4°C 
 
1 liter SOC 20 g Bacto-Tryptone 
 5 g yeast extract 
 0.5 g NaCl 
 2.5 ml 1M KCl 
 10ml 1M MgCl2 
 200 µl 5 M NaOH 
 980 ml ddH2O 
 sterilized by autoclaving 
 20 ml sterile 1 M glucose added 
 
Ampicillin (1000x) stock 100 mg/ml in ddH2O (complete  
 solubilization achieved by adding  
 NaOH), used for cultures at 100 µg/ml 
 
Kanamycin (1000x) stock 25 mg/ml in ddH2O, used for  
 cultures at 25 µg/ml 
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Fetal calf serum (FCS) Sigma 
100x L-Glutamine (200 mM) Sigma 
100x Penicillin-Streptomycin solution Sigma 
100x MEM vitamin solution Amimed 
Puromycin Clontech, stock in distilled  
 ddH2O at 1 mg/ml, used for  
 cultures at 1 µg/ml 
10x Trypsin-EDTA solution Sigma 
Amino acid depleting buffer (- AA buffer); 500ml 900 µl 1 M CaCl2 
 100 µl 0.5 mg/ml  Fe(NO3)3 
 405 µl 1 M MgSO4 
 2.685 ml 1 M KCl 
 22 ml 1 M NaHCO3 
 18.22 ml 3 M NaCl 
 181.2 µl 2.5 M NaH2PO4 
 12.5 ml 1 M Glucose 
 20 ml 100x MEM vitamins 
 ddH2O filled up to 500 ml 
 pH adjusted to 7.4 and  
 sterilized by filtrating through  
 a 0.22 µm filter  
 (Steritop, Millipore) 
 




Name Vector Insert Constructor 
(reference) 
Application 
pcDNA3__p9 pcDNA3  www.invitrogen.com Subcloning and transfection 
pRK5_Myc-S6K1__p237 pRK5 S6K1 George Thomas 
University of Cincinnati 
(Cincinnati Ohio, USA) 
Expression of myc-tagged S6K1 




pcDNA3 hVps34 Laboratory plasmid 
collection 
Matthias P. Wymann 
University of Basel 
(Switzerland) 
Expression of GST-hVps34 in 
mammalian cells 
pEGFP-N1_PH-Btk__p530 pEGFP-N1 PH Btk Tamas Balla 
National institute of child 




PtdIns(3,4,5)P3 sensor  
Expression of EGFP-PH-Btk in 
mammalian cells for western 
blotting purpose  
pcDNA3_p110g wt-CAAX-
KI__p594 
pcDNA3 p110 wt-CAAX Laboratory plasmid 
collection 
Matthias P. Wymann 
University of Basel 
(Switzerland) 
Subcloning CAAX box of K-Ras 
to c-terminus of Raptor (into 
plasmid #1275) 
pEGFP-C1__p601 pEGFP-C1  www.clonetech.com Subcloning, GFP expression 
pEGFP-
C2_2xFYVEHRS__p607 
pEGFP-C2 2xFYVE HRS Laboratory plasmid 
collection 
Matthias P. Wymann 




HRS in eukaryotic cells for 




pEGFP-C1 PH TAPP1 Laboratory plasmid 
collection 
Matthias P. Wymann 
University of Basel 
(Switzerland) 
PtdIns(3,4)P2 sensor 
Expression of EGFP-PH-TAPP1 




pcDNA3 hVps34 Anna Melone  Expression of wild type HA-
hVps34 in mammalian cells 
pcDNA3_tkGST-hVps34 
K636R__p1122 
pcDNA3 hVps34 K636R Anna Melone  Expression of kinase-dead GST-
hVps34 in mammalian cells 
pcDNA3_tkHA-hVps34 
K636R__p1130 
pcDNA3 hVps34 K636R Anna Melone  Expression of kinase inactive 
HA-hVps34 in mammalian cells 
pRK5_HA-Raptor__p1275 pRK5 HA-Raptor Mike Hall 
University of Basel 
(Switzerland) 
Subcloning and expression of 




pEGFP-C1 Rheb1 Mike Hall 
University of Basel 
(Switzerland) 
Subcloning the very last 15 
amino acids of Rheb to the C-
terminus of Raptor (into plasmid 
#1275) 
pcDNA3.1_Rab5a__p1287 pcDNA3.1 Rab5a Missouri S&T Resource 
Center, www.cdna.org 
Subcloning into pEGFP-C1 
expression vector 
pcDNA3.1_Rab7__p1289 pcDNA3.1 Rab7 Missouri S&T Resource 
Center, www.cdna.org 




pEGFP-C1 Rab5a Anna Melone Detection of EGFP-Rab5a 
compartments by microscopy 
pEGFP-C1_Rab7__p1315 pEGFP-C1 Rab7 Anna Melone  Detection of EGFP-Rab7 





Anna Melone  Expression of HA-tagged Raptor-
CAAX (K-Ras) in mammalian 





Anna Melone  Expression of HA-tagged Raptor-
Rheb15 in mammalian cells for 




pEGFP-C2 2xFYVE HRS 
C215S 
Harald Stenmark 





HRS C215S in mammalian cells 
for microscopy and western 
blotting purposes 
Plasmid maps can be found in Appendix 7.3. 




Name Sequence (5’-3’) Source Application 
GPO-1#135 ACT CCT ACG GGA GGC AGC AGT A Emilio Hirsch  
University of Torino 
(Italy) 
Testing for mycoplasma 
contamination 
MGSO#136 TGC ACC ATC TGT CAC TCT GTT 
AAC CTC 
Emilio Hirsch  
University of Torino 
(Italy) 
Testing for mycoplasma 
contamination 
spV34BEf#475 TTA GAG GAA TAA TTC CGG AAA 
CAG CT 
Anna Melone  Sequencing primer upstream 
of BspEI site in human 
Vps34 
sphV34Bef#599 GAA GGC AGT ACA ACG CGA AAG 
TGG 
Anna Melone Forward sequencing primer 
for the generation of K636R 
hVps34 by SOE-PCR 
mpV34KRf#717 CCA GTT ATA TTT CGC CAT GGA 
GAT GAT TTA CGT CAA GAT CA 
Anna Melone Forward mutagenesis primer 
for the generation of K636R 
hVps34 by SOE-PCR 
mpV34KRr#718 ATC TCC ATG GCG AAA TAT AAC 
TGG ATA TTT GCC TCC ATC 
Anna Melone Reverse mutagenesis primer 
for the generation of K636R 
hVps34 by SOE-PCR 
spV34BHr#719 AAG AGG CTT TGG ATC CCG ACC CA Anna Melone Reverse sequencing primer 
for the generation of K636R 
hVps34 by SOE-PCR 
sppRK5r#860 
 
CGC CGA ATT AAT TCC CGA TCC 
AGA 
Anna Melone Reverse sequencing primer 
for pRK5 plasmids reading 
into the insert’s c-terminus 
spRAPTORf#863 GGA GAG CTC ATC AAC AAC ATC 
AAG T 
Anna Melone Forward sequencing primer 
reading from human 
Raptor’s C-terminus into its 
3’UTR 
spRapBEf#873 TGC TGA TTT GGA AAA GAA CCC 
AGA G 
Anna Melone Forward sequencing primer 
upstream of BstEII site in 
human Raptor 
spCAAXXor#874 CCC TCT AGA TGC ATG CTC GAG TC Anna Melone Reverse sequencing primer 
for K-Ras CAAX box  
mpCAAXRapf#875 ACT CGG TGG AGA AGC GTG TCA 
GAG GTA CCG ATA TCA ATG CTT 
GCA CG 
Anna Melone Forward mutagenesis primer 
for CAAX box containing C-
terminus of Raptor (to 
generate Raptor-CAAX by 
SOE-PCR) 
mpRapCAAXr#876 CGT GCA AGC ATT GAT ATC GGT 
ACC TCT GAC ACG CTT CTC CAC 
CGA GT 
Anna Melone Reverse mutagenesis primer 
for Raptor’s C-terminus 
containing initial part of 
CAAX box (to generate 
Raptor-CAAX by SOE-PCR) 
mpRhebXor#877 GCG CTC TCT CGA GCC TCA CAT 
CAC CGA GCA CGA AGA C 
Anna Melone Reverse mutagenesis primer 
to append XhoI restriction 
site after stop codon of 
Rheb1 
mpRhebRapf#878 ACT CGG TGG AGA AGC GTG TCA 
GAG GTA CCA TTG ACG GAG CGG 
CTT CAC AAG G 
Anna Melone Forward mutagenesis primer 
to generate Raptor-Rheb15 
fusion protein by SOE-PCR 
primer contains C-terminus 
of Raptor, KpnI site and 
Rheb appendage 
mpRapRhebr#879 CCT TGT GAA GCC GCT CCG TCA 
ATG GTA CCT CTG ACA CGC TTC 
TCC ACC GAG T 
Anna Melone Reverse mutagenesis primer 
to generate Raptor-Rheb15 
fusion protein by SOE-PCR 
primer contains C-terminus 
of Raptor, KpnI site, Rheb 
appendage 
spRaptorf#880 CGA GGG TCA CTG CCA TGG AGT 
ATC 
Anna Melone forward sequencing primer 




Remarks: underlined bold letters mark introduced point mutations; italic and bold letters mark Raptor appendages; 
underlined letters mark KpnI restriction site; underlined italic letters mark XhoI restriction site 
Primers were obtained from Microsynth GmbH, Balgach, Switzerland 
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6.9 siRNA duplex targeting sequences for human PI3Ks 
 





sense GGAAUAUGGUGUGACAGGAUCCUUU PI3K catalytic domain 
anti-sense AAAGGAUCCUGUCACACCAUAUUCC 
HSS107993 #2 
sense GGAUGUAGCAGAGUGUGAUCUUGUU Phox domain 
anti-sense AACAAGAUCACACUCUGCUACAUCC 
HSS107994 #3 
sense UCAACUUGAGCAAAGAGACGGUUAA C2 domain (the 2
nd
 at the 




sense GAGAGAUGAGGAGGUUGCUGCAUUU before the Ras-binding 
domain anti-sense AAAUGCAGCAACCUCCUCAUCUCUC 
HSS107997 #2 
sense UGGCUGAUGGAGACUUCCCACUGAA between the Ras-binding 




sense CAGCGCCCGUUGGAGUGCACCUAAU between the C2 domain 









Remarks: all siRNA duplex were purchased from Invitrogen 
 
6.10 Lentiviral shRNA targeting sequence for hVps34 
 
Name Vector shRNA insert (5’->3’)  Targeting site 






















gene targeting in 
human cells 
Remarks:  
- underlined bold letters mark plasmid overhang 
- italic bold letters mark loop 
 
Fig.1:Targeting sites of the single RNAi 
targeting sequences in PI3K-C2α, PI3K-C2β 
and hVps34 
Arrow heads point to the sites where the single 
RNAis are targeted within the protein.  
siRNA PI3K-C2α: C2A#1-3 
siRNA PI3K-C2β: C2B#1-3 
siRNA hVps34: V34#3 








Name Isotype Antigen/Target Source Application 
(dilution) 
anti-phospho p70 








Western blot (1:2000) 
anti-p70 S6 Kinase 
#9202 
rabbit, polyclonal S6K Cell Signaling 
Technology 
















Western blot (1:1000) 
anti-PKB (19G7/C7) mouse, monoclonal PKB Gift from Emilio 
Hirsch  
University of Torino 
(Italy) 
Western blot (1:5000) 
anti-Myc-Tag (9B11) mouse, monoclonal 
IgG2a 






anti-GFP (mixture of 
clones 7.1 and 13.1) 
mouse, monoclonal 
IgG1 















Western blot (1:2000) 
anti-hVps34 #38-
2100 
rabbit, polyclonal hVps34 Zymed 
Laboratories/ 
Invitrogen 





PI3 Kinase C2 alpha BD Transduction 
Laboratories 






PI3 Kinase C2 beta BD Transduction 
Laboratories 




















anti-rabbit IgG (H+L) 
#A11036 
goat, polyclonal rabbit IgG (heavy 
and light chains) 





goat, polyclonal mouse IgG (heavy 
and light chains) 









goat, polyclonal Mouse IgG Sigma Western blot (1:5000) 
 
6.12 Bacterial strains and culture conditions 
 
Name Source Culture medium Culture conditions Application 
E.coli XL1-Blue G. Christophori 
Centre of 
Biomedicine 
University of Basel 
LB-Miller 37°C , 250 rpm Propagation of 
plasmid DNA and 
cloning purposes 
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6.13 Mammalian cells and culture conditions 
 
Name Cell type Source Culture medium Application 







- Transfection and gene 
expression 
- Nutrient stimulation 
- Immunofluorescence 
microscopy 
HER911 Human embryonic 










- Transfection and gene 
expression 
- Nutrient stimulation 
HEK293 Human embryonic 






- Transfection and gene 
expression 
- Nutrient stimulation 
- Proliferation 
- siRNA-mediated gene 





kidney cells with empty 
pLKO.1 vector 





1 µg/ml puromycin (added 
to the cell every second 
day) 
- Transfection and gene 
expression 





kidney cells with 
silenced hVps34 





1 µg/ml puromycin (added 
to the cell every second 
day) 
- Transfection and gene 
expression 
- Nutrient stimulation 
- Proliferation 
A375 Human malignant 
melanoma cell line 
PTEN wt 
BRafV600E 












- Knockdown of hVps34 
- Transfection and gene 
expression 







melanoma cells with 
empty pLKO.1 vector 
PTEN wt 
BRafV600E 
NRas wt  
p53 wt 





1 µg/ml puromycin (added 
to the cell every second 
day) 
- Transfection and gene 
expression 











NRas wt  
p53 wt 





1 µg/ml puromycin (added 
to the cell every second 
day) 
- Transfection and gene 
expression 




Cells and cell lines were cultured at 37°C in a humified atmosphere at 5% CO2. 
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6.14 Molecular biological methods 
 
6.14.1 Agarose gel electrophoresis of DNA fragments 
 
Agarose gel electrophoresis was performed for either analytical or preparative 
purposes prepared in 1 x TAE buffer containing ethidium bromide (10µg/ml). Agarose 
gels of 1% were used to separate fragments of 10-0.5 kb size and 2% for fragments 
of 2.5-0.1 kb size. DNA samples were prepared for gel electrophoresis by adding 10x 
blue juice. Electrophoresis was performed at 80 V in gel electrophoresis chambers 
(Werkstatt, Institute of Biochemistry Fribourg). 
 
6.14.2 Preparation of CaCl2-competent E.coli XL-1 Blue 
 
Materials: 
- 50 mM CaCl2 (cooled to 4°C) 
- 50 mM CaCl2/10% glycerol (cooled to 4°C) 
 
A 100 ml pre-culture derived from a single colony and grown o/n at 37°C and 300 
rpm was used to inoculate 1L of LB-Miller (1:100). The culture was grown at 37°C 
with vigorous shaking to an OD600 of 0.6, and then the flask was placed on ice for 20 
min. All of the following steps were carried out at 4°C. Bacteria were pelleted at 3000 
rpm at 4°C for 20 min (Sorvall RC5C, rotor SLC4000). The pellet resuspended in 500 
ml ice-cold CaCl2 and mixed strongly and stored a few hours at 4°C while mixing 
occasionally. The bacteria were centrifuged at 3000 rpm for 15 min, and the pellet 
resuspended in 100 ml CaCl2/glycerol. Aliquots of 500 µl were prepared to be used 
for transformation, flash-frozen in liquid nitrogen and stored at -80°C. 
 
6.14.3 Transformation of CaCl2-competent E.coli XL-1 Blue 
 
A 500 µl aliquot of CaCl2-competent E.coli was thawed on ice (15-20 min) and 100 µl 
of it were added to 4 µl ligation mix and mixed by flicking the tube. After 20 min 
incubation on ice, the bacteria were heat-shocked for 2 min at 42°C, incubated for 2 
min on ice and 800 µl of pre-warmed SOC medium added. After shaking (250 rpm) 
for 1 h at 37°C, bacteria were spun down (8000 rpm, 5 min, RT), resuspended in 
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100µl LB-Miller medium and plated onto LB-Miller agar containing the appropriate 
antibiotic. After O/N incubation at 37°C, single colonies were picked, expanded in 
liquid culture and DNA isolated and analyzed for correct ligation by restriction 
enzyme digest 
 
6.14.4 General cloning procedures 
 
6.14.4.1 Preparation of plasmid DNA from E.coli cultures 
Plasmid DNA from E.coli was prepared by using commercially available kits from 
QIAGEN (Maxi, Mini) and Sigma (Maxi Endofree, Mini) according to the 
manufacture’s protocols. Purified plasmids were dissolved in TE buffer for long 
storage at 4°C.  
 
6.14.4.2 Isopropanol precipitation of DNA 
Precipitation of plasmid DNA was performed by adding 0.1 volume of 3 M sodium 
acetate pH 5.2 and 0.7 volume of isopropanol to the DNA. After mixing by inverting 
the tube, DNA was pelleted by centrifugation (20’000 x g, 30 min, 4°C), washed once 
with 1.5 ml 70% ethanol and centrifuged as before for 10 min. The DNA pellet was 
air-dried and dissolved in TE buffer to a final concentration of 1 µg/µl. 
 
6.14.4.3 Restriction enzyme digestion of plasmid DNA and PCR products 
For analytical purposes 0.25-1 µg plasmid DNA was digested with the appropriate 
restriction enzyme (5 U/µg DNA) for 1 h at 37°C in a total volume of 20 µl. For 
preparative purposes 2 µg vector or PCR product were digested with 20 U/µg of the 
appropriate enzyme for 1-2 h at 37°C in a total volume of 40 µl. All restriction 
enzymes were purchased from New England Biolabs (NEB).  
 
6.14.4.4 Purification of DNA from agarose gel 
Under UV illumination, bands of interests were quickly excised from the gel and DNA 
fragments purified from agarose gels using either QIAquick gel extraction kit 
(QIAGEN) or GenElute Gel Extraction kit (Sigma) according to the manufacturer’s 
protocol. 
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6.14.4.5 Ligation of DNA fragments into vectors 
Ligation of DNA fragments with cohesive ends was performed at a molar ratio 
between vector and insert of 1:2 in a reaction volume of 20 µl using the T4 DNA 
ligase (NEB). The ligation reactions were set up as follows: 
 
x µl vector (50 ng) 
x µl insert DNA 
2 µl 10x ligation buffer 
0.5 µl T4 DNA ligase (400 U/µl) 
filled up to 20 µl with ddH2O 
 
The ligation mix were incubated either for 1 h at RT or O/N at 4°C to obtain a 
maximum number of transformants. Four µl of the reaction were transformed into 
CaCl2-competent E.coli. 
 
6.14.4.6 Polymerase chain reaction (PCR)  
Materials: 
- Endotoxin-free water (Sigma) 
- 10 mM dNTPs mix (Sigma) 
- 5 U/µl Pwo Polymerase (Roche) 
- Primer (10 µM in endotoxin-free water) 
- T3 thermocycler (Biometra) 
 
PCR was performed with the Pwo Polymerase (Roche) to introduce appropriate 
restriction sites for subcloning the PCR products. Two reaction mixes were prepared 
on ice in 200 µl PCR tubes as follows: 
 
Mix 1: 
template DNA (10 ng/µl) 1 µl (10 ng) 
10 mM dNTPs mix 1 µl (200 µM final concentration) 
10 µM forward primer 1 µl (200 nM final concentration) 
10 µM reverse primer 1 µl (200 nM final concentration) 
ddH2O filled up to 25 µl 21 µl 
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Mix 2: 
Pwo Polymerase 5U/µl 0.5 µl 
10x PCR buffer with 20 mM MgCl2 5 µl 
ddH2O filled up to 25 µl 19.5 µl 
 
Mix 1 and 2 were combined on ice, vortexed gently and spun down. The PCR was 
performed on a T3 thermocycler (Biometra) using the following protocol: 
 
1. initial denaturation of DNA 95°C 5 min  
2. denaturation of DNA 95°C 20 sec  
3. annealing* 55-68°C 30 sec (temperature depending on 
primer) 
4. elongation 72°C 50 sec  
30 cycles 
5. final elongation 72°C 7 min  
6. cooling 4°C ∞  
 
After the reaction, the PCR product was analyzed by gel electrophoresis, purified 
using Min Elute PCR purification kit (QIAGEN) according to manufacture’s protocol 
and digested with the appropriate enzyme for cloning. 
 
6.14.4.7 Generation of GST-hVps34K636R kinase-dead mutant by site-directed 
mutagenesis using sequence-overlap extension PCR (SOE-PCR) 
For generation of kinase-dead GST-hVps34K636R three point mutations (3587AAG3589 -> 
3587CGC3589) were inserted by SOE-PCR in plasmid pcDNA3_tkGST-hVps34__p256. 
In a first PCR, the coding sequence for the N-terminal region including the three point 
mutations was generated using the primer pair sphV34BEf#595/mpV34KRr#718 
resulting in the BspEI-hVps34KR fragment. The coding sequence for the C-terminal 
region including the three point mutations was generated using the primer pair 
mpV34KRf#717/mpV34BHr#719 resulting in the hVps34KR-BamHI fragment. In a 
second round of PCR, BspEI-hVps34KR together with hVps34KR-BamHI were used as 
templates and with primers sphV34BEf#595/mpV34BHr#719 the BspEI-hVps34KR-
BamHI fragment was amplified and afterwards subcloned into BspEI and BamHI 
restriction sites of pcDNA3_tkGST-hVps34__p256 vector. 
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6.14.4.8 Generation of HA-Raptor-CAAX and HA-Raptor-Rheb15 by SOE-PCR 
For the generation of HA-Raptor-CAAX and HA-Raptor-Rheb15 the same approach 
as described above was undertaken. 
 
Generation of HA-Raptor-CAAX: 
- First round of PCR: 
PCR with primers spRapBEf#873/mpRapCAAXr#876 on pRK5<HA-Raptor>#1275 
and mpCAAXRapf#875/spCAAXXor#874 on pcDNA3<p110 wt-CAAX KI>#594 
resulted into fragments BstEII-Raptor-CAAX and Raptor-CAAX-XhoI, respectively. 
- Second round of PCR: 
Primer pair spRapBEf#873/spCAAXXor#874 and templates BstEII-Raptor-CAAX and 
Raptor-CAAX-XhoI were used resulting into BstEII-Raptor-CAAX-XhoI fragment. 
After digestion with BstEII and XhoI restriction enzymes, the fragment was subcloned 
into BstEII and XhoI restriction sites of pRK5_HA-Raptor__p1275. 
 
Generation of HA-Raptor-Rheb15: 
- First round of PCR: 
PCR with primers spRapBEf#873/mpRapRhebr#879 on pRK5_HA-Raptor__p1275 
and mpRhebRapf#878/mpRhebXor#877 on pEGFP-C1<Rheb>#1277 resulted into 
fragments BstEII-Raptor-Rheb15 and Raptor-Rheb15-XhoI, respectively. 
- Second round of PCR: 
Primer pair spRapBEf#873/mpRhebXor#877 and templates BstEII-Raptor-Rheb15 
and Raptor-Rheb15-XhoI were used resulting into BstEII-Raptor-Rheb15-XhoI 
fragment. After digestion with BstEII and XhoI restriction enzymes, the fragment was 
subcloned into BstEII and XhoI restriction sites of pRK5_HA-Raptor__p1275. 
 
6.14.4.9 Sequencing of plasmid DNA 
Sequencing of plasmid DNA was performed at Microsynth GmbH (Balgach, 
Switzerland). For economy run sequencing following mixture was set up: 
 
0.8 µg plasmid DNA x µl 
50 µM primer 0.4 µl (2 µM final concentration) 
endotoxin-free H2O filled up to 10 µl 
 
Sequences were analyzed using DNA Strider (version 1.4f13) or Serial Cloner 2.1. 
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6.15 Cell culture methods 
 
6.15.1 Determination of cell numbers 
 
The number of viable cells was determined using the CASY Cell Counter (Schärfe 
Systems, Reutlingen, Germany). Fifty µl of cell suspension was diluted into 10 ml 
CASYton dilution solution, mixed by inversion and cell number counted using a cell 
specific program. 
 
6.15.2 Freezing and thawing of cells 
 
For freezing, a cell suspension was prepared, centrifuged (900rpm, 5min, RT) and 
the pellet resuspended in freezing medium (10% (v/v) DMSO in FCS) at a minimal 
density of 5-10 x 106 cells/ml. Then 1 ml aliquots were transferred to 2 ml cryotubes 
(Nunc), placed into a freezing container (Nalgene) and put O/N at -80°C prior to the 
final storage in the liquid nitrogen. 
Thawing of cells was performed by transferring cells from the liquid nitrogen into a 
37°C water bath. Due to DMSO’s toxicity, the cell suspension was immediately 
diluted in 10 ml of pre-warmed appropriate medium and centrifuged (900 rpm, 5 min, 
RT). The pellet was gently resuspended in medium and transferred into a culture 
flask. 
 
6.15.3 Trypsinization of adherent cells for subculture 
 
Adherent cells were washed 1x with PBS and trypsinized with 1x Trypsin/PBS for 3-5 
min at 37°C until cells were detached from the culture surface. Afterwards 
Trypsin/PBS was quenched by adding 9 volumes of cell culture medium, cells 
resuspended and either splitted into new culture flasks or centrifuged for freezing 
(see above). 
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6.15.4 Testing cells for mycoplasma contamination 
 
Cells were grown for a couple of days without changing the medium. 500 µl aliquot of 
the cell supernatants was boiled for 15 min at 95°C, centrifuged for 5 min at 
maximum speed and 5 µl used to run the PCR reaction. The PCR reaction was set 
as follows: 
 
boiled medium 5 µl 
dNTPs (10 mM) 1 µl 
primer GPO-1#135 (50 µM) 1 µl 
primer: MGSO#136 (50 µM) 1 µl  
10x PCR buffer with 15 mM MgCl2 5 µl 
Taq Polymerase 0.5 µl 
H2O filled up to 50 µl 36.5 µl 
 
The primers above amplify a 717 bp DNA fragment within the 16S rRNA gene, and 
should detect a wide range of mycoplasma (e.g. Mycoplasma arginini, Acholeplasma 
laidlawii, Mycoplasma hyorhinis, Mycoplasma orale, and Mycoplasma fermentans) 
(Dussurget and Roulland-Dussoix, 1994; Rawadi and Dussurget, 1995). 
 
PCR Program: 
1. pre-heat 94°C 4 min 
2. denaturation of DNA 94°C 1 min 
3. annealing 58°C 1.5 min 
4. elongation 72°C 1.5 min 
 30 cycles 
5. final elongation 72°C 10 min 
6. cooling 4°C ∞ 
 
In case of mycoplasma contamination a band of approximate 700 bp size should be 
detectable.  
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6.15.5 Transfection of adherent cells with JetPEITM 
 
For optimal transfection conditions, cells should be 50-60% confluent. 
Number of cells to seed the day before transfection: 
Culture vessel Number of cells to seed per well or dish 
 HEK293 HeLa HER911 A375 
12 well 2 x 105 5 x 104 5 x 104 5 x 104 
3.5 cm 0.3 x106    
6 cm 0.6 x106 0.25 x106 2 x105 0.35 x106 
10 cm 1.6 x106 0.7 x106 0.65 x106  
 
Complex preparation for different cell culture formats: 

















12 well 1 µg 40 2 40 80 
3.5 cm 1.5 µg 50 3 50 100 
6 cm 3 µg 100 6 100 200 
10 cm 8 µg 270 16 270 540 
 
Mixing of the JetPEI and DNA solutions was done as follows: 
After vortexing for 10 sec and centrifugation the JetPEI solution was added to the 
DNA solution, vortexed for 10 sec and spun down. After 20 min incubation at RT the 
JetPEI/DNA mixture was added drop wise onto the cells. Medium was replaced 9 to 
24 h later with complete medium. Cell lysis occurred various times after transfection.  
 
6.15.6 siRNA transfection 
 
Materials: 
- RNAi duplex (20 µM stock solution, Invitrogen) 
- Lipofectamine RNAiMAX (Invitrogen) 
- Opti-MEM (Invitrogen) 
 
Cells were plated into a 6-well plate (180.000 HEK293 cells/well) containing 1.5 ml 
DMEM/10% FCS/2mM Gln w/o antibiotics and let adhere O/N. The following two 
solutions were prepared for each well to be transfected: 
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a) To 150 µl Opti-MEM 0.9 µl siRNA (20 µM stock) were added and mixed gently by 
inverting the tubes several times. 
b) To 150 µl Opti-MEM 3 µl Lipofectamine RNAiMAX was added and mixed gently by 
inverting the tubes several times.  
The diluted RNAi duplex (solution a) was combined with the diluted Lipofectamine 
RNAiMAX (solution b), mixed gently and incubated for 20 min at RT. Afterwards the 
RNAi/Lipofectamine complexes were added onto the cells to give a final volume of 
1.8 ml and a final RNA concentration of 10 nM. The plate was mixed gently by 
rocking back and forth and after incubation for 4 – 6 h at 37°C in a CO2 incubator, 
medium was replaced with 1.5 ml DMEM/10% FCS/2mM Gln w/o antibiotics. Gene 
knockdown was assayed 48-72 h after transfection. 
 
6.15.7 Proliferation assay 
 
Materials: 
- Cells: HEK293 and A375 
- Medium: DMEM complete and RPMI complete 
- CASY Cell Counter (Schärfe Systems, Reutlingen, Germany) 
- CASYton dilution solution for cell culture 
 
On day 0 either 1.5 x 105 cells/6cm dish for HEK293 or 1.2 x 105 cells/6cm for A375 
were plated in triplicate in complete medium. At different time intervals cells were 
washed 1x in PBS, trypsinized, taken up in 4 ml complete medium and cell 
suspension transferred to a 15 ml tube. After centrifugation at 900 rpm for 5 min cells 
were resuspended in 1 ml complete medium and cell number and cell volume 
measured using the automated cell counter as described above.  
 
6.15.8 MTT-based cell proliferation assay 
 
Materials: 
- MTT (Sigma, #5655) dissolved in PBS (5mg/ml) 
- Solubilization buffer (95% isopropanol, 5% formic acids) 
- 96 well-plate (flat bottom) 
- HEK293 cells (normal, shRNA mock and shRNA hVps34) 
- A375 cells (normal, shRNA mock ans shRNA hVps34) 
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- Inhibitors: 1µM NVP-BEZ235, 100nM Rapamycin, 1µM pp242, 1µM ZSTK474, 1µM 
YM201636 (indicated concentrations are the final concentrations in the assay) 
- Spectrophotometer Spectra Max 340 (Molecular Devices) with software SoftMax 
Pro 4.8  
 
Principle of the assay: 
This is a colorimetric assay that measures the reduction of yellow 3-(4,5-
dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) to purple formazan salts 
by mitochondrial succinate dehydrogenase. The formazan is then solubilised with 
acidified isopropanol and the concentration measured spectrophotometrically. Since 
reduction of MTT can only occur in metabolically active cells the level of activity is a 
measure of the viability of the cells. 
 
Procedure: 
Either 3000 HEK293 cells or 1000 A375 cells were plated per well in quadruplicate in 
100 µl in 96-well tissue culture plates. On day zero 0.5µl inhibitors were added to 
cells with the final concentration as described above. Each inhibitor treatment was 
done in quadruplicate and MTT assay was performed each day from day 0 until day 
4 post-inhibitor treatment as follows. To each well 11 µl MTT (10% of the culture 
medium volume) solution was added and plate shaken carefully. After incubation for 
2h at 37°C and 5% CO2, 100 µl solubilization solution was added to each well and 
pipetted up and down several times to dissolve the formazan salt. After 10 min of 
gently mixing on a table shaker absorbance was measured at 570 nm and 
background absorbance at 690 nm. After measurement solution was mixed again, 
incubated for 10 min and absorbance measured a second time as described before.  
 
6.15.9 Amino acid and serum starvation and stimulation of cells 
 
Materials: 
- Culture medium: DMEM, RPMI 
- Amino acid depletion buffer pH 7.4 (homemade, see chapter 6.6: 1.8 mM CaCl2, 
0.248 µM Fe(NO3)3, 810 µM MgSO4, 5.37 mM KCl, 44 mM NaHCO3, 109.5 mM NaCl, 
906 µM NaH2PO4, 25 mM Glucose, 4x MEM vitamins) 
- IGF-II (Sigma) 
- Cells grown in 6 cm culture plates 
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The day before amino acid depletion, cells were washed 2x with PBS and incubated 
for 15-18 h in 3 ml serum-free culture medium supplemented with 2mM L-glutamine. 
Following 2x wash with PBS cells were incubated for 2 h in 3 ml amino acid depletion 
buffer. During the last 15 min of amino acid depletion cells were pre-treated either 
with DMSO or inhibitors. Afterwards, starvation buffer was replaced with 3 ml serum-
free culture medium supplemented with 2mM L-glutamine containing either DMSO or 
inhibitors and incubated for 30 min at 37°C. Total cell lysis was performed as 
described below. 
For IGF-II stimulation, cells were over night serum starved in serum-free culture 
medium supplemented with 2mM L-glutamine as described above and stimulated 
with 50 ng/ml IGF-II for 5 min at 37°C.  
 




- PtdIns(3)P/AM (kind gift from Carsten Schultz, EMBL, Germany), diluted to 20mM 
in DMSO 
- Pluronic F-127 (kind gift from Carsten Schultz) 
- HEK293 cells were grown in 6 cm cell culture plates 
 
Preparation of PtdIns(3)P/AM shortly before use! 
To 2.5 µl 20mM PtdIns(3)P/AM 1 µl pluronic F127 were added and mixed by 
pipetting up and down. 
 
Serum starvation of HEK293 cells was performed as described above. After 2x wash 
with PBS, cells were incubated for 2 h in 1 ml amino acids depletion buffer. During 
the last 30 min of amino acid starvation cells were pre-treated with 50 µM 
PtdIns(3)P/AM as follows. To the above prepared PtdIns(3)P/AM 100 µl cell 
supernatant was added, pipetted up and down and re-added back to cells and mixed 
by carefully rocking back and forth. After 30 min incubation, starvation/PtdIns(3)P/AM 
buffer was replaced with 1 ml serum-free culture medium supplemented with 2mM L-
glutamine and incubated for 30 min. Cell lysis was performed as described below. 
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6.16 Biochemical methods 
 
6.16.1 Preparation of total cell lysates from adherent cells 
 
Materials: 
- NP-40 based lysis buffer (20 mM Tris-HCl pH 8.0, 138 mM NaCl, 2.7 mM KCl, 5% 
glycerol, 1% NP-40) supplemented with protease and phosphatase inhibitors (40 mM 
NaF, 2mM Na3VO4, 20 µM Leupeptin, 18 µM Pepstatin, 5 µM Aprotinin, 1 mM PMSF, 
1 mM MgCl2, 1 mM CaCl2, 5 mM EDTA) 
- PBS 
- Plastic cell scrapers (SPL Life Sciences) 
 
All works were performed on ice and in cooled centrifuges. Adherent cells were 
washed 2x with ice cold PBS, scraped in lysis buffer and cell lysate transferred to a 
1.5 ml Eppendorf tube. After 10 min incubation on ice, cell lysate was cleared by 
centrifugation (13’2000 rpm, 15min, 4°C), supernatant transferred to a new 1.5 ml 
Eppendorf tube and protein concentration determined with the Bradford method. 
Equal amounts of proteins were mixed with 1/5th of 5x loading buffer, boiled for 6 min 
at 95°C, centrifuged and loaded onto SDS-PAGE. 
 
6.16.2 Determination of protein concentrations 
 
Materials: 
- Cell lysates 
- Semi-micro cuvette (1.6 ml, Greiner Bio-One) 
- Bradford (Bio-Rad) 
- BioPhotometer (Eppendorf) 
 
Bradford reagent was prepared by diluting the dye reagent 1:5 with ddH2O. To each 
cuvette containing 1 ml of Bradford reagent, 1 µl cell lysate was added and mixed by 
pipetting up and down. After 5 min incubation at RT, absorbance was measured with 
a spectrophotometer at 595 nm.  
 





- Protein G Sepharose 4 Fast Flow (GE Healthcare) 
- Anti-myc antibody (Cell Signaling Technology) 
- Wash buffer 1 (lysis buffer containing 1% NP-40, 40 mM NaF, 2 mM Na3VO4) 
- Wash buffer 2 (0.1 M Tris-HCl pH 7.4/0.5 M LiCl) 
- 1x PBS 
 
Following cell lysis and determination of protein concentration 100-200 µg proteins 
were incubated with anit-myc antibody (diluted 1:1000) while rotating for 1h in the 
cold room (4°C). In the meantime protein G Sepharose beads were washed 3x in 
PBS and resuspended in lysis buffer containing protease and phosphatase inhibitors 
to give a 50% beads slurry. Afterwards 20 µl of 50% beads slurry were added to 
each sample and rotated for an additional 1 h in the cold room (4°C). Then the beads 
were washed 2x with wash buffer 1 (13’200 rpm, 1min, 4°C), 2x with wash buffer 2 
(13’200 rpm, 1min, 4°C) and 1x with PBS (13’200 rpm, 1min, 4°C) using a volume of 
500 µl each time. Then 12 µl of 2x concentrated SDS-sample buffer were added, 
samples boiled for 6 min at 95°C, centrifuged, resolved by SDS-PAGE and analyzed 
by western blotting. 
 
6.16.4 GST pulldown 
 
Materials: 
- Glutathione Sepharose 4B (GE Healthcare)  
- GST wash buffer (Lysis buffer, 1% NP-40, 1 mM DTT) 
- Wash buffer 1 (lysis buffer containing 1% NP-40, 40 mM NaF, 2 mM Na3VO4) 
- Wash buffer 2 (1mM Tris-HCl pH 7.4/0.5 M LiCl) 
- 1x PBS 
- Cells were grown in 10 cm culture dishes 
 
Preparation of Glutathione Sepharose 4B: 
Desired volume of 70% slurry was transferred into a 1.5 ml tube, washed 3x with 
GST wash buffer and resuspended in lysis buffer supplementend with protease and 
phosphatase inhibitors and 1 mM DTT to give a 50% slurry. 
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Following cell lysis and determination of protein concentration, 200-400 µg proteins 
were added to a 1.5 ml Eppendorf tube containing 20 µl 50% of glutathione 
sepharose slurry. After 2 h rotation in the cold room (4°C), beads were washed 2x 
with wash buffer 1 (13’200 rpm, 1min, 4°C), 2x with wash buffer 2 (13’200 rpm, 1min, 
4°C) and 1x with PBS (13’200 rpm, 1min, 4°C) using 500 µl each time. Pulled down 
proteins were denatured by the addition of 12 µl 2x concentrated sample buffer and 
boiled for 6 min at 95°C, subjected to SDS-PAGE and analyzed by western blotting. 
 
6.16.5 SDS polyacrylamide gel electrophoresis 
 
The polyacrylamide gel for SDS-PAGE consists of two separate regions: the upper 
stacking gel and the lower separating. The stacking gel is less concentrated (larger 
pore size) than the separating gel and is prepared in a buffer of lower ionic strength 
and lower pH leading to a rapid movement of the proteins through the upper gel and 
therefore accumulating at the boundary between stacking and separating gel. The 
concentration of acrylamide in the separating gel is chosen based on the size of the 
proteins to be analyzed. 
 
Preparation of ten minigels (8 cm x 10 cm x 0.75 cm) 
Ten gels were cast up at once using the Mighty Small gel caster (Amersham 
Biosciences).  
Following solutions were prepared for 10 gels: 
 Separating gel 
(Total: 75 ml) 
Stacking gel 
(Total: 30 ml) 
 6% 7.5% 10% 12% 15% 5% 
40% Acrylamide Stock 11.3 ml 14.1 ml 18.8 ml 22.5 ml 28.1 ml 4.8 ml 
Distilled H2O 47.7 ml 44.9 ml 40.2 ml 36.5 ml 30.9 ml 21.6 ml 
Tris-HCl pH 8.8 (1.875 M) 15 ml 15 ml 15 ml 15 ml 15 ml --- 
Tris-HCl pH 6.8 (1.25 M) --- --- --- --- --- 3 ml 
10% (w/v) SDS 750 µl 750 µl 750 µl 750 µl 750 µl 300 µl 
10% APS 250 µl 250 µl 250 µl 250 µl 250 µl 102 µl 
TEMED 37.5 µl 37.5 µl 37.5 µl 37.5 µl 37.5 µl 30 µl 
 
APS and TEMED were added just prior to pouring the gels. Separating gel solution 
was poured and overlaid with isopropanol to get a flat surface. After polymerization 
isopropanol was removed, gels rinsed with H2O, stacking gel solution poured on top 
of the separating gel and combs inserted avoiding air bubbles. 
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Loading and running of gels 
For Western blotting 10 µg proteins from cell lysates were loaded per lane. The 
appropriate sample volume were mixed with 5x sample buffer and heated for 6 min at 
95°C while mixing, centrifuged briefly and loaded onto the gel. Running of the gels 
was carried out at 20 mA/minigel and 250 V for approximate 60 min.  
 
6.16.6 Semi-dry transfer and western blotting 
 
Materials: 
- Transfer buffer (25 mM Tris, 192 mM Glycine, 20% methanol, pH 8.3) 
- Immobilon P PVDF membrane (Millipore), cut 9 x 6.5 cm 
- For 1 minigel 6x Whatman paper (Macherey & Nagel), cut 9 x 6.5 cm  
- Semidry blotting device (Witec AG) 
- TBS, 0.1% Tween (TBST) 
 
Preparation for semi-dry transfer: 
PVDF membrane was activated in 100% Methanol for 15 sec and equilibrated in 1x 
transfer buffer for at least 5 min. Filter papers were soaked in 1x transfer buffer. 
 
Following gel electrophoresis, proteins were transferred onto a positively charged 
PVDF membrane using the semi-dry transfer technique. The blot was assembled on 
the lower electrode (anode) as follows: three Whatman papers, PVDF membrane, 
gel, three Whatman papers and the upper electrode (cathode). After removal of air 
bubbles, the transfer was run at 1 mA/cm2 (65 mA/minigel) and 20 V for 75 min. 
Afterwards the membrane was blocked under agitation in TBS-Tween containing 5% 
non-fat milk (5% milk TBST) for at least 30 min and incubated with primary antibody 
diluted either in 5% milk TBST or 5% BSA TBST (for detection of phospho proteins) 
for 1h at RT or O/N at 4°C. Following three washes of 5 min with TBST, membrane 
was incubated with HRP-coupled secondary antibody (diluted in 5% milk TBST) for 
1h and afterwards washed 6x 5 min with TBST. For immunodetection, the membrane 
was covered for 1 min with 2 ml chemiluminescent HRP substrate (Immobilon 
Western, Millipore). The membrane was placed in an autoradiography cassette and 
exposed to films for different times or detection was carried out with the Fusion Fx7 
imaging system (analysis-software FUSION CAPT, version 15.16 for Windows). 
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6.16.7 Stripping of membranes for reprobing 
 
In order to remove primary and secondary antibodies, the membrane was incubated 
under agitation in stripping buffer (100 mM β-mercaptoethanol, 2% SDS, 62.5 mM 
Tris-HCl pH 6.7) for 30 min at 50°C. After washing 3x 10 min with TBST, the 
membrane was blocked in 5% milk TBST for at least 30 min and western blotting was 
continued as described above.  
 
6.16.8 Lipid kinase assay 
 
Materials: 
- GST-pull down of GST-hVps34wt or GST-hVps34K636R 
- Sonicater (IKA Labortechnik, Staufen); settings: cycle = 1 and Amplitude = 50% 
- Thermomixer (Eppendorf) 
- Sped vac (UNIVAPO 150H) 
- wash buffer (lysis buffer containing 1% NP-40, 40 mM NaF, 2 mM Na3VO4) 
- 0.1 M Tris-HCl pH 7.4, 0.5 M LiCl (Tris-HCl/LiCl) 
- Kinase buffer for hVps34: 20 mM HEPES pH 7.4, 5 mM MnCl2 
- Kinase buffer for p110α, p110β, p110δ: 20 mM HEPES pH 7.4, 1 mM MgCl2 
- Kinase buffer for p110γ: 20 mM HEPES pH 7.4, 5 mM MgCl2 
- Phosphatidyl-L-serine (PS; Sigma): 1 mg/ml in Chloroform:Methanol (2:1) 
- L-α-Phosphatidyl-D-myo-inositol 5-monophosphate (PI; Sigma): 1 mg/ml in 
Chloroform:Methanol (2:1) 
- [γ-32P]-ATP (6000 Ci; Perkin Elmer) 
- 6 mM ATP (Roche) 
- 1 M HCl 
- Chloroform:Methanol (1:1) 
 
Preparation of 1ug/ul PS/PI lipid substrate solution: 
PS/PI vesicles were generated by mixing 300 µl of PI (1mg/ml) and 300 µl of PS 
(1mg/1ml) together in a 1.5 ml Eppendorf tube. After drying under a N2 stream, lipids 
were resuspended in 300 µl kinase buffer and shortly before starting the kinase 
assay lipids were extensively sonicated for a few seconds. 
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Preparation of [γ-32P]-ATP/ATP solution: 
Cold ATP (6mM, 100x) was diluted to 60 µM in kinase buffer and 2 µCi [
32
P]-
ATP/10µl was added. 
 
Following GST pull-down of either GST-hVps34wt or GST-hVps34K636R, in vitro lipid 
kinase assay was performed as follows. GST pull-downs were washed 2x with wash 
buffer, 2x with Tris-HCl/LiCl and 2x with kinase buffer using 500 µl each time. After 
resuspending in 40 µl kinase buffer either DMSO or wortmannin were added and 
mixed extensively for 15 min at 37°C. Afterwards 10 µl of PS/PI vesicles and 10 µl [γ-
32P]-ATP/ATP solution were added and mixed constantly for 10 min at 30°C. 
Reaction was stopped by the addition of 100 µl 1 M HCl, mixed shortly and lipid 
extracted with 200 µl Chloroform:Methanol (1:1). Following vortexing and 
centrifugation (3000 rpm, 3 min, RT) the organic lower phase was transferred into a 
new 1.5 ml Eppendorf tube. After perforating the lid of the Eppendorf tube 3x with a 
needle, lipids were dried in a speed vac for 30 min and stored O/N or until use at -
20°C. 
 
6.16.9 Thin layer chromatography (TLC) for lipid separation 
 
Materials: 
- TLC plates, Silica gel 60 W F254s (Merck) 
- Hamilton glass syringe with flat tip 






- Films (Fuji) 
- Phosphoimager screen (BioRad) 
 
TLC plate was prepared by pre-heating (200°C) in the microwave in order to remove 
excess H2O. To the dried lipids 20 µl Chloroform:Methanol (2:1) were added and 
mixed by tapping on the tube several times. Lipids were applied drop wise on TLC 
plate with a Hamilton syringe 2 cm from the bottom edge. Lipid resuspension and 
application on TLC plate was repeated a second time. Between samples Hamilton 
syringe was cleaned by overfilling 3 times with Chloroform:Methanol. When all 
samples were applied, the TLC plate was air dried and placed in a horizontal 
developing container containing solvent chloroform/methanol/H2O/NH4OH. When the 
solvent front had moved to about 2 cm of the top end of the plate (after 1 ½ h), the 
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TLC plate was removed from the developing container and dried at RT. PtdIns(3)-32P 
was either visualized by autoradiography or by phosphoimager (Typhoon with 




6.17.1 Indirect immunofluorescence of cells 
 
Materials: 
- Glass coverslips (round Ø 18 mm, Thermo Scientific) 
- Microscope slides (Menzel-Gläser) 
- Hoechst 33342 (Juro supply, stock solution 1 mM, diluted in ddH2O) 
- Parafilm 
- Mowiol (Clariant GMBH) 
- Confocal scanning laser microscope: Axiovert 200M and laser scanning module 
LSM 510 Meta (Zeiss) with LSM 510 software  
 
Preparation of 3% (w/v) paraformaldehyde in PBS: 
To prepare 20 ml of 3% paraformaldheyde, 18 ml of ddH2O and 7.5 µl of 1 M NaOH 
were added to 600 mg paraformaldehyde and suspension was stirred on a hot plate 
(100°). After complete dissolution, 2 ml 10x PBS pH 6.55 were added, mixed, cooled 
to 37°C and pH adjusted to pH 7.2. 
 
For staining, cells were grown in a 12-well plate on glass coverslips. The medium 
was aspirated from the cells and each well washed 2x with PBS (RT) and cells were 
fixed in freshly prepared pre-warmed 3% paraformaldehyde for 10 min at 37°C. 
Afterwards cells were washed 2x with PBS, quenched with PBS/50 mM glycine for 5 
min at RT and washed 1x with PBS. For intracellular staining, cells were 
permeabilized for 20 min at RT with 0.1% (w/v) saponin dissolved in PBS (1 ml/well). 
After washing 1x with PBS coverslips were removed from the 12-well plate with a 
forceps and blocked with 250 µl 5% goat serum in PBS inverted on a layer of 
Parafilm for 20 min at RT. All the subsequent steps were performed with inverted 
coverslips on Parafilm. Following incubation with 60 µl primary antibody (diluted in 
5% goat serum/PBS) for 1 h RT, cells were washed 2x with PBS (300 µl/cover slips) 
and incubated with 60 µl secondary antibody coupled to a fluorescent dye (diluted in 
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5% goat serum/PBS) for 1 h at RT in the dark. After 2x wash with PBS nuclei were 
stained with 300 µl Hoechst (final concentration 1 µM, diluted 1:1000 in PBS,) for 15 
min at RT and washed 2x with PBS (300 µl/cover slip). For mounting a drop of 
Mowiol was added onto a microscope slide and coverslips were washed 1x with 
ddH2O, residual liquid was soaked from the edge with a fine paper towel and placed 
upside down onto the Mowiol containing slide. Slides were stored at 4°C in the dark 




Dussurget, O., and Roulland-Dussoix, D. (1994). Rapid, sensitive PCR-based detection of 
mycoplasmas in simulated samples of animal sera. Appl Environ Microbiol 60, 953-959. 
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7.1 The seek for a hVps34-specific inhibitor 
 
For quite a few months during my Ph.D. research period I was occupied with testing 
some PI3K inhibitors, which we had at that time in the lab, on their efficacies to block 
hVps34 catalytic activity. Since there is no Vps34-specific inhibitor available, most of 
the studies concerning Vps34 role in cellular functions are done with ectopic 
expressed Vps34 wild type or kinase-dead mutants and with RNAi-mediated Vps34 
deletion. However, RNAi targeting does not result into a complete deletion of Vps34, 
so that there is still some Vps34 expression left. Ectopic expression leads 
presumably to a delocalization of Vps34 and therefore to off-target effects. With a 
specific Vps34 inhibitor one could circumvent these problems. At present wortmannin 
and 3-methyladenine are used to inhibit Vps34. However, wortmannin is a pan-PI3K 
inhibitor, while 3-methyladenine is used at 10 mM concentration and might influence 
other PI3Ks as well or have additional non-specific effects. Therefore, we undertook 
to test the efficacies of different PI3K inhibitors on inhibiting Vps34 in an in vitro lipid 
PI3K kinase assay and compared it with the inhibition of class IA PI3Kα, p110α. The 
idea was to find an inhibitor that might inhibit hVps34 at a low concentration, while for 
the inhibition of p110α a higher concentration is needed. Moreover, we examined 




Effect of different PI3K inhibitors on the catalytic activity of hVps34 
Different PI3K and dual PI3K/mTOR inhibitors (see Table 1) were tested on their 
efficacies to inhibit the catalytic activity of hVps34 and p110α. An in vitro lipid kinase 
assay was performed with GST pulldown of ectopically expressed GST-hVps34 from 
HEK293 cells and with recombinant p110α (kind gift from Doriano Fabbro, Novartis 
Basel). Both kinases were pretreated either with DMSO or with 3 different 
concentrations of the indicated inhibitors (10µM, 1µM and 100nM for hVps34 and 
100nM for p110α) (Fig. 1) for 10 min at 30°C, while vigorously shaking. After addition 
of 10 µg of unilaminar PtdIns/phosphatidylserine vesicles and 2 µCi [γ-32ATP]/10 µM 
cold ATP, lipid kinase assay was performed at 30°C for 15 min while vigorously 
shaking. Lipids were extracted and separated on a thin layer chromatography (TLC) 








Compound Comments Chemical structure 
Wortmannin 
 
Pan-PI3K inhibitor, also 
active against DNA-PK, 
























Class I PI3K, mTORC1 




Class I PI3K inhibitor 
 









Fig. 1: Efficacies of different inhibitors in inhibiting hVps34 and p110α. 
hVps34 (A) and p110α (B) were treated with different inhibitors as indicated and an in vitro lipid PI3K 
kinase assay performed. Quantification of n = 3 experiments are shown and data are represented as 
mean ± SEM. 




Inhibitors at a low concentration of 100 nM, except wortmannin and BGT226, badly 
blocked the catalytic activity of hVps34, while the same concentration inhibited 
p110α to a much higher extent. Interestingly, BGT226 at 100 nM concentration 
blocked hVps34 to a similar extent as p110α. In parallel the vesicular distribution of 
EGFP-2xFYVEHRS, which was used to detect PtdIns(3)P by microscopy, was 
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analyzed after inhibitor treatment in HeLa cells (Fig. 2). Similar to the lipid kinase 
assay, BGT226 treatment resulted in a diffused cytoplasmic localization of EGFP-
2xFYVEHRS, alike wortmannin treatment, indicating a block in PtdIns(3)P synthesis. 
BEZ235 and PI-103, which both blocked p110α to high extent but not hVps34, did 
not affect vesicular localization of EGFP-2xFYVEHRS.  
Consequently, the inhibitors tested here cannot be used at a low concentration to 





Fig. 2: Cellular distribution of the PtdIns(3)P sensor EGFP-FYVE
HRS
 after inhibitor treatment.  
HeLa cells ectopically expressed EGFP-2xFYVE
HRS
 (green) in order to visualize PtdIns(3)P-containing 
endosomes. Cells were maintained in complete medium (DMEM supplemented with 2 mM L-glutamine 
and 10% FCS) and 48h after transfection cells were either treated with DMSO or with the indicated 
inhibitors for 30min. After fixation, nuclei were stained with Hoechst (blue) and cells imaged with a 





Effect of 3-methyladednine on class I PI3K isoforms and hVps34 
3-Methyladenine is a compound used to block autophagy and as an hVps34 specific 
inhibitor (Li and Fan, 2010; Petiot et al., 2000). Because its working concentration is 
10mM, we were wondering whether 3-methyladenine would also affect other PI3Ks. 
For that purpose in vitro lipid kinase assays were performed with recombinant class I 
PI3K isoforms (p110α, p110β, p110δ and p110γ) and with GST pull downed GST-
hVps34 as described above. Interestingly, 10 mM 3-methyladenine effectively 
inhibited the catalytic activity of p110γ and hVps34 (Fig. 3), while p110α and p110δ 
were inhibited to 20% and p110β to around 25% in respect to DMSO treated controls 
(Fig. 3). Consequently, this result demonstrates that 3-methyladenine is not a 
hVps34 specific inhibitor, but it also negatively affects class I PI3K isoforms, 
especially p110γ. In support to our results, Ito et al. could demonstrate that 10 mM 3-
methyladenine inhibits all 3 classes of PI3Ks as effective as 100 nM wortmannin (Ito 
et al., 2007).  
 
Fig. 3: 3-Methyladenine (3-MA) is not an 
hVps34 specific inhibitor. 
Class I PI3K isoforms (p110α, p110β, p110δ 
and p110γ) and hVps34 were treated with 
10mM 3-methyladenine in an in vitro lipid 
kinase assay. Quantification of n = 3 
experiments are shown and data are 





PI3Ks class I isoform-specific inhibitors are available on the market but not for 
Vps34. Recently, the catalytic domain of Drosophila Vps34 has been crystallized 
(Miller et al., 2010), which will facilitate the design of selective Vps34 inhibitors. It has 
been demonstrated that Vps34 has a smaller ATP binding pocket compared to 
p110γ. The small size most probably restricts the binding of typical PI3K inhibitors 
such as PI-103 into the ATP binding pocket of Vps34 and thereby explaining why 
class I PI3K inhibitors have lower affinities for Vps34. The low molecular weight 
compound 3-methyladenine has been shown to accommodate very well into the ATP 
binding pocket of hVps34 (Miller et al., 2010). However, because of its smallness 3-
methyladenine probably binds as well into the ATP binding cavities of the other 
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PI3Ks, especially p110γ, thereby blocking them. Nevertheless, thanks to the 
structural insights gained from the crystal structure of Vps34, Miller et al. were able to 
synthesize an analog of PIK93, termed PT210, that is 10-fold more selective for 
Vps34 (IC50 450nM) than for p110γ (IC50 4,428 nM) (Table 2). Moreover, the authors 
were able to reverse the selectivity of PIK93 for p110γ over Vps34 (Table 2) (Miller et 
al., 2010). Consequently, selective Vps34 inhibitors will sooner or later become 
available.  
 
Table 2: Structural and IC50 comparison between PIK93 and PT210 
PIK93 PT210 
  
IC50 Vps34: 36 nM 
IC50 p110γ: 4 nM 
IC50 Vps34: 450 nM 
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Phosphoinositides (PIs) play fundamental roles as signalling molecules in numerous cellular processes.
Direct analysis of PIs is typically accomplished by metabolic labelling with 3H-inositol or inorganic 32P
followed by deacylation, ion-exchange chromatography and flow scintillation detection. This analysis is





we established a robust, non-radioactive LC–ESI–MS assay for the separation and analysis of deacylated
PIs that allows discrimination of all isomers without the need for radioactive labelling. We applied the
method to various cell types to study the PI levels upon specific stimulation.
© 2010 Elsevier B.V. All rights reserved.SI
eversed phase ion-pair chromatography
. Introduction
The inositol containing glycerophospholipids, collectively
nown as phosphoinositides (PIs), play a fundamental role in
iverse cellular functions such as cell growth and differentiation,
otility, calcium mobilisation and oncogenesis [1,2]. The family
f the phosphoinositides consists of the non-phosphorylated pre-
ursor phosphatidylinositol (PtdIns) and seven derivatives with
ifferent phosphorylation patterns on the myo-inositol ring, where
he 3-, 4- and 5-positions can be phosphorylated by specific kinases
Fig. 1A).
PIs derived from PtdIns and its phosphorylation pro-
ucts phosphatidylinositol-4-phosphate (PtdIns4P) and phospha
idylinositol-4,5-bisphosphate (PtdIns(4,5)P2) form the so called
anonical pathway [3] and are believed to be kept at constant
evels at the plasma membrane. The other PIs are considered to
e low-abundant signalling molecules that transiently appear
pon stimulation. Stimulation with growth factors or insulin
eads to increased PtdIns(3,4,5)P3 levels, which in turn produces
pecific cellular responses. The bisphosphorylated PIs containing
tdIns(3,4)P2, PtdIns(4,5)P2, and PtdIns(3,5)P2 moieties play dis-
inct roles in signal prolongation after PtdIns(3,4,5)P3 inducing
timuli, regulation of the actin cytoskeleton and vesicle transport,
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ern, Switzerland. Tel.: +41 31 344 40 48.
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P. Küenzi).
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oi:10.1016/j.jpba.2010.03.029respectively [4–8]. PIs containing phosphoinositide monophos-
phates were long thought to be mere intermediates in the pathway
but are now recognised to possess specific functions by themselves
in protein sorting, vesicular trafficking and in osmotic stress
response [9–12].
Analysis of PIs has been achieved in several ways. Most fre-
quently, metabolic radioisotope labelling with inorganic 32P or
3H-inositol, lipid extraction, hydrolysis followed by chromato-
graphic separation and radiographic analysis of phosphoinositides
has been used [13–15]. Metabolic labelling involves very high doses
of radioactivity (GBq), long labelling times and only detects the
turnover of PIs, whereas dormant pools of PIs remain unlabelled.
More recent approaches include fluorescent-labelled binding pro-
teins for specific PIs, and antibodies directed against PIs [16,17].
However, differentiation of all the mono- and bisphosphorylated
positional isomer PIs, has not been achieved yet.
Two fundamentally different approaches have been pursued in
PI analysis: (i) a comprehensive profiling of intact PIs [18–21] and
(ii) head group analysis after cleavage of the lipid moieties [22,23].
The first approach used in lipidomics leads to a highly complex
picture due to a plethora of closely related molecules that only
vary in their lipid moieties. This approach including quantification
has been successfully applied to cells producing phophoinositides
with limited complexity in their lipid residues, such as platelets
[24–26]. Even though the analysis of intact PIs would be the pre-
ferred approach, it is currently unsuitable for most cells due to
the overwhelming complexity of their PI patterns. Therefore, sep-
aration and detection of the head groups following deacylation
(Fig. 1B) is a more suitable approach if the focus lies on the detec-








































ig. 1. (A) Structure of a typical PtdIns, sn-1-stearoyl-2-arachidonyl-phosphatidyli
tructure of phosphatidylinositol-3,4,5-trisphosphate (PtdInsP3); numbering of the
ion of the change in phosphorylation pattern that exerts the major
nfluence on the subsequently elicited signalling. Given the low
bundance of certain PIs, even the analysis of deacylated lipids is
ighly challenging.
As alternatives to radioisotope labelling, analysis by mass
pectrometry [27], suppressed conductivity detection [28] and
vaporative light scattering detection (ELSD) [29] have been used.
nfortunately, none of these allowed a discrimination of all iso-
ers. An LC–ESI–MS method for separation of deacylated PtdInsP2
somers has been recently published [14]. However, chromatogra-
hy suffered from poor peak shape and co-elution of PtdIns(3,5)P2
nd PtdIns(3,4,5)P3.
Since the PtdIns moieties of PIs can be interconverted by specific
inases and phosphatases, inhibition, stimulation, modification, or
eletion of one of these enzymes may have profound implications
n the biological response. Therefore, separation and simultane-
us detection of all headgroups of PIs is of major importance for
better understanding of their biological roles, and a robust and




HPLC separation was carried out on a series 1100 system
quipped with degasser, binary high pressure mixing pump, and
olumn thermostat (Agilent Technologies). A liquid handler 215
Gilson) was used as autosampler. The HPLC was coupled to an
squire 3000 ion trap mass spectrometer equipped with an elec-
rospray (ESI) interface (Bruker Daltonics). Data acquisition and




N,N-dimethylhexylamine (DMHA; Acros, Thermo Fisher) was
sed as ion-pair reagent. Mobile phase A consisted of water con-
aining 5 mM DMHA and 4 mM glacial acetic acid (Sigma–Aldrich)
nd mobile phase B of acetonitrile or methanol with 5 mM DMHA
nd 4 mM glacial acetic acid. All solvents were from Scharlau
Scharlau, Barcelona, Spain)..2.2. Columns
Various columns were tested for suitability in phosphoinosi-
ide analysis, including Atlantis C18 (150 mm × 4.6 mm, 5 m)
nd T3 (150 mm × 3.5 mm, 3 m; Waters, Baden, Switzerland),l and the performed deacylation step, resulting in cleavage of the lipid moiety. (B)
inositol ring is indicated.
Nucleosil C100 (250 mm × 4.6 mm, 5 m; Macherey-Nagel, Düren,
Germany), liChrospher diol (125mm × 4.0 mm, 5 m; Merck,
Darmstadt, Germany) and Aqua C18 (250 mm × 4.6 mm, 5 m and
75 mm × 2.0 mm, 3 m; Phenomenex, Torrance, CA).
2.2.3. Separation of phosphoinositides
2.2.3.1. Method 1. Separation of deacylated PIs with different num-
bers of phosphorylations; PtdIns, PtdInsP, PtdInsP2 and PtdInsP3,
was achieved by ion-pair chromatography on a Aqua C18 column
(3 m, 125 Å, 75 mm × 2.0 mm). A gradient from mobile phase B
(acetonitrile) 0.1 to 50% in 25 min and a wash step (50% B to 100%
B in 3 min, 100% B for 12 min, 100% B to 0.1% B in 5 min, 0.1% B for
5 min) was applied.
2.2.3.2. Method 2. Separation of deacylated PIs with different
numbers of phosphorylation plus additional separation of phos-
phoinositides bisphosphate isomers PtdIns(4,5)P2, PtdIns(3,5)P2,
PtdIns(3,4)P2, was achieved by ion-pair chromatography on an
Aqua C18 column (125 Å, 250 mm × 4.6 mm, 5 m). A gradient from
mobile phase B (acetonitrile) 15 to 35% in 40 min followed by a wash
sequence (35% B to 100% B in 2 min, 100% B for 15 min, 100% B to
15% B in 3 min, 15% B for 5 min) was applied.
2.2.3.3. Method 3. Separation of PtdIns(3)P, PtdIns(4)P and
PtdIns(5)P, additionally to separation of all other PIs, was per-
formed with methanol as mobile phase B and a gradient from 15 to
50% in 60 min, followed by a wash step (50% B to 100% B in 2 min,
100% B for 15 min, 100% B to 15% B in 3 min, 15% B for 5 min).
2.3. Mass spectrometry
Negative ion LC–MS spectra on the ion trap instrument were
recorded after optimization of settings, under ion charge control
conditions (ICC 20000) at a scan speed of 13,000 m/z/s, using a gauss
filter width of 0.2 m/z. Nitrogen was used as a drying gas at a flow
rate of 10 l/min and as a nebulizing gas at a pressure of 30 psi. The
nebulizer temperature was set to 300 ◦C. Spectra were recorded in
the range of m/z 200–600 in negative mode. Capillary voltage was at
4500 V, endplate offset at −500 V, capillary end voltage at −115.0 V,
skimmer voltage −40.0 V and trap drive at 53.4.
2.4. Flow scintillation analysisLevels of radioactively labelled intracellular phosphatidylinosi-
tides were determined essentially as described [30]. Briefly, 4
million cells were incubated with 500 Ci 32Pi for 60 min at 37 ◦C.
After removal of non-incorporated 32Pi, cells were extracted as
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ned online with a FLO-ONE A500 -detector (Packard–Perkin
lmer).
.5. Chemicals and cell culture
Murine bone marrow cells were cultured in Iscove’s Modified
ulbecco’s medium (IMDM; Sigma–Aldrich) supplemented with
0% heat-inactivated fetal calf serum (FCS; Amimed, Basel, Switzer-
and), 100 U/ml penicillin/streptomycin and 2 mM l-glutamine
both from Invitrogen, Basel, Switzerland). Cells were grown in
umified atmosphere containing 5% CO2 and maintained with
ng/ml recombinant murine interleukin-3 (IL3; PeproTech EC Ltd.,
ondon, UK).
Human embryonic kidney cells HEK 293 were cultured in
ulbecco’s Modified Eagle’s Medium (DMEM; Sigma–Aldrich) sup-
lemented with 10% FCS, 100 U/ml penicillin/streptomycin and
mM l-glutamine. Cells were transfected with jetPEI cationic poly-
er transfection reagent (Polyplus-Transfection, Illkirch, France)
ccording to the manufacturers’ instructions. Twenty-four hour
efore transfection, cells were plated at 106 cells/25 cm2 flask, then
ransfected with 2.6 g GST-Vps34 and 0.4 g Myc-S6K. Thirty hour
fter transfection, cells were starved over night and experiments
ere performed the following day.
Platelets were isolated from blood of healthy donors. Blood sam-
les were mixed with acid citrate dextrose ACD (10.1 mM glucose,
0 M citric acid, pH 6.5 in 0.9% NaCl, all from Sigma–Aldrich) and
entrifuged for 5 min at 1000 × g [31]. Platelet rich plasma was
ollected and washed in PBS.
Chemicals used for experiments were: adenosine (Ade),
-formyl-Met-Leu-Phe (fMLP), wortmannin (wort) (all from
igma–Aldrich).
Phosphoinositide standards used were: Phosphoinositides
odium salt from bovine brain (Sigma–Aldrich), PtdIns(3,4)P2,
tdIns(3,5)P2 and PtdIns(3,4,5)P2 as 1,2-dioctanoyl-sn-glycero-
-phosphoinositolphosphates ammonium salt and PtdIns3P and
tdIns5P as 1-heptadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-
n-glycero-3-phosphoinositolphosphates ammonium salt from
vanti Polar Lipids (Avanti Polar Lipids, Alabaster, AL).
.6. Extraction, deacylation and sample preparation
Extraction of PIs was adapted from Ogiso et al. [27], who
escribed a modified acidic Bligh-Dyer extraction [32] with addi-
ion of NaCl to the aqueous phase to help reducing loss of PIs.
riefly, ca. 106 cells were extracted with 2 ml methanol, 2 ml 1 M
Cl, 0.15 ml 2 M NaCl and 2 ml chloroform (solvents from Scharlau,
ther reagents from Sigma–Aldrich). Methanol was supplemented
ith PhosSTOP (Roche, Basel, Switzerland), 1 mM NaF, 3 mM BHT
nd 0.5 mM phosphatidic acid (all from Sigma–Aldrich). The two
hases were mixed well and centrifuged shortly for separation.
he lower organic phase was removed, evaporated by nitrogen
tream and transferred to deacylation. Dried samples were incu-
ated with methylamine solution in water/methanol/n-butanol
43:46:11) at 53 ◦C for 50 min, all solvent was evaporated under
acuum, and then extracted with a mixture of n-butanol/petrol
ther 40–60◦/ethyl formiate (20:4:1) and water [33]. The water-
hase was dried in vacuum and the samples were dissolved in 40 l
f solvent A for LC–MS analysis.
. Results and discussion.1. Separation of phosphoinositides in order of increasing
hosphorylation
Separation of anionic or phosphorylated compounds is typi-
ally achieved by ion-exchange chromatography. However, typicalBiomedical Analysis 53 (2010) 552–558
ion-pairing reagents are not volatile and, hence, not compatible
with LC–MS. We tested several volatile and MS-compatible ion-
pairing reagents, such as formic acid, ammonium formiate and
N,N-dimethyl-hexylamine (DMHA) and applied them on various
columns (Nucleosil C100, LiChrospher Diol and Phenomenex Aqua
C18). The only acceptable separation of a phosphoinositide refer-
ence mixture was achieved on a short (75 mm) Phenomenex Aqua
C18 column with the addition of DMHA. Subsequently, we tested
different gradient profiles, column temperatures, pH and concen-
trations of DMHA to optimize separation. Column temperature had
a slight impact, and the best separation was obtained at 15 ◦C. In
contrast, pH of the mobile phase was critical. Best results were
obtained around pH 7, while lower pH values lead to peak tailing
and split peaks and higher pH resulted in shorter retention times.
Increase of DMHA concentration from 5 to 10 mM and 20 mM did
not enhance the quality of the separation. A water-acetonitrile gra-
dient was applied and the final gradient program was 0.1–50% ACN
(containing 5 mM DMHA) in 25 min, leading to the separation of a
PI standard mixture shown in Fig. 2A. Peaks shown resulted from
0.1 g of deacylated PtdIns(3,4,5)P3 standard mixed with 4 g of
deacylated phosphoinositde extract (mixture of PtdIns, PtdIns4P
and PtdIns(4,5)P2).
Separation of a mixture of PIs standards was also achieved under
isocratic conditions (27% ACN and 73% water) but separation of
biological samples, however, could not be achieved under these
conditions, probably due to interference with the biological matrix.
To test the applicability of our method to biological samples,
we analysed mast cell extracts. Mast cells are known to produce
large amounts of PtdIns(3,4,5)P3 upon activation that can be pro-
voked in vitro by stimulation with adenosine [30]. Murine bone
marrow derived mast cells (BMMCs) were stimulated with 5 M
adenosine for 30 s, the lipids were extracted, deacylated and anal-
ysed with method 1. Our method clearly succeeded in reproducing
the increased amounts of PtdIns(3,4,5)P3 upon stimulation of mast
cells with adenosine, whereas peaks of PtdIns and PtdInsP remained
constant (Fig. 2B and C).
3.2. Positional isomer separation of phosphatidylinositol
bisphosphates
To achieve separation of PtdInsP2 positional isomers vari-
ous columns were tested, including Nucleosil C100, Atlantis C18,
Atlantis T3 and Phenomenex Aqua C18. The separation was only
achieved on a Phenomenex Aqua column (column length 250 mm)
and a water–acetonitrile gradient (containing 5 mM DMHA as ion-
pair reagent) (method 2). A mixture of standards of all PtdInsP2
isomers was separated in the elution order of PtdIns(3,4)P2,
PtdIns(4,5)P2 and PtdIns(3,5)P2 (Fig. 3A and B). Peaks shown
resulted from 0.1 g of deacylated PtdIns(3,5)P2 and PtdIns(3,4)P2
standard mixed with 4 g of deacylated phosphoinositde extract
(mixture of PtdIns, PtdIns4P and PtdIns(4,5)P2). Several other sol-
vent mixtures and addition of modifiers were tested. A separation
with a different elution order (PtdIns(3,4)P2, PtdIns(3,5)P2 and
PtdIns(4,5)P2) was obtained with a water–methanol gradient (con-
taining 5 mM DMHA) (method 3) (Fig. 3C and D).
Vps34 transfected HEK 293 cells under hyperosmolar stress
were used as a model to test the analysis of PtdIns(3,5)P2 from
biological samples. The PI3-kinase Vps34 is known to stimulate
osmotic stress related production of PtdIns(3,5)P2 in yeast [22,28].
HEK Vps34 were incubated for 10 min in a medium supplemented
with 1 M NaCl solution to induce stimulation of Vps34, and gen-
eration of PtdIns3P leading to production of PtdIns(3,5)P2. As can
be seen in Fig. 4A and B, the transfection with Vps34 already
induced some production of PtdIns(3,5)P2, which was then further
increased upon NaCl hyperosmotic stimulation.
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Fig. 2. (A) Extracted ion chromatogram (EIC) of deacylated phosphoinositide stan-
dards (PtdIns, PtdInsP, PtdInsP2 and PtdInsP3) mixture. (B) EIC of cell samples from 4
mio BMMC and standards. Cells were stimulated with adenosine (Ade) 5 M for 30 s


















major concern. As extensively discussed by Ogiso et al. [27], recov-ells in relation to stimulated cells, levels of PtdInsP3 increased after stimulation
ith adenosine. Column: Phenomenex Aqua C18 (75 mm × 2 mm, 3 m). Solvent A:
2O (+5 mM DMHA), solvent B: acetonitrile (+5 mM DMHA). Gradient: 0.1% B to 50%
in 25 min.
Analysis of PtdIns(3,4)P2 in biological samples was tested with
uman blood platelets. In comparison to many other cell mod-
ls, platelets produce PtdIns(3,4)P2 in relatively large amounts
pon activation. PtdIns(3,4,5)P3 is degraded to PtdIns(3,4)P2 by
he 5-phosphatase SHIP1 [34]. PtdIns(3,4)P2 is responsible for the
ersistence of the signal induced by PtdIns(3,4,5)P3 [8,35]. For
etection of PtdIns(3,4)P2, platelets were stimulated for 90 s with
MLP. This resulted in elevated amounts of PtdIns(3,4)P2 which
ere not present in control cells (Fig. 4C and D).
.3. Positional isomer separation of phosphatidylinositol
onophosphatesSeparation of the mono-phosphorylated isomers was only
chieved with methanol–water mixtures as mobile phase (Fig. 5A
nd B), whereas the use of acetonitrile resulted in co-elution of
tdIns3P and PtdIns5P.Biomedical Analysis 53 (2010) 552–558 555
The method was applied to Vps34 transfected HEK cells as
model. Vps34 is stimulated by amino acid addition through a yet
unknown mechanism [36]. Starvation and subsequent amino acid
supplementation stimulates Vps34 and induces the generation of
PtdIns3P [37,38]. Thus, HEK Vps34 cells were serum and amino
acid starved for 12 and 2 h, respectively. By addition of serum and
amino acids, cells were stimulated for 30 min prior to extraction
of lipids, deacylation and analysis. The stimulation with serum and
amino acids induced production of PtdIns3P, which, in contrast, was
inhibited by incubation with the PI3-kinase inhibitor wortmannin
15 min prior to and during stimulation with amino acids and serum
(Fig. 5C and D).
3.4. Comparison with radiolabelling method
For comparison with the standard detection method of scin-
tillation analysis, we applied radiolabelled samples to the newly
developed HPLC method combined with subsequent scintillation
analysis. This also gave a reconfirmation of the peaks measured
with MS. The large loop size of 1 ml within the flow scintilla-
tion analyser and a flow rate of only 0.5 ml/min resulted in very
broad and asymmetric peaks. Nevertheless, peaks of the major PIs
could be detected (Fig. 6A and B). A radioactive labelled cell sample
showed all major PI peaks (Fig. 6C) at the same retention times as
when detected with MS. So did a radioactive labelled standard of
PtdIns3P (Fig. 6C) that was clearly different to the retention time of
the cellular PtdIns4P peak.
3.5. Discussion
The separation of PIs differing in number of phosphorylations
was successfully achieved with method 1 and applied to analysis
of phosphoinositides in cell samples. For analysis of PtdIns(3,4,5)P3
this method offers a good alternative to the assay involving radi-
olabelling and anion-exchange HPLC. The short analysis time
facilitates handling of large sample numbers.
Separation of isomers was achieved on the same column type,
but of longer size and hence increased separation capacity (method
2). This assay offers new perspectives for research on phosphoinosi-
tide signalling. The low-abundant PtdInsP2 isomers can now be
separated and analysed without the need for radioactive labelling.
Replacing acetonitrile by methanol enabled the separation of
PtdIns3P, PtdIns4P and PtdIns5P (method 3). This isomer sepa-
ration has not been possible before. Also the PtdInsP2 isomers
could be separated with method 3, albeit in a different elution
order when compared to method 2. This hampered a complete
separation of the highly abundant PtdIns(4,5)P2 from the trace iso-
mer PtdIns(3,5)P2. Therefore, analysis of the biologically important
PtdIns(3,5)P2 should be performed with method 2.
Separation of PtdInsP2 isomers has been shown before on a
cyclodextrin column [14], but co-eluting peaks of PtdIns(3,4,5)P3
and PtdIns(3,5)P2 limited the usefulness of the method. Also, sep-
aration of PtdInsP isomers was neither shown nor discussed in
that publication. Compared to a cyclodextrin column the polar
endcapped RP-column used here exhibits a more predictable
chromatographic behaviour, offers more options for method refine-
ment, and is widely applicable. Furthermore, robustness of the
column and reproducibility and stability of separations are very
high.
The methods presented here were successfully applied to rele-
vant biological samples. The extraction procedure of PIs remains aery rates of PIs are generally poor and decrease with increasing
phosphorylation. Due to the amphiphilic properties these lipids
are difficult to extract. The ionic headgroup adsorbs easily to glass
surfaces, whereas the lipid moiety adsorbs to plastic. However,
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ig. 3. (A and B) Separation of a standard mixture of PIs containing all PtdInsP2
tdIns(4,5)P2 and PtdIns(3,5)P2. Column: Phenomenex Aqua C18 (250 mm × 4.6 mm
n 40 min. (C and D) Separation of a standard mixture of PIs containing all PtdInsP2 re
nd PtdIns(4,5)P2. Column: Phenomenex Aqua C18 (250 mm × 4.6 mm, 5 m). A: Me
easures can be taken to reduce loss of analytes, such as use of
ilanized glassware to prevent adsorption at glass surfaces [26],
nd lipid pre-treatment of plastic surfaces with lipids as adsorption
rotectants. We used plastic tubes, added lipids as adsorption pro-
ectants, and phosphatase inhibitors to prevent hydrolysis. These
ombined measures noticably increased extraction yields. How-
ver, further optimization is needed towards a robust and fully
alidated quantitative analysis of PI headgroups. This could be
ig. 4. Analysis of phosphoinositide cell samples. (A and B) Extracted ion chromatogra
hat were further increased by stimulation with 1 M NaCl for 10 min. (C and D) EIC of lip
timulation induced generation of PtdIns(3,4)P2 that was not present in the control sam
MHA), B: acetonitrile (+5 mM DMHA). Gradient: 15% B to 35% B in 40 min.isomers. (B) Elution of the isomers of PtdInsP2 in following order: PtdIns(3,4)P2,
). A: H2O (+5 mM DMHA), B: acetonitrile (+5 mM DMHA). Gradient: 15% B to 35% B
mers. (D) Separation of PtdInsP2 isomers in sequence of PtdIns(3,4)P2, PtdIns(3,5)P2
l (+5 mM DMHA), B: acetonitrile (+5 mM DMHA). Gradient: 15% B to 50% B in 60 min.
achieved by spiking with suitable internal standards at the begin-
ning of the extraction procedure which ideally should be a PI with
a stable-isotope labelled headgroup. However, such standards are
not commercially available. An issue is the efficiency of extrac-
tion of phospholipids with different degrees of phosphorylation.
There are clear indications that replacing the widely used extrac-
tion with chloroform/methanol by butanol increases the yield of
highly phosphorylated PtdIns isoforms ([26], Traynor-Kaplan and
ms (EIC) of HEK Vps34 cell samples showed increased amounts of PtdIns(3,5)P2,
ids extracted from platelets, control sample and stimulated with fMLP for 1 min.
ple. Column: Phenomenex Aqua C18 (250 mm × 4.6 mm, 5 m). A: H2O (+5 mM
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Fig. 5. (A and B) Extracted ion chromatogram (EIC) and base peak chromatogram
(BPC) of mixed standards of phosphoinositide monophosphates separated accord-
ing to method 3. Separation of PtdIns3P, PtdIns4P and PtdIns5P was achieved. (C)
BPC and EIC of a HEK Vps34 cell sample. (D) EIC of HEK Vps34 cell samples that were
amino acid stimulated and incubated with wortmannin 15 min prior to and during
amino acid stimulation. The increase in PtdIns3P following amino acid starvation
and subsequent stimulation was blocked by addition of wortmannin. Column: Phe-
nomenex Aqua C18 (250 mm × 4.6 mm, 5 m). A: H2O (+5 mM DMHA), B: methanol
(+5 mM DMHA). Gradient: 15% B to 50% B in 60 min.
Fig. 6. (A and B) Total ion chromatogram (TIC) and extracted ion chromatogram
(EIC) of a HEK Vps34 control cell sample separated according to method 3. (C)
Chromatogram of parallel online flow scintillation analysis of the same HEK
Vps34 cell sample and a standard of PtdIns3P. Column: Phenomenex Aqua C18
(250 mm × 4.6 mm, 5 m). A: Methanol (+5 mM DMHA), B: acetonitrile (+5 mM
DMHA). Gradient: 15% B to 50% B in 60 min.
Küenzi, unpublished data). Thus, a semi-quantitative analysis that
compares peak intensities of highly variable (e.g. PtdIns(3,4,5)P3)
and basically unvaried (e.g. PtdIns(4,5)P2) headgroups is currently
the most suitable approach.
The direct parallel analysis with online flow scintillation and
mass spectrometry showed the comparability of the two meth-
ods. The LC–MS assay presented here offers a superior approach
for analysis of intracellular PI levels including differentiation of the
biologically relevant PtdInsP and PtdInsP2 isomers.
Further development of the method can be envisaged by a trans-
lation to UPLC, thereby taking advantage of shorter analyses and
equal or superior chromatographic resolution. There is a general
need for further improvement of sample workup in PI analysis,
as isolation and deacylation of the PtdIns is time-consuming and
difficult. Also, the issue of possible discriminatory extraction of cer-
tain PtdIns needs further investigation. Nevertheless, the LC–MS
methods presented here enable simultaneous analysis of all cur-
rently known deacylated PtdIns and thus are a useful tool for cell
signalling studies.
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Myc-tag starts at 953 
Human S6K1 with AGVF at 983, and ends with RMNL at 2488. 
Unique sites are depicted in light yellow. 








GST-tag starts at 965 
hVps34 with MGEA at 1682, and ends with QYWRK at 4345. 
Unique sites are depicted in light yellow. 









EGFP at 1202-1915 
PH domain of Btk starts at 650 and ends at 1180. 
Unique sites are depicted in light yellow. 








p110g wt at 937-4242 followed by GT (KpnI site, depicted in violet) and CAAX box of 
K-Ras with STOP codon at 4359. 
Unique sites are depicted in light yellow. 








EGFP at 616-1329 
2xFYVEHRS (tandem FYVE domain of HRS) starts at 1369 and ends at 1848. 
Unique sites are depicted in light yellow. 









EGFP at 616-1329 
PH domain of TAPP1 starts at 1372 and ends at 1737. 
Unique sites are depicted in light yellow. 







ORF: 898-3624,  
HA-tag starts at 907 
hVps34 starts with MGEA at 961 and ends with QYWRK at 3624. 
Unique sites are depicted in light yellow. 









GST-tag starts at 965 
hVps34 with MGEA at 1682, and ends with QYWRK at 4345. 
K->R mutation introduced through 3 point mutations at 3587-3589 (aag -> cgc; 
depicted in green). 
Unique sites are depicted in light yellow. 







ORF: 898-3624,  
HA-tag starts at 907 
hVps34 starts with MGEA at 961 and ends with QYWRK at 3624. 
K->R mutation introduced through 3 point mutations at 2866-2868 (aag -> cgc; 
depicted in green). 
Unique sites are depicted in light yellow. 








HA-tag starts at 924 
mTOR starts at 964 with MLGTG and ends with WCPFW at 8613. 
Unique sites are depicted in light yellow. 








HA-tag starts at 975 
Raptor starts at 1032 with MESEML and ends with VEKRVR at 5039. 
3'-UTR of Raptor: 5040-7099 (depicted in green) 
Unique sites are depicted in light yellow. 








EGFP at 616-1329 
Rat Rheb starts at 1345 with MPQSKS and ends at 1899. 
Unique sites are depicted in light yellow. 








Rab5a starts at 938 and ends at 1585 
Unique sites are depicted in light yellow. 








Rab7 starts at 938 and ends at 1561 
Unique sites are depicted in light yellow. 








EGFP at 616-1329 
Rab5a starts at 1348 and ends at 1995. 
Unique sites are depicted in light yellow. 








EGFP at 616-1329 
Rab7 starts at 1348 and ends at 1971. 
Unique sites are depicted in light yellow. 








HA-tag starts at 975 
Raptor starts at 1032 with MESEML and ends with VEKRVR at 5036 followed by GT 
(KpnI site; depicted in violet) and CAAX box of K-Ras with STOP at 5153.  
Unique sites are depicted in light yellow. 








HA-tag starts at 975 
Raptor starts at 1032 with MESEML and ends with VEKRVR at 5036 followed by GT 
(KpnI site; depicted violet) and last 15 amino acids of Rheb (IDGAASQGKSSCSVM; 
taken from p1277) with STOP at 5090.  
Unique sites are depicted in light yellow. 









EGFP at 613-1329 
2xFYVE HRS C215S starts at 1369 and ends at 848. 
2x C->S mutations introduced through 4 point mutations (depicted in red): G1574C, 
C1575A, G1820C and C1821A 
Unique sites are depicted in light yellow. 






A375 human malignant melanoma cell line 
AA amino acids 
Akt product of the retrovirus AKT8 
AMP adenosine monophosphate 
AMPK adenosine monophosphate-activated protein kinase 
APS ammonium persulfate 
Arg arginine 
ATP adenosine trisphosphate 
base pair bp 
BSA bovine serum albumin 
Btk Bruton’s tyrosine kinase 
Ca2+ calcium ions 
cm centimeter 
DEPTOR DEP domain-containing mTOR-interacting protein 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxynucleoside triphosphate 
DTT dithiothreitol 
4E-BP1 eukaryotic initiation factor 4E-binding protein 
E. coli escherichia coli 
EAA essential amino acids 
EEA1 early endosomal antigen 1 
EGFP enhanced green fluorescent protein 
ERK extracellular-signal related kinase 
ETDA ethylenediamine tetraacetate 
EtOH ethanol 
FCS fetal calf serum 
FRB FKBP12-rapamycin binding domain 
FYVE Zinc finger domain as present in Fab1, YOTB, Vac1, and EEA1 
g gram 
GAP GTPase activating protein 
GDP guanosine diphosphate 
GEF guanine exchange factor 
Gln L-glutamine 
Grb2 Growth factor receptor-bound protein 2 




HEK293 human embryonic kidney 293 cell line 
HeLa human cervical adenocarcinoma cell line 
HER911 human embryonic retinoblast cell line 
HOPS homotypic fusion and vacuole protein sorting 
HRP Horseradish peroxidase 
HRS hepatocyte growth factor-regulated tyrosine kinase substrate 
IGF insulin growth factor 
IRS insulin receptor substrate 
kDA kilo Dalton 
l liter 
LB luria broth 
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LKB1 liver kinase B1 
M mol/l 
MAPK mitogen-activated protein kinase 
MEF mouse embryonic fibroblast 
MEK MAPK/ERK kinase 
min minute(s) 
ml milliliter 
mLST8 mammalian lethal with sec thirteen 
mRNA messenger RNA 
mSin1 mammalian stress-activated map kinase-interacting protein 1 
mTOR mammalian target of rapamycin 





OD optical density 
O/N over night 
PA phosphatidic acid 
PAGE Polyacrylamide gel electrophoresis 
PAT proton-assisted amino acid transporter 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PDK phosphoinositide-dependent kinase 
PEST penicillin-streptomycin 
PFA paraformaldehyde 
PH pleckstrin homology 
pH potential hydrogenii 
PI phosphoinositide 
PI3K phosphatidylinositol 3-kinase 
PIKfyve PtdIns(3)P 5-kinase 
PIKK PI3K-related protein kinase 
PKB protein kinase B 
PLD phospholipase D 
PMSF phenylmethylsulfonylfluoride 
PRAS40 proline-rich Akt substrate of 40 kDa 
Protor protein observed with rictor 
PtdIns phosphatidylinositol 
PtdIns(3)P phosphatidylinositol 3-phosphate 
PtdIns(3,4)P2 phosphatidylinositol 3,4-bisphosphate 
PtdIns(3,4,5)P3 phosphatidylinositol 3,4,5-triphosphate 
PtdIns(3,5)P2 phosphatidylinositol 3,5-bisphosphate 
PtdIns(4,5)P2 phosphatidylinositol 4,5-bisphosphate 
PVDF polyvinylidene fluoride 
PX phox homology domain 
Rab GTPase 
Rag GTPase 
Ragulator Rag and mTORC1 regulator 
Raptor regulatory-associated protein of mTOR 
Ras GTPase 
Rheb Ras homologue enriched in brain 
Rictor rapamycin-insensitive companion of mTOR 
RNA ribonucleic acid 
RNAi RNA interference 
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rpm revolutions per minute 
RPMI Roswell Park Memorial Institute (medium) 
RSK p90 ribosomal S6 kinase 
RT room temperature 
RTK receptor tyrosine kinase 
S6K p70 ribosomal S6 kinase 
SB sample buffer 
SDS sodium dodecylsulfate 
SEM standard error of the mean 
Ser serine 
shRNA short hairpin RNA 
siRNA small interference RNA 
Sos son of sevenless 
TAE Tris-acetate-EDTA 
TAPP1 tandem PH domain containing protein 1 
TBS Tris buffered saline 
TBST Tris buffered saline with Tween 
TE Tris-EDTA 
TEMED N, N, N’, N’-tetraethylmethlylendiamide 
Thr threonine 
TLC thin layer chromatography 
TOS TOR signaling motif 
Tris Tris(hydroxymethyl)aminomethane 
TSC tuberous sclerosis complex 
TSC1 also named hamartin 




Vps vacuolar protein sorting 
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